Methods of Using Bispecific CD33 and CD3 Binding Proteins

By developing bispecific CD33 and CD3 binding proteins, especially double-chain antibodies, the problem of difficult to effectively target the killing of CD33-positive leukemia cells in the prior art is solved, and the effective therapeutic effect on AML is achieved.

JP7583014B2Active Publication Date: 2024-11-13ANJI BRUNO LLC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2022211080
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2015-12-11
Filing Date
2022-12-28
Publication Date
2024-11-13
Estimated Expiration
2036-05-26

AI Technical Summary

Technical Problem

It is difficult for the prior art to effectively target CD33-positive leukemia cells, especially acute myeloid leukemia (AML), and traditional therapies have problems such as low efficiency and major side effects.

Method used

Bispecific CD33 and CD3 binding proteins, especially tandem diabodies, were developed to activate T cells to kill target cells by simultaneously binding CD33-positive leukemia cells and T cells.

Benefits of technology

It has achieved efficient killing of CD33-positive leukemia cells, showed efficient cell lysis ability, especially in AML cells, and showed significant anti-leukemia effects, and showed significant activity in in vitro and in vitro models. It is suitable for AML patients at different stages.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007583014000018
    Figure 0007583014000018
  • Figure 0007583014000019
    Figure 0007583014000019
  • Figure 0007583014000020
    Figure 0007583014000020
Patent Text Reader

Abstract

Methods are provided for the treatment of acute myeloid leukemia (AML) in patients who have undergone hematopoietic stem cell transplantation. Methods are provided that involve administering binding proteins that specifically bind human CD33, particularly bispecific binding proteins that specifically bind human CD33 and human CD3. Additionally, bispecific tandem diabodies that bind CD33 and CD3, and their use for immunotherapy of CD33+ cancers, diseases, and conditions, such as acute myeloid leukemia (AML), are provided.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] cross reference This application claims the benefit of U.S. Provisional Patent Application No. 62 / 168,641, filed May 29, 2015, and U.S. Provisional Patent Application No. 62 / 266,438, filed December 11, 2015, both of which are incorporated herein by reference in their entireties.

[0002] Sequence Listing This application contains a Sequence Listing that has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. The ASCII copy created on May 25, 2016, is named 45375_705_601_SeqList.txt and is 250,173 bytes in size. [Background technology]

[0003] Background of the Invention Acute myeloid leukemia (AML) is an acute leukemia in adults and children. The majority of AML myeloblasts express CD33. Some reports suggest that CD33 is generally restricted to early multilineage myeloid progenitor cells and is absent from normal pluripotent hematopoietic stem cells. Summary of the Invention

[0004] Provided herein are binding proteins that specifically bind to human CD33, and bispecific binding proteins that specifically bind to human CD33 and human CD3. Additionally, provided herein are anti-CD33 variable domains and anti-CD3 variable domains for generating several bispecific CD33 / CD3 binding proteins, e.g., tandem diabodies. Also provided herein are bispecific tandem diabodies that bind to CD33 and CD3, and their use for immunotherapy of acute myeloid leukemia (AML) and other hematological malignancies, disorders, or conditions.

[0005] In particular, binding proteins are provided that exhibit binding to both cynomolgus monkey and human CD33. These CD33 / CD3 tandem diabodies bind to autologous T cells from AML patients as well as polyclonal CD3 from healthy donors. + T cells were cultured at a low E:T cell ratio with CD33 + It is demonstrated in the Examples that AML cells can be redirected to be efficiently lysed. + In this process, which depends on the presence of both target cells and T cells, the redirected T cells are activated and stimulated to proliferate, as indicated by the induction of CD25 and CD69. The anti-AML efficacy of these tandem diabodies has been shown to depend not only on the E:T cell ratio but also on the concentration of antibody used. Tandem diabodies are tetravalent, possessing two binding sites for CD33 and two binding sites for CD3. A special feature of the CD33 / CD3 tandem diabodies described herein is that they promote potent and efficient apoptosis as a result of bivalent binding that confers avidity for each antigen, i.e., CD33 and CD3.

[0006] In summary, the provided CD33 / CD3 binding proteins, particularly tandem diabodies, described herein inhibit CD33 in vitro. + They induce potent cytolysis of leukemia cells and primary AML cells. Exemplary bispecific CD33 / CD3 binding proteins in tandem diabody antibody format demonstrate cytolytic activity in vivo in cell lines, primary AML cells, and in vivo models with AML cell lines and patient-derived primary AML cells. This demonstrates particularly noteworthy high in vivo activity in stringent AML PDX models. Furthermore, exemplary bispecific CD33 / CD3 binding proteins in tandem diabody antibody format demonstrate cytolytic activity ex vivo in samples from patients with all stages of AML, including newly diagnosed, relapsed, and refractory patients.

[0007] Furthermore, these CD33 / CD3 binding proteins described herein can achieve significant lysis of CD33-expressing cells within about 4 hours. The CD33 / CD3 binding proteins therefore exhibit high cytotoxicity not only at low effector:target (E:T) ratios but also at low CD33 densities on the cell surface. In addition, the CD33 / CD3 binding proteins described herein not only exhibit strong CD33 and CD3 binding affinity for human proteins, but also exhibit strong CD33 and CD3 binding affinity for human proteins, e.g., human:cynomolgus K D Furthermore, the CD33 / CD3 binding proteins described herein also exhibit excellent cross-reactivity with the corresponding cynomolgus monkey proteins, with a ratio of 0.5 to 0.2. + In the absence of target cells, they do not induce significant cytokine release, which is an essential element of the safety profile of these molecules. Furthermore, the CD33 / CD3 tandem diabodies described herein belong to a class of molecules with half-lives in the approximate range of 8 to 24 hours, which should allow for convenient dosing.

[0008] In one aspect, provided herein is a CD33 binding protein that specifically binds to an epitope of human CD33. In some embodiments, the binding protein comprises a heavy chain variable domain and a light chain variable domain derived from a human.

[0009] In some embodiments, the CD33 binding protein has at least one binding site comprising a light chain variable domain and a heavy chain variable domain, wherein the light chain variable domain comprises a CDR1 consisting of a sequence selected from the group consisting of SEQ ID NOs:21-27, a CDR2 consisting of a sequence selected from the group consisting of SEQ ID NOs:28-34, and a CDR3 consisting of a sequence in the group consisting of SEQ ID NOs:35-41.

[0010] In some embodiments, the CD33 binding protein has at least one binding site comprising a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain comprises a CDR1 consisting of a sequence selected from the group consisting of SEQ ID NOs:42-48, a CDR2 consisting of a sequence selected from the group consisting of SEQ ID NOs:49-55, and a CDR3 selected from the group consisting of SEQ ID NOs:56-63.

[0011] In one example, CDR1, CDR2, and CDR3 of the light chain variable domain are selected from the group consisting of SEQ ID NOs: 21, 28, and 35; SEQ ID NOs: 22, 29, and 36; SEQ ID NOs: 23, 30, and 37; SEQ ID NOs: 24, 31, and 38; SEQ ID NOs: 25, 32, and 39; SEQ ID NOs: 26, 33, and 40; and SEQ ID NOs: 27, 34, and 41.

[0012] In one example, CDR1, CDR2 and CD3 of the heavy chain variable domain are selected from the group consisting of SEQ ID NOs: 42, 49 and 56; SEQ ID NOs: 43, 50 and 57; SEQ ID NOs: 43, 50 and 58; SEQ ID NOs: 43, 50 and 59; SEQ ID NOs: 43, 50 and 60; SEQ ID NOs: 44, 51 and 61; SEQ ID NOs: 45, 52 and 62; SEQ ID NOs: 46, 53 and 63; SEQ ID NOs: 47, 54 and 63; and SEQ ID NOs: 48, 55 and 63.

[0013] In one example, the human CD33 binding sites of the variable heavy chain domain and the variable light chain domain are selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:11; SEQ ID NO:2 and SEQ ID NO:12; SEQ ID NO:3 and SEQ ID NO:13; SEQ ID NO:4 and SEQ ID NO:14; SEQ ID NO:5 and SEQ ID NO:15; SEQ ID NO:6 and SEQ ID NO:16; SEQ ID NO:7 and SEQ ID NO:17; SEQ ID NO:8 and SEQ ID NO:18; SEQ ID NO:9 and SEQ ID NO:19; and SEQ ID NO:10 and SEQ ID NO:20.

[0014] In some embodiments, the CD33 epitope is the epitope of human CD33. 62 DQEVQEETQ 70 (SEQ ID NO:94) (amino acid residues 62-70 of SEQ ID NO:93).

[0015] In any of the above embodiments, the CD33 binding protein comprises at least one additional functional domain. In some examples, the functional domain is an effector domain that binds to an effector cell. In one example, the effector domain is a CD3 binding site that includes at least one antibody variable heavy chain domain and at least one variable light chain domain that form an antigen-binding site for human CD3.

[0016] In one example, the CD3 binding site comprises a heavy chain variable domain comprising the CDR1 sequence of STYAMN (SEQ ID NO:72), the CDR2 sequence of RIRSKYNNYATYYADSVKD (SEQ ID NO:73), and the CDR3 sequence of HGNFGNSYVSWFAY (SEQ ID NO:74). In another example, the CD3 binding site comprises a light chain variable domain comprising the CDR1 sequence of RSSTGAVTTSNYAN (SEQ ID NO:90), the CDR2 sequence of GTNKRAP (SEQ ID NO:91), and the CDR3 sequence of ALWYSNL (SEQ ID NO:92).

[0017] In some examples, the CD3 binding site comprises a heavy chain variable domain of SEQ ID NO:64 and a variable light chain domain of SEQ ID NO:68; a heavy chain variable domain of SEQ ID NO:65 and a variable light chain domain of SEQ ID NO:69; a heavy chain variable domain of SEQ ID NO:66 and a variable light chain domain of SEQ ID NO:70; or a heavy chain variable domain of SEQ ID NO:67 and a variable light chain domain of SEQ ID NO:71.

[0018] In any of the above embodiments, the CD33 binding protein is a dimeric protein. In any of the above embodiments, the CD33 binding protein is multifunctional.

[0019] In one example, the multifunctional CD33 binding protein has dual specificity for CD33 and CD3, and the binding specificities are SEQ ID NOs: 2, 12, 65 and 69; SEQ ID NOs: 3, 13, 65 and 69; SEQ ID NOs: 4, 14, 65 and 69; SEQ ID NOs: 5, 15, 65 and 69; SEQ ID NOs: 1, 11, 64 and 68; SEQ ID NOs: 2, 12, 64 and 68; SEQ ID NOs: 2, 12, 66 and 70; SEQ ID NOs: 4, 14, 66 and 70; SEQ ID NOs: 5, 15, 66 and 70; SEQ ID NOs: 3, 13, 64 and 68; SEQ ID NOs: 3, 13, 67 and 71; SEQ ID NOs: 4, 14, 64 and 68; SEQ ID NOs: 5, 15, 64 and 68; SEQ ID SEQ ID NOs:7, 17, 64 and 68; SEQ ID NOs:6, 16, 64 and 68; SEQ ID NOs:6, 16, 67 and 71; SEQ ID NOs:8, 18, 64 and 68; SEQ ID NOs:9, 19, 64 and 68; SEQ ID NOs:9, 19, 67 and 71; and heavy and light chain variable domains for CD33 and CD3 selected from the group consisting of SEQ ID NOs:10, 20, 64 and 68.

[0020] In another aspect, provided herein are bispecific antigen-binding tandem diabodies specific for human CD3 and human CD33. In some embodiments, the tandem diabody comprises a first polypeptide and a second polypeptide, each polypeptide having at least four sequentially linked variable chain domains, each polypeptide comprising a variable heavy chain domain specific for human CD33, a variable light chain domain specific for human CD33, a variable heavy chain domain specific for human CD3, and a variable light chain domain specific for human CD3, wherein in each polypeptide, the four variable chain domains are VL(CD3) -L1-VH(CD33)-L2-VL(CD33)-L3-VH(CD3); VH(CD3)-L1-VL(CD33)-L2-VH(CD33)-L3-VL(CD3); VL(CD33)-L1-VH(CD3)-L2-VL(CD3)-L3-VH(CD33); or VH(CD33)-L1-VL(CD3)-L2-VH(CD3)-L3-VL(CD33), linked sequentially by peptide linkers L1, L2, and L3.

[0021] In some embodiments, the VL domain specific for human CD33 comprises a CDR1 consisting of a sequence selected from the group consisting of SEQ ID NOs:21-27, a CDR2 consisting of a sequence selected from the group consisting of SEQ ID NOs:28-34, and a CDR3 consisting of a sequence from the group consisting of SEQ ID NOs:35-41.

[0022] In some embodiments, the VH domain specific for human CD33 comprises a CDR1 consisting of a sequence selected from the group consisting of SEQ ID NOs: 42-48, a CDR2 consisting of a sequence selected from the group consisting of SEQ ID NOs: 49-55, and a CDR3 consisting of a sequence selected from the group consisting of SEQ ID NOs: 56-63.

[0023] In some embodiments, the CDR1, CDR2 and CDR3 of the VL domain specific for human CD33 are sequences selected from the group consisting of SEQ ID NOs: 21, 28 and 35; SEQ ID NOs: 22, 29 and 36; SEQ ID NOs: 23, 30 and 37; SEQ ID NOs: 24, 31 and 38; SEQ ID NOs: 25, 32 and 39; SEQ ID NOs: 26, 33 and 40; and SEQ ID NOs: 27, 34 and 41.

[0024] In some embodiments, the CDR1, CDR2 and CDR3 of the VH domain specific for human CD33 are sequences selected from the group consisting of SEQ ID NOs: 42, 49 and 56; SEQ ID NOs: 43, 50 and 57; SEQ ID NOs: 43, 50 and 58; SEQ ID NOs: 43, 50 and 59; SEQ ID NOs: 43, 50 and 60; SEQ ID NOs: 44, 51 and 61; SEQ ID NOs: 45, 52 and 62; SEQ ID NOs: 46, 53 and 63; SEQ ID NOs: 47, 54 and 63; and SEQ ID NOs: 48, 55 and 63.

[0025] In some embodiments, the CD33-specific VL and VH domains are sequences selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:11; SEQ ID NO:2 and SEQ ID NO:12; SEQ ID NO:3 and SEQ ID NO:13; SEQ ID NO:4 and SEQ ID NO:14; SEQ ID NO:5 and SEQ ID NO:15; SEQ ID NO:6 and SEQ ID NO:16; SEQ ID NO:7 and SEQ ID NO:17; SEQ ID NO:8 and SEQ ID NO:18; SEQ ID NO:9 and SEQ ID NO:19; and SEQ ID NO:10 and SEQ ID NO:20.

[0026] In some embodiments, the VH domain specific for human CD3 comprises the CDR1 sequence of STYAMN (SEQ ID NO:72), the CDR2 sequence of RIRSKYNNYATYYADSVKD (SEQ ID NO:73), and the CDR3 sequence of HGNFGNSYVSWFAY (SEQ ID NO:74) or HGNFGNSYVSYFAY (SEQ ID NO:75).

[0027] In some embodiments, the VL domain specific for human CD3 comprises the CDR1 sequence of RSSTGAVTTSNYAN (SEQ ID NO:90), the CDR2 sequence of GTNKRAP (SEQ ID NO:91), and the CDR3 sequence of ALWYSNL (SEQ ID NO:92).

[0028] In some embodiments, the CD3-specific VL and VH domains are sequences selected from the group consisting of SEQ ID NO:64 and SEQ ID NO:68; SEQ ID NO:65 and SEQ ID NO:69; SEQ ID NO:66 and SEQ ID NO:70; and SEQ ID NO:67 and SEQ ID NO:71.

[0029] In some embodiments, each polypeptide is selected from the group consisting of SEQ ID NOs:2, 12, 65 and 69; SEQ ID NOs:3, 13, 65 and 69; SEQ ID NOs:4, 14, 65 and 69; SEQ ID NOs:5, 15, 65 and 69; SEQ ID NOs:1, 11, 64 and 68; SEQ ID NOs:2, 12, 64 and 68; SEQ ID NOs:2, 12, 66 and 70; SEQ ID NOs:4, 14, 66 and 70; SEQ ID NOs:5, 15, 66 and 70; SEQ ID NOs:3, 13, 64 and 68; SEQ ID NOs:3, 13, 67 and 71; SEQ ID NOs:4, 14, 64 and 68; SEQ ID NOs:5, 15, 64 and 68; SEQ ID NOs:7, 17, 64 and 68; SEQ IDs SEQ ID NOs:6, 16, 64 and 68; SEQ ID NOs:6, 16, 67 and 71; SEQ ID NOs:8, 18, 64 and 68; SEQ ID NOs:9, 19, 64 and 68; SEQ ID NOs:9, 19, 67 and 71; and SEQ ID NOs:10, 20, 64 and 68.

[0030] In some embodiments, linkers L1, L2, and L3 consist of about 12 or fewer amino acid residues. In one example, linkers L1, L2, and L3 are each independently GGSGGS (SEQ ID NO:95), GGSG (SEQ ID NO:96), or GGSGG (SEQ ID NO:97). In other examples, linkers L1 and L3 are GGSGGS (SEQ ID NO:95) and linker L2 is GGSG (SEQ ID NO:96) or GGSGG (SEQ ID NO:97).

[0031] In some embodiments, the bispecific tandem diabody with a C-terminal hexahistidine (6xHis) tag comprises a sequence selected from the group consisting of SEQ ID NOs:98-121. In other embodiments, the bispecific tandem diabody is selected from the group consisting of tandem diabodies 01 (SEQ ID NO:98), 02 (SEQ ID NO:99), 03 (SEQ ID NO:100), 04 (SEQ ID NO:101), 05 (SEQ ID NO:102), 06 (SEQ ID NO:103), 07 (SEQ ID NO:104), 08 (SEQ ID NO:105), 09 (SEQ ID NO:106), 10 (SEQ ID NO:107), 11 (SEQ ID NO:108), 12 (SEQ ID NO:109), 13 (SEQ ID NO:110), 14 (SEQ ID NO:111), 15 (SEQ ID NO:112), 16 (SEQ ID NO:113), 17 (SEQ ID NO:114), 18 (SEQ ID NO:115), 19 (SEQ ID NO:116), 20 (SEQ ID NO:117), 21 (SEQ ID NO:118), 22 (SEQ ID NO:119), 23 (SEQ ID NO:120), 24 (SEQ ID NO:121), 25 (SEQ ID NO:122), 26 (SEQ ID NO:123), 27 (SEQ ID NO:124), 28 (SEQ ID NO:125), 29 (SEQ ID NO:126), 30 (SEQ ID NO:127), 31 (SEQ ID NO:128), 32 (SEQ ID NO:129), 33 (SEQ ID NO:130), 34 (SEQ ID NO:131), 35 (SEQ ID NO:132), 36 (SEQ ID NO:133), 37 (SEQ ID NO:134), 38 (S NO:115), 19 (SEQ ID NO:116), 20 (SEQ ID NO:117), 21 (SEQ ID NO:118), 22 (SEQ ID NO:119), 23 (SEQ ID NO:120), or 24 (SEQ ID NO:121).

[0032] In some embodiments, the bispecific tandem diabody comprises a sequence selected from the group consisting of SEQ ID NOs: 123-146. In other embodiments, the bispecific tandem diabody is selected from the group consisting of tandem diabodies 01 (SEQ ID NO:123), 02 (SEQ ID NO:124), 03 (SEQ ID NO:125), 04 (SEQ ID NO:126), 05 (SEQ ID NO:127), 06 (SEQ ID NO:128), 07 (SEQ ID NO:129), 08 (SEQ ID NO:130), 09 (SEQ ID NO:131), 10 (SEQ ID NO:132), 11 (SEQ ID NO:133), 12 (SEQ ID NO:134), 13 (SEQ ID NO:135), 14 (SEQ ID NO:136), 15 (SEQ ID NO:137), 16 (SEQ ID NO:138), 17 (SEQ ID NO:139), 18 (SEQ ID NO:140), 19 (SEQ ID NO:141), 20 (SEQ ID NO:142), 21 (SEQ ID NO:143), 22 (SEQ ID NO:144), 23 (SEQ ID NO:145), 24 (SEQ ID NO:146), 25 (SEQ ID NO:147), 26 (SEQ ID NO:148), 27 (SEQ ID NO:149), 29 (SEQ ID NO:150), 30 (SEQ ID NO:151), 31 (SEQ ID NO:152), 32 (SEQ ID NO:153), 33 (SEQ ID NO:154), 34 (SEQ ID NO:155), 35 (SEQ ID NO:156), 36 (SEQ ID NO:157), 37 (SEQ ID NO:158), 38 (SEQ ID NO:159), 39 In some embodiments, the bispecific tandem diabody is tandem diabody 01 (SEQ ID NO: 123). In some embodiments, the bispecific tandem diabody is tandem diabody 02 (SEQ ID NO: 124). In some embodiments, the bispecific tandem diabody is tandem diabody 03 (SEQ ID NO: 125). In some embodiments, the bispecific tandem diabody is tandem diabody 04 (SEQ ID NO: 126). In some embodiments, the bispecific tandem diabody is tandem diabody 05 (SEQ ID NO: 127). In some embodiments, the bispecific tandem diabody is tandem diabody 06 (SEQ ID NO: 128). In some embodiments, the bispecific tandem diabody is tandem diabody 07 (SEQ ID NO: 129).In some embodiments, the bispecific tandem diabody is tandem diabody 08 (SEQ ID NO: 130). In some embodiments, the bispecific tandem diabody is tandem diabody 09 (SEQ ID NO: 131). In some embodiments, the bispecific tandem diabody is tandem diabody 10 (SEQ ID NO: 132). In some embodiments, the bispecific tandem diabody is tandem diabody 11 (SEQ ID NO: 133). In some embodiments, the bispecific tandem diabody is tandem diabody 12 (SEQ ID NO: 134). In some embodiments, the bispecific tandem diabody is tandem diabody 13 (SEQ ID NO: 135). In some embodiments, the bispecific tandem diabody is tandem diabody 14 (SEQ ID NO: 136). In some embodiments, the bispecific tandem diabody is tandem diabody 15 (SEQ ID NO: 137). In some embodiments, the bispecific tandem diabody is tandem diabody 16 (SEQ ID NO: 138). In some embodiments, the bispecific tandem diabody is tandem diabody 17 (SEQ ID NO: 139). In some embodiments, the bispecific tandem diabody is tandem diabody 18 (SEQ ID NO: 140). In some embodiments, the bispecific tandem diabody is tandem diabody 19 (SEQ ID NO: 141). In some embodiments, the bispecific tandem diabody is tandem diabody 20 (SEQ ID NO: 142). In some embodiments, the bispecific tandem diabody is tandem diabody 21 (SEQ ID NO: 143). In some embodiments, the bispecific tandem diabody is tandem diabody 22 (SEQ ID NO: 144). In some embodiments, the bispecific tandem diabody is tandem diabody 23 (SEQ ID NO: 145).In some embodiments, the bispecific tandem diabody is tandem diabody 24 (SEQ ID NO:146).

[0033] In some embodiments, the bispecific antigen-binding tandem diabody is a CD33 antibody selected from HL-60, KG-1, and U-937. + Binding K of 50 nM or less to CD33 on tumor cells D In some embodiments, the bispecific antigen-binding tandem diabody comprises a CD33 antibody selected from HL-60, KG-1, and U-937. + Binding K of 10 nM or less to CD33 on tumor cells D In some embodiments, the bispecific antigen-binding tandem diabody has + Binding K of 15 nM or less to CD33 on HL-60 tumor cells D It has.

[0034] In some embodiments, the bispecific antigen-binding tandem diabody is 62 DQEVQEETQ 70 (SEQ ID NO:94) (amino acid residues 62-70 of SEQ ID NO:93).

[0035] In another aspect, provided herein is a polynucleotide encoding the CD33 binding protein or bispecific tandem diabody of any of the above embodiments. In another aspect, provided herein is a vector comprising the described polynucleotide. In another aspect, provided herein is a host cell transformed with the described vector.

[0036] In yet another aspect, provided herein is a pharmaceutical composition comprising a CD33 binding protein or bispecific tandem diabody of any of the above embodiments and a pharmaceutically acceptable carrier.

[0037] In yet another aspect, provided herein is a method of producing a CD33 binding protein or bispecific tandem diabody of any of the above embodiments, the method comprising introducing a polynucleotide encoding the CD33 binding protein or bispecific tandem diabody of any of the above embodiments or a vector comprising the described polynucleotide into a host cell, culturing the host cell under conditions such that the CD33 binding protein or bispecific tandem diabody is expressed, and purifying the expressed CD33 binding protein or bispecific tandem diabody.

[0038] Furthermore, the bispecific tandem diabody of any of the above embodiments may further comprise a CD33 + CD33, including administration to an individual suffering from cancer + Also provided herein are methods for the treatment of cancer. In some embodiments, CD33 + The cancer is acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), B-cell precursor lymphoblastic leukemia, myeloid sarcoma, multiple myeloma, acute lymphoma, acute lymphoblastic lymphoma, or chronic myelomonocytic leukemia (CMML). In some embodiments, CD33 + The cancer is acute myeloid leukemia (AML). In some embodiments, CD33 + The cancer is multiple myeloma. + The cancer is acute lymphoblastic leukemia (ALL).

[0039] Also provided herein are methods for treating acute myeloid leukemia (AML), comprising administering a bispecific tandem diabody of any of the above embodiments to an individual afflicted with AML. In some embodiments, the AML is AML with a recurrent genetic abnormality, AML with myelodysplasia-associated changes, therapy-related myeloid neoplasm, myeloid sarcoma, myeloproliferation associated with Down's syndrome, blastic plasmacytoid dendritic cell neoplasm, or AML not otherwise classified. In some embodiments, the AML is AML-M0, AML-M1, AML-M2, AML-M3, AML-M4, AML-M5, AML-M6, or AML-M7. In further embodiments, the AML is newly diagnosed, relapsed, or refractory.

[0040] Further provided herein is a method for the treatment of myeloid dysplastic syndrome (MDS), comprising administration of a bispecific tandem diabody of any of the above embodiments to an individual suffering from MDS.

[0041] Further provided herein is a method for the treatment of a myeloproliferative disorder (MPD) comprising administering a bispecific tandem diabody of any of the above embodiments to an individual suffering from an MPD.

[0042] Further provided herein is a method for the treatment of chronic myelomonocytic leukemia (CMML), comprising administration of a bispecific tandem diabody of any of the above embodiments to an individual afflicted with CMML.

[0043] Further provided herein is a method for the treatment of myeloid-derived suppressor cell (MDSC)-mediated immunosuppression comprising administering a bispecific tandem diabody of any of the above embodiments to an individual suffering from immunosuppression.

[0044] In certain embodiments of the above-described methods for treatment, the method further comprises administering cytarabine, azacitidine, decitabine, anthracyclines (e.g., daunorubicin, idarubicin, doxorubicin, etc.), amsacrine, fludarabine, clofarabine, cladribine, nelarabine, methotrexate, bortezomib, carfilzomib, melphalan, ibrutinib, thalidomide, lenalidomide, pomalidomide, apremilast, epipodophyllotoxins (e.g., etoposide, teniposide, etc.), anthracenediones (e.g., mitoxantrone, pixantrone, losoxantrone, piroxantrone, amethantrone, etc.), anti-CD20 agents (e.g., rituximab, ocrelizumab, ofatumumab, etc.), or combinations thereof.

[0045] Provided herein are methods for treating acute myeloid leukemia (AML) in patients undergoing hematopoietic stem cell transplantation, the methods comprising administering a therapeutically effective amount of a protein that binds to human CD33 and human CD3. In some embodiments, the methods are provided wherein the transplant is allogeneic. In some embodiments, the methods are provided wherein the transplant is autologous. In some embodiments, the methods are provided wherein the patient does not undergo a conditioning regimen. In some embodiments, the methods are provided wherein the method further comprises administering a conditioning regimen to the patient. In some embodiments, the methods are provided wherein the conditioning regimen is myeloablative. In some embodiments, the methods are provided wherein the conditioning regimen is non-myeloablative.

[0046] In any of the above embodiments, the method is provided wherein the protein is administered after conditioning therapy. In any of the above embodiments, the method is provided wherein the patient is in complete remission. In any of the above embodiments, the method is provided wherein the patient has minimal residual disease. In any of the above embodiments, the method is provided wherein the patient has failed chemotherapy or radiation. In any of the above embodiments, the method is provided wherein the patient has failed induction chemotherapy. In any of the above embodiments, the method is provided wherein the patient has failed consolidation or maintenance (post-remission) chemotherapy.

[0047] In any of the above embodiments, the method is provided wherein the AML is relapsed. In any of the above embodiments, the method is provided wherein the AML is refractory. In any of the above embodiments, the method is provided wherein the AML is high-risk and in remission. In any of the above embodiments, the method is provided wherein the protein is administered immediately after hematopoietic stem cell transplantation. In any of the above embodiments, the method is provided wherein the protein is administered 3 days after hematopoietic stem cell transplantation. In any of the above embodiments, the method is provided wherein the protein is administered 7 days after hematopoietic stem cell transplantation. In any of the above embodiments, the method is provided wherein the protein is administered 2 weeks after hematopoietic stem cell transplantation. In any of the above embodiments, the method is provided wherein the protein is administered 4 weeks after hematopoietic stem cell transplantation. In any of the above embodiments, the method is provided wherein the protein is administered for a period selected from the group consisting of 4 weeks, 8 weeks, 3 months, 4 months, 6 months, 8 months, 10 months, 12 months, 18 months, and 24 months. In any of the above embodiments, the method is provided wherein the protein is administered at the time of disease progression in an allogeneic setting with donor lymphocytes. In any of the above embodiments, a method is provided wherein the protein is administered at the time of disease progression in an allogeneic setting without donor lymphocytes.

[0048] In any of the above embodiments, the method is provided wherein the protein comprises human CD33 and heavy and light chain domains specific for human CD3. In any of the above embodiments, the method is provided wherein the protein is an antibody or an antibody derivative. In any of the above embodiments, the method is provided wherein the protein comprises a Fab, Fab', or F(ab')2 fragment. In any of the above embodiments, the method is provided wherein the protein is a single-chain Fv, tandem single-chain Fv, bispecific T-cell engager, dual-affinity retargeting antibody, diabody, or bispecific tandem diabody. In any of the above embodiments, the method is provided wherein the protein is a bispecific tandem diabody. In any of the above embodiments, a method is provided, wherein the tandem diabody comprises a first polypeptide and a second polypeptide, each polypeptide having at least four sequentially linked variable chain domains, wherein each polypeptide comprises a variable heavy chain (VH) domain specific for human CD33; a variable light chain (VL) domain specific for human CD33; a VH domain specific for human CD3, and a VL domain specific for human CD3. In any of the above embodiments, a method is provided, wherein in each polypeptide, the four variable chain domains are sequentially linked by peptide linkers L1, L2, and L3 in the order of VL(CD3)-L1-VH(CD33)-L2-VL(CD33)-L3-VH(CD3); VH(CD3)-L1-VL(CD33)-L2-VH(CD33)-L3-VL(CD3); VL(CD33)-L1-VH(CD3)-L2-VL(CD3)-L3-VH(CD33); or VH(CD33)-L1-VL(CD3)-L2-VH(CD3)-L3-VL(CD33). In any of the above embodiments, the method is provided, wherein the VL domain specific for human CD33 comprises a CDR1 consisting of a sequence selected from the group consisting of SEQ ID NOs: 21 to 27, a CDR2 consisting of a sequence selected from the group consisting of SEQ ID NOs: 28 to 34, and a CDR3 consisting of a sequence in the group consisting of SEQ ID NOs: 35 to 41.

[0049] In any of the above embodiments, a method is provided, wherein the VH domain specific for human CD33 comprises a CDR1 consisting of a sequence selected from the group consisting of SEQ ID NOs: 42 to 48, a CDR2 consisting of a sequence selected from the group consisting of SEQ ID NOs: 49 to 55, and a CDR3 consisting of a sequence selected from the group consisting of SEQ ID NOs: 56 to 63. In any of the above embodiments, a method is provided, wherein the CDR1, CDR2, and CDR3 of the VL domain specific for human CD33 are sequences selected from the group consisting of SEQ ID NOs: 21, 28, and 35; SEQ ID NOs: 22, 29, and 36; SEQ ID NOs: 23, 30, and 37; SEQ ID NOs: 24, 31, and 38; SEQ ID NOs: 25, 32, and 39; SEQ ID NOs: 26, 33, and 40; and SEQ ID NOs: 27, 34, and 41. In any of the above embodiments, there is provided a method, wherein the CDR1, CDR2 and CDR3 of the VH domain specific for CD33 are sequences selected from the group consisting of SEQ ID NOs: 42, 49 and 56; SEQ ID NOs: 43, 50 and 57; SEQ ID NOs: 43, 50 and 58; SEQ ID NOs: 43, 50 and 59; SEQ ID NOs: 43, 50 and 60; SEQ ID NOs: 44, 51 and 61; SEQ ID NOs: 45, 52 and 62; SEQ ID NOs: 46, 53 and 63; SEQ ID NOs: 47, 54 and 63; and SEQ ID NOs: 48, 55 and 63.In any of the above embodiments, a method is provided, wherein the CD33-specific VL and VH domains are sequences selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:11; SEQ ID NO:2 and SEQ ID NO:12; SEQ ID NO:3 and SEQ ID NO:13; SEQ ID NO:4 and SEQ ID NO:14; SEQ ID NO:5 and SEQ ID NO:15; SEQ ID NO:6 and SEQ ID NO:16; SEQ ID NO:7 and SEQ ID NO:17; SEQ ID NO:8 and SEQ ID NO:18; SEQ ID NO:9 and SEQ ID NO:19; and SEQ ID NO:10 and SEQ ID NO:20. In any of the above embodiments, a method is provided, wherein the VH domain specific for human CD3 comprises the CDR1 sequence of STYAMN (SEQ ID NO:72), the CDR2 sequence of RIRSKYNNYATYYADSVKD (SEQ ID NO:73), and the CDR3 sequence of HGNFGNSYVSWFAY (SEQ ID NO:74) or HGNFGNSYVSYFAY (SEQ ID NO:75). In any of the above embodiments, a method is provided, wherein the VL domain specific for human CD3 comprises the CDR1 sequence of RSSTGAVTTSNYAN (SEQ ID NO:90), the CDR2 sequence of GTNKRAP (SEQ ID NO:91), and the CDR3 sequence of ALWYSNL (SEQ ID NO:92). In any of the above embodiments, the method is provided, wherein the CD3-specific VL and VH domains are sequences selected from the group consisting of SEQ ID NO:64 and SEQ ID NO:68; SEQ ID NO:65 and SEQ ID NO:69; SEQ ID NO:66 and SEQ ID NO:70; and SEQ ID NO:67 and SEQ ID NO:71.In any of the above embodiments, the method is provided, wherein each polypeptide is selected from the group consisting of SEQ ID NOs:2, 12, 65 and 69; SEQ ID NOs:3, 13, 65 and 69; SEQ ID NOs:4, 14, 65 and 69; SEQ ID NOs:5, 15, 65 and 69; SEQ ID NOs:1, 11, 64 and 68; SEQ ID NOs:2, 12, 64 and 68; SEQ ID NOs:2, 12, 66 and 70; SEQ ID NOs:4, 14, 66 and 70; SEQ ID NOs:5, 15, 66 and 70; SEQ ID NOs:3, 13, 64 and 68; SEQ ID NOs:3, 13, 67 and 71; SEQ ID NOs:4, 14, 64 and 68; SEQ ID NOs:5, 15, 64 and 68; SEQ ID NOs:7, 17, 64 and 68; SEQ ID and SEQ ID NOs: 10, 20, 64, and 68. In any of the above embodiments, the method is provided, wherein the linkers L1, L2, and L3 consist of about 12 or less amino acid residues. In any of the above embodiments, the method is provided, wherein the linkers L1, L2, and L3 are each independently selected from GGSGGS (SEQ ID NO: 95), GGSG (SEQ ID NO: 96), or GGSGG (SEQ ID NO: 97). In any of the above embodiments, a method is provided, wherein the tandem diabody with a C-terminal hexahistidine (6xHis) tag has a sequence selected from the group consisting of SEQ ID NOs: 98-121.In any of the above embodiments, there is provided a method, wherein the tandem diabody is tandem diabody 01 (SEQ ID NO:98), 02 (SEQ ID NO:99), 03 (SEQ ID NO:100), 04 (SEQ ID NO:101), 05 (SEQ ID NO:102), 06 (SEQ ID NO:103), 07 (SEQ ID NO:104), 08 (SEQ ID NO:105), 09 (SEQ ID NO:106), 10 (SEQ ID NO:107), 11 (SEQ ID NO:108), 12 (SEQ ID NO:109), 13 (SEQ ID NO:110), 14 (SEQ ID NO:111), 15 (SEQ ID NO:112), 16 (SEQ ID NO:113), 17 (SEQ ID NO:114), 18 (SEQ ID NO:115), 19 (SEQ ID NO:116), 20 (SEQ ID NO:117), 21 (SEQ ID NO:118), 22 (SEQ ID NO:119), 23 (SEQ ID NO:120), 24 (SEQ ID NO:121), 25 (SEQ ID NO:122), 26 (SEQ ID NO:123), 27 (SEQ ID NO:124), 28 (SEQ ID NO:125), 29 (SEQ ID NO:126), 30 (SEQ ID NO:127), 31 (SEQ ID NO:128), 32 (SEQ ID NO:129), 33 (SEQ ID NO:130), 34 (SEQ ID NO:131), 35 (SEQ ID NO:132), 36 (SEQ ID NO:133), 37 (SEQ ID NO:134), 38 ( NO:115), 19 (SEQ ID NO:116), 20 (SEQ ID NO:117), 21 (SEQ ID NO:118), 22 (SEQ ID NO:119), 23 (SEQ ID NO:120), or 24 (SEQ ID NO:121).

[0050] In any of the above embodiments, a method is provided wherein the tandem diabody has a sequence selected from the group consisting of SEQ ID NOs: 123-146. In any of the above embodiments, there is provided a method, wherein the tandem diabody is tandem diabody 01 (SEQ ID NO:123), 02 (SEQ ID NO:124), 03 (SEQ ID NO:125), 04 (SEQ ID NO:126), 05 (SEQ ID NO:127), 06 (SEQ ID NO:128), 07 (SEQ ID NO:129), 08 (SEQ ID NO:130), 09 (SEQ ID NO:131), 10 (SEQ ID NO:132), 11 (SEQ ID NO:133), 12 (SEQ ID NO:134), 13 (SEQ ID NO:135), 14 (SEQ ID NO:136), 15 (SEQ ID NO:137), 16 (SEQ ID NO:138), 17 (SEQ ID NO:139), 18 (SEQ ID NO:140), 19 (SEQ ID NO:141), 20 (SEQ ID NO:142), 21 (SEQ ID NO:143), 22 (SEQ ID NO:144), 23 (SEQ ID NO:145), 24 (SEQ ID NO:146), 25 (SEQ ID NO:147), 26 (SEQ ID NO:148), 27 (SEQ ID NO:149), 29 (SEQ ID NO:150), 30 (SEQ ID NO:151), 31 (SEQ ID NO:152), 32 (SEQ ID NO:153), 33 (SEQ ID NO:154), 34 (SEQ ID NO:155), 35 (SEQ ID NO:156), 36 (SEQ ID NO:157), 37 (SEQ ID NO:158), 38 (SEQ ID NO:159), 3 ID NO:140), 19 (SEQ ID NO:141), 20 (SEQ ID NO:142), 21 (SEQ ID NO:143), 22 (SEQ ID NO:144), 23 (SEQ ID NO:145) or 24 (SEQ ID NO:146).

[0051] In any of the above embodiments, a method is provided, further comprising administering cytarabine, azacitidine, decitabine, an anthracycline, fludarabine, clofarabine, cladribine, nelarabine, methotrexate, bortezomib, carfilzomib, melphalan, ibrutinib, thalidomide, lenalidomide, pomalidomide, apremilast, an epipodophyllotoxin, an anthracenedione, an anti-CD20 agent, or a combination thereof. In any of the above embodiments, a method is provided, wherein the AML is AML with a recurrent genetic abnormality, AML with myelodysplasia-associated changes, therapy-related myeloid neoplasm, myeloid sarcoma, myeloid proliferation associated with Down's syndrome, blastic plasmacytoid dendritic cell neoplasm, or AML not otherwise classified. In any of the above embodiments, a method is provided wherein the AML is AML-M0, AML-M1, AML-M2, AML-M3, AML-M4, AML-M5, AML-M6, or AML-M7. In any of the above embodiments, a method is provided wherein administering a protein to patients who have undergone myeloablative conditioning followed by allogeneic hematopoietic stem cell transplantation results in an improved overall response rate to treatment with the protein. In any of the above embodiments, a method is provided wherein administering a protein to patients who have undergone non-myeloablative conditioning followed by allogeneic hematopoietic stem cell transplantation results in an improved overall response rate to treatment with the protein.

[0052] [The present invention 1001] 1. A method for the treatment of acute myeloid leukemia (AML) in a patient who has undergone hematopoietic stem cell transplantation, comprising: The method comprises: A method comprising administering to human CD33 a therapeutically effective amount of a protein that binds to human CD3. [The present invention 1002] 1001. The method of claim 1001, wherein the transplant is allogeneic. [The present invention 1003] The method of claim 1001, wherein the transplant is autologous. [The present invention 1004] The method of any of claims 1001-1003, wherein the patient does not undergo conditioning. [The present invention 1005] The method of any of claims 1001-1003, further comprising the step of administering conditioning treatment to the patient. [The present invention 1006] The method of claim 1005, wherein the transplant conditioning treatment is myeloablative. [The present invention 1007] The method of claim 1005, wherein the transplant conditioning treatment is non-myeloablative. [The present invention 1008] The method of any of claims 1005-1007, wherein the protein is administered after conditioning. [The present invention 1009] The method of any of claims 1001-1008, wherein the patient is in complete remission. [The present invention 1010] The method of any of claims 1001-1008, wherein the patient has minimal residual disease. [The present invention 1011] The method of any of claims 1001-1008, wherein the patient has failed chemotherapy or radiation therapy. [The present invention 1012] The method of any of claims 1001-1008, wherein the patient has failed induction chemotherapy. [The present invention 1013] The method of any of claims 1001-1008, wherein the patient has failed consolidation or maintenance (post-remission) chemotherapy. [The present invention 1014] The method of any of claims 1001-1013, wherein the AML is relapsed. [The present invention 1015] The method of any of claims 1001-1013, wherein the AML is refractory. [The present invention 1016] The method of any of claims 1001-1013, wherein the AML is high risk and in remission. [The present invention 1017] The method of any of claims 1001-1016, wherein the protein is administered immediately after hematopoietic stem cell transplantation. [The present invention 1018] The method of any of claims 1001-1016, wherein the protein is administered three days after hematopoietic stem cell transplantation. [The present invention 1019] The method of any of claims 1001-1016, wherein the protein is administered 7 days after hematopoietic stem cell transplantation. [The present invention 1020] The method of any of claims 1001-1016, wherein the protein is administered two weeks after hematopoietic stem cell transplantation. [The present invention 1021] The method of any of claims 1001-1016, wherein the protein is administered 4 weeks after hematopoietic stem cell transplantation. [The present invention 1022] 10. The method of any of claims 1001-1021, wherein the protein is administered for a period selected from the group consisting of 4 weeks, 8 weeks, 3 months, 4 months, 6 months, 8 months, 10 months, 12 months, 18 months, and 24 months. [The present invention 1023] The method of any of claims 1001-1002, wherein the protein is administered at the time of progression in an allogeneic setting along with donor lymphocytes. [The present invention 1024] The method of any of claims 1001-1002, wherein the protein is administered at the time of progression in an allogeneic setting without donor lymphocytes. [The present invention 1025] The method of any of claims 1001-1024, wherein the protein comprises human CD33 and heavy and light chain domains specific for human CD3. [The present invention 1026] The method of any of claims 1001-1025, wherein the protein is an antibody or a derivative of an antibody. [The present invention 1027] The protein is Fab, Fab', or F(ab') 2 10. The method of any one of claims 1001-1025, comprising a fragment of [The present invention 1028] The method of any of claims 1001-1025, wherein the protein is a single chain Fv, a tandem single chain Fv, a bispecific T cell engager, a dual affinity retargeting antibody, a bispecific antibody, or a bispecific tandem bispecific antibody. [The present invention 1029] The method of any of claims 1001-1025, wherein the protein is a bispecific tandem bispecific antibody. [The present invention 1030] A tandem bispecific antibody comprises a first polypeptide and a second polypeptide, each polypeptide having at least four variable chain domains linked in sequence, wherein each polypeptide comprises: (i) a variable heavy (VH) domain specific for human CD33; (ii) a variable light chain (VL) domain specific for human CD33; (iii) a VH domain specific for human CD3, and (iv) a VL domain specific for human CD3; The method of the present invention 1029, comprising: [The present invention 1031] In each polypeptide, the four variable chain domains are: VL(CD3)-L1-VH(CD33)-L2-VL(CD33)-L3-VH(CD3); VH(CD3)-L1-VL(CD33)-L2-VH(CD33)-L3-VL(CD3); VL(CD33)-L1-VH(CD3)-L2-VL(CD3)-L3-VH(CD33); or VH(CD33)-L1-VL(CD3)-L2-VH(CD3)-L3-VL(CD33) 1030. The method of claim 1030, wherein the amino acids L1, L2 and L3 are successively linked by peptide linkers L1, L2 and L3 in the order: [The present invention 1032] Any of the methods of claims 1029-1031, wherein the VL domain specific to human CD33 comprises a CDR1 consisting of a sequence selected from the group consisting of SEQ ID NOs: 21-27, a CDR2 consisting of a sequence selected from the group consisting of SEQ ID NOs: 28-34, and a CDR3 consisting of a sequence in the group consisting of SEQ ID NOs: 35-41. [The present invention 1033] Any of the methods of claims 1029-1032, wherein the VH domain specific to human CD33 comprises a CDR1 consisting of a sequence selected from the group consisting of SEQ ID NOs: 42-48, a CDR2 consisting of a sequence selected from the group consisting of SEQ ID NOs: 49-55, and a CDR3 consisting of a sequence selected from the group consisting of SEQ ID NOs: 56-63. [The present invention 1034] CDR1, CDR2 and CDR3 of the VL domain specific for human CD33 are (i) SEQ ID NOs: 21, 28 and 35; (ii) SEQ ID NOs: 22, 29 and 36; (iii) SEQ ID NOs: 23, 30 and 37; (iv) SEQ ID NOs: 24, 31 and 38; (v) SEQ ID NO: 25, 32 and 39; (vi) SEQ ID NOs: 26, 33 and 40; and (vii) SEQ ID NOs: 27, 34, and 41 1031-1033. The method of any of claims 1031-1033, wherein the sequence is selected from the group consisting of: [This invention 1035] CDR1, CDR2 and CDR3 of the CD33-specific VH domain are (i) SEQ ID NOs: 42, 49 and 56; (ii) SEQ ID NOs: 43, 50 and 57; (iii) SEQ ID NOs: 43, 50 and 58; (iv) SEQ ID NOs: 43, 50 and 59; (v) SEQ ID NO: 43, 50 and 60; (vi) SEQ ID NOs: 44, 51 and 61; (vii) SEQ ID NOs: 45, 52 and 62; (viii) SEQ ID NOs: 46, 53 and 63; (ix) SEQ ID NOs: 47, 54, and 63; and (x) SEQ ID NOs: 48, 55 and 63 1029-1034, wherein the sequence is selected from the group consisting of: [The present invention 1036] The CD33-specific VL and VH domains are (i) SEQ ID NO:1 and SEQ ID NO:11; (ii) SEQ ID NO:2 and SEQ ID NO:12; (iii) SEQ ID NO:3 and SEQ ID NO:13; (iv) SEQ ID NO:4 and SEQ ID NO:14; (v) SEQ ID NO:5 and SEQ ID NO:15; (vi) SEQ ID NO:6 and SEQ ID NO:16; (vii) SEQ ID NO:7 and SEQ ID NO:17; (viii) SEQ ID NO:8 and SEQ ID NO:18; (ix) SEQ ID NO:9 and SEQ ID NO:19; and (x) SEQ ID NO: 10 and SEQ ID NO: 20 1029-1035. The method of any of claims 1029-1035, wherein the sequence is selected from the group consisting of: [This invention 1037] Any of the methods of claims 1029-1036, wherein the VH domain specific for human CD3 comprises the CDR1 sequence of STYAMN (SEQ ID NO:72), the CDR2 sequence of RIRSKYNNYATYYADSVKD (SEQ ID NO:73), and the CDR3 sequence of HGNFGNSYVSWFAY (SEQ ID NO:74) or HGNFGNSYVSYFAY (SEQ ID NO:75). [The present invention 1038] Any of the methods of claims 1029-1037, wherein the VL domain specific for human CD3 comprises the CDR1 sequence of RSSTGAVTTSNYAN (SEQ ID NO:90), the CDR2 sequence of GTNKRAP (SEQ ID NO:91), and the CDR3 sequence of ALWYSNL (SEQ ID NO:92). [This invention 1039] The CD3-specific VL and VH domains are (i) SEQ ID NO:64 and SEQ ID NO:68; (ii) SEQ ID NO:65 and SEQ ID NO:69; (iii) SEQ ID NO: 66 and SEQ ID NO: 70; and (iv) SEQ ID NO: 67 and SEQ ID NO: 71 1027-1036. The method of any of claims 1027-1036, wherein the sequence is selected from the group consisting of: [The present invention 1040] Each polypeptide is (i) SEQ ID NOs: 2, 12, 65 and 69; (ii) SEQ ID NOs: 3, 13, 65 and 69; (iii) SEQ ID NOs: 4, 14, 65 and 69; (iv) SEQ ID NOs: 5, 15, 65 and 69; (v) SEQ ID NOs: 1, 11, 64 and 68; (vi) SEQ ID NOs: 2, 12, 64 and 68; (vii) SEQ ID NOs: 2, 12, 66 and 70; (viii) SEQ ID NOs: 4, 14, 66 and 70; (ix) SEQ ID NOs: 5, 15, 66 and 70; (x) SEQ ID NO: 3, 13, 64 and 68; (xi) SEQ ID NOs: 3, 13, 67 and 71; (xii) SEQ ID NOs: 4, 14, 64 and 68; (xiii) SEQ ID NOs: 5, 15, 64 and 68; (xiv) SEQ ID NOs: 7, 17, 64 and 68; (xv) SEQ ID NOs: 6, 16, 64 and 68; (xvi) SEQ ID NOs: 6, 16, 67 and 71; (xvii) SEQ ID NOs: 8, 18, 64 and 68; (xviii) SEQ ID NOs: 9, 19, 64 and 68; (xix) SEQ ID NOs: 9, 19, 67 and 71; and (xx) SEQ ID NOs: 10, 20, 64 and 68 1029. The method of any of claims 1029-1039, comprising four variable chain domains selected from the group consisting of: [This invention 1041] The method of any of claims 1029-1040, wherein linkers L1, L2 and L3 consist of about 12 or less amino acid residues. [The present invention 1042] 1029-1041. The method of any of claims 1029-1041, wherein linkers L1, L2, and L3 are each independently selected from GGSGGS (SEQ ID NO:95), GGSG (SEQ ID NO:96), or GGSGG (SEQ ID NO:97). [This invention 1043] The method of any of claims 1029-1042, wherein the tandem bispecific antibody comprises a sequence selected from the group consisting of SEQ ID NOs: 98-121. [This invention 1044] The tandem bispecific antibodies are tandem bispecific antibodies 01 (SEQ ID NO:98), 02 (SEQ ID NO:99), 03 (SEQ ID NO:100), 04 (SEQ ID NO:101), 05 (SEQ ID NO:102), 06 (SEQ ID NO:103), 07 (SEQ ID NO:104), 08 (SEQ ID NO:105), 09 (SEQ ID NO:106), 10 (SEQ ID NO:107), 11 (SEQ ID NO:108), 12 (SEQ ID NO:109), 13 (SEQ ID NO:110), 14 (SEQ ID NO:111), 15 (SEQ ID NO:112), 16 (SEQ ID NO:113), 17 (SEQ ID NO:114), 18 (SEQ ID NO:115), 19 (SEQ ID NO:116), 20 (SEQ ID NO:117), 21 (SEQ ID NO:118), 22 (SEQ ID NO:119), 23 (SEQ ID NO:120), 24 (SEQ ID NO:121), 25 (SEQ ID NO:122), 26 (SEQ ID NO:123), 27 (SEQ ID NO:124), 28 (SEQ ID NO:125), 29 (SEQ ID NO:126), 30 (SEQ ID NO:127), 31 (SEQ ID NO:128), 32 (SEQ ID NO:129), 33 (SEQ ID NO:130), 34 (SEQ ID NO:131), 35 (SEQ ID NO:132), 36 (SEQ ID NO:133), 37 (SEQ ID NO:134), 38 (SEQ ID NO:135), 39 (S 1029-1043, wherein the method of any of claims 1029-1043 is ... [This invention 1045] The method of any of claims 1029-1042, wherein the tandem bispecific antibody comprises a sequence selected from the group consisting of SEQ ID NOs: 123-146. [The present invention 1046] The tandem bispecific antibodies are tandem bispecific antibodies 01 (SEQ ID NO: 123), 02 (SEQ ID NO: 124), 03 (SEQ ID NO: 125), 04 (SEQ ID NO: 126), 05 (SEQ ID NO: 127), 06 (SEQ ID NO: 128), 07 (SEQ ID NO: 129), 08 (SEQ ID NO: 130), 09 (SEQ ID NO: 131), 10 (SEQ ID NO: 132), 11 (SEQ ID NO: 133), 12 (SEQ ID NO: 134), 13 (SEQ ID NO: 135), 14 (SEQ ID NO: 136), 15 (SEQ ID NO: 137), 16 (SEQ ID NO: 138), 17 (SEQ ID NO: 139), 18 (SEQ ID NO: 140), 19 (SEQ ID NO: 141), 20 (SEQ ID NO: 142), 21 (SEQ ID NO: 143), 22 (SEQ ID NO: 144), 23 (SEQ ID NO: 145), 24 (SEQ ID NO: 146), 25 (SEQ ID NO: 147), 26 (SEQ ID NO: 148), 27 (SEQ ID NO: 149), 29 (SEQ ID NO: 150), 30 (SEQ ID NO: 151), 31 (SEQ ID NO: 152), 32 (SEQ ID NO: 153), 33 (SEQ ID NO: 154), 34 (SEQ ID NO: 155), 35 (SEQ ID NO: 156), 36 (SEQ ID NO: 157), 37 (SEQ ID The method of any of claims 1029-1042 and 1045, wherein the compound is selected from the group consisting of 1 (SEQ ID NO: 140), 19 (SEQ ID NO: 141), 20 (SEQ ID NO: 142), 21 (SEQ ID NO: 143), 22 (SEQ ID NO: 144), 23 (SEQ ID NO: 145) and 24 (SEQ ID NO: 146). [This invention 1047] Any of the methods of claims 1001-1046, wherein the method further comprises administering cytarabine, azacitidine, decitabine, an anthracycline, fludarabine, clofarabine, cladribine, nelarabine, methotrexate, bortezomib, carfilzomib, melphalan, ibrutinib, thalidomide, lenalidomide, pomalidomide, apremilast, epipodophyllotoxin, an anthracenedione, an anti-CD20 agent, or a combination thereof. [This invention 1048] Any of the methods of inventions 1001-1047, wherein the AML is AML with a recurrent genetic abnormality, AML with myelodysplasia-associated changes, therapy-related myeloid neoplasm, myeloid sarcoma, myeloproliferation associated with Down's syndrome, blastic plasmacytoid dendritic cell neoplasm, or otherwise unclassified AML. [This invention 1049] A The method of any of claims 1001-1048, wherein ML is AML-M0, AML-M1, AML-M2, AML-M3, AML-M4, AML-M5, AML-M6, or AML-M7. [The present invention 1050] Any of the methods of claims 1001-1049, wherein administering the protein results in an improved overall response rate to protein treatment in patients who have undergone myeloablative conditioning followed by an allogeneic hematopoietic stem cell transplant. [This invention 1051] Any of the methods of claims 1001-1049, wherein administering the protein results in an improved overall response rate to protein treatment in patients undergoing an allogeneic hematopoietic stem cell transplant after non-myeloablative conditioning. [This invention 1052] A bispecific antigen-binding tandem bispecific antibody specific for human CD33 and human CD3, wherein the bispecific antigen-binding tandem bispecific antibody comprises a sequence selected from SEQ ID NOs: 123-146. [This invention 1053] The bispecific antigen-binding tandem bispecific antibodies include tandem bispecific antibodies 01 (SEQ ID NO: 123), 02 (SEQ ID NO: 124), 03 (SEQ ID NO: 125), 04 (SEQ ID NO: 126), 05 (SEQ ID NO: 127), 06 (SEQ ID NO: 128), 07 (SEQ ID NO: 129), 08 (SEQ ID NO: 130), 09 (SEQ ID NO: 131), 10 (SEQ ID NO: 132), 11 (SEQ ID NO: 133), 12 (SEQ ID NO: 134), 13 (SEQ ID NO: 135), 14 (SEQ ID NO: 136), 15 (SEQ ID NO: 137), 16 (SEQ ID NO: 138), 17 (SEQ ID NO: 139), 18 (SEQ ID NO: 140), 19 (SEQ ID NO: 141), 20 (SEQ ID NO: 142), 21 (SEQ ID NO: 143), 22 (SEQ ID NO: 144), 23 (SEQ ID NO: 145), 24 (SEQ ID NO: 146), 25 (SEQ ID NO: 147), 26 (SEQ ID NO: 148), 27 (SEQ ID NO: 149), 29 (SEQ ID NO: 150), 30 (SEQ ID NO: 151), 31 (SEQ ID NO: 152), 32 (SEQ ID NO: 153), 33 (SEQ ID NO: 154), 34 (SEQ ID NO: 155), 35 (SEQ ID NO: 156), 36 (SEQ ID NO: 157), 3 1052. A bispecific antigen-binding tandem bispecific antibody of the present invention, wherein the antibody is selected from the group consisting of: 19 (SEQ ID NO: 141), 20 (SEQ ID NO: 142), 21 (SEQ ID NO: 143), 22 (SEQ ID NO: 144), 23 (SEQ ID NO: 145) and 24 (SEQ ID NO: 146). [This invention 1054] The bispecific antigen-binding tandem bispecific antibodies were selected from HL-60, KG-1, and U-937 to identify CD33 + Binding K of 50 nM or less to CD33 on tumor cells D 1053. A bispecific antigen-binding tandem bispecific antibody of the present invention, comprising: [This invention 1055] Dual-specific antigen binding tandem bispecific antibodies target CD33 + Binding K of 15 nM or less to CD33 on HL-60 tumor cells D 1054. A bispecific antigen-binding tandem bispecific antibody of the present invention, comprising: [This invention 1056] Bispecific antigen-binding tandem bispecific antibodies targeting human CD33 62 DQEVQEETQ 70 A bispecific antigen-binding tandem bispecific antibody of the present invention 1055 that specifically binds to an epitope of human CD33 within (SEQ ID NO:94) (amino acid residues 62-70 of SEQ ID NO:93). [This invention 1057] 1052-1056. The bispecific antigen-binding tandem bispecific antibody of any of claims 1052-1056, wherein the bispecific antigen-binding tandem bispecific antibody is tandem bispecific antibody 01 (SEQ ID NO: 123). [This invention 1058] 1052-1056. The bispecific antigen-binding tandem bispecific antibody of any of claims 1052-1056, wherein the bispecific antigen-binding tandem bispecific antibody is tandem bispecific antibody 02 (SEQ ID NO: 124). [This invention 1059] 1052-1056. The bispecific antigen-binding tandem bispecific antibody of any of claims 1052-1056, wherein the bispecific antigen-binding tandem bispecific antibody is tandem bispecific antibody 03 (SEQ ID NO: 125). [The present invention 1060] 1052-1056. The bispecific antigen-binding tandem bispecific antibody of any of claims 1052-1056, wherein the bispecific antigen-binding tandem bispecific antibody is tandem bispecific antibody 04 (SEQ ID NO: 126). [This invention 1061] 1052-1056. The bispecific antigen-binding tandem bispecific antibody of any of claims 1052-1056, wherein the bispecific antigen-binding tandem bispecific antibody is tandem bispecific antibody 05 (SEQ ID NO: 127). [This invention 1062] 1052-1056. The bispecific antigen-binding tandem bispecific antibody of any of claims 1052-1056, wherein the bispecific antigen-binding tandem bispecific antibody is tandem bispecific antibody 06 (SEQ ID NO: 128). [This invention 1063] 1052-1056. The bispecific antigen-binding tandem bispecific antibody of any of claims 1052-1056, wherein the bispecific antigen-binding tandem bispecific antibody is tandem bispecific antibody 07 (SEQ ID NO: 129). [This invention 1064] 1052-1056. The bispecific antigen-binding tandem bispecific antibody of any of claims 1052-1056, wherein the bispecific antigen-binding tandem bispecific antibody is tandem bispecific antibody 08 (SEQ ID NO: 130). [This invention 1065] 1052-1056. The bispecific antigen-binding tandem bispecific antibody of any of claims 1052-1056, wherein the bispecific antigen-binding tandem bispecific antibody is tandem bispecific antibody 09 (SEQ ID NO: 131). [The present invention 1066] 1052-1056. The bispecific antigen-binding tandem bispecific antibody of any of claims 1052-1056, wherein the bispecific antigen-binding tandem bispecific antibody is tandem bispecific antibody 10 (SEQ ID NO: 132). [This invention 1067] 1052-1056. The bispecific antigen-binding tandem bispecific antibody of any of claims 1052-1056, wherein the bispecific antigen-binding tandem bispecific antibody is tandem bispecific antibody 11 (SEQ ID NO: 133). [The present invention 1068] 1052-1056. The bispecific antigen-binding tandem bispecific antibody of any of claims 1052-1056, wherein the bispecific antigen-binding tandem bispecific antibody is tandem bispecific antibody 12 (SEQ ID NO: 134). [The present invention 1069] 1052-1056. The bispecific antigen-binding tandem bispecific antibody of any of claims 1052-1056, wherein the bispecific antigen-binding tandem bispecific antibody is tandem bispecific antibody 13 (SEQ ID NO: 135). [The present invention 1070] 1052-1056. The bispecific antigen-binding tandem bispecific antibody of any of claims 1052-1056, wherein the bispecific antigen-binding tandem bispecific antibody is tandem bispecific antibody 14 (SEQ ID NO: 136). [This invention 1071] 1052-1056. The bispecific antigen-binding tandem bispecific antibody of any of claims 1052-1056, wherein the bispecific antigen-binding tandem bispecific antibody is tandem bispecific antibody 15 (SEQ ID NO: 137). [This invention 1072] 1052-1056. The bispecific antigen-binding tandem bispecific antibody of any of claims 1052-1056, wherein the bispecific antigen-binding tandem bispecific antibody is tandem bispecific antibody 16 (SEQ ID NO: 138). [This invention 1073] 1052-1056. The bispecific antigen-binding tandem bispecific antibody of any of claims 1052-1056, wherein the bispecific antigen-binding tandem bispecific antibody is tandem bispecific antibody 17 (SEQ ID NO: 139). [This invention 1074] 1052-1056. The bispecific antigen-binding tandem bispecific antibody of any of claims 1052-1056, wherein the bispecific antigen-binding tandem bispecific antibody is tandem bispecific antibody 18 (SEQ ID NO: 140). [This invention 1075] 1052-1056. The bispecific antigen-binding tandem bispecific antibody of any of claims 1052-1056, wherein the bispecific antigen-binding tandem bispecific antibody is tandem bispecific antibody 19 (SEQ ID NO: 141). [This invention 1076] 1052-1056. The bispecific antigen-binding tandem bispecific antibody of any of claims 1052-1056, wherein the bispecific antigen-binding tandem bispecific antibody is tandem bispecific antibody 20 (SEQ ID NO: 142). [This invention 1077] 1052-1056. The bispecific antigen-binding tandem bispecific antibody of any of claims 1052-1056, wherein the bispecific antigen-binding tandem bispecific antibody is tandem bispecific antibody 21 (SEQ ID NO: 143). [This invention 1078] 1052-1056. The bispecific antigen-binding tandem bispecific antibody of any of claims 1052-1056, wherein the bispecific antigen-binding tandem bispecific antibody is tandem bispecific antibody 22 (SEQ ID NO: 144). [This invention 1079] 1052-1056. The bispecific antigen-binding tandem bispecific antibody of any of claims 1052-1056, wherein the bispecific antigen-binding tandem bispecific antibody is tandem bispecific antibody 23 (SEQ ID NO: 145). [The present invention 1080] 1052-1056. The bispecific antigen-binding tandem bispecific antibody of any of claims 1052-1056, wherein the bispecific antigen-binding tandem bispecific antibody is tandem bispecific antibody 24 (SEQ ID NO: 146). <Incorporated by reference> All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. [Brief explanation of the drawings]

[0053] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings.

[0054] [Figure 1]

[0023] Figure 1 is a schematic diagram of the genetic organization and domain order of the CD3 / CD33 tandem diabody (TandAb®). The tandem diabody is expressed as a single polypeptide composed of four variable domains connected by short peptide linkers L1, L2, and L3. After expression, the two monomeric polypeptides non-covalently associate head-to-tail to form a functional homodimeric tandem diabody molecule. L1, L2, L3: linker; VH: heavy chain variable domain; VL: light chain variable domain. [Figure 2] CD3-binding tandem diabodies and their mechanism of action. Tandem diabodies are tetravalent, bispecific proteins that can bind cytotoxic T cells via binding to CD3. Tandem diabodies bind to CD33+ tumor cells with two of their four binding domains and to CD3 with their other two binding domains. This T cell / target cell binding (cross-linking) event promotes T cell activation and subsequent destruction of tumor cells by ADCC. [Figure 3] CD33 / CD3 tandem diabody domain order variants. Variation in the variable heavy (VH) and variable light (VL) domain order within the gene sequence encoding the tandem diabody allows for the production of antibodies with CD33 and CD3 specificity located either internally or externally in the molecule. The domain specificities are shown, as well as the locations of the signal sequence (ss), linkers (L1, L2, L3), affinity tag (His), and 5'- and 3'-ends. [Figure 4]Comparison of positively enriched healthy donor T cells vs. negatively selected healthy donor T cells. KG-1a cells were incubated with either negatively selected or positively selected healthy donor T cells at 10 pM (approximately 1 ng / mL) and 25 pM (approximately 2.5 ng / mL) of one of 10 selected tandem diabodies at an E:T cell ratio of 1:1 or 3:1, as indicated. After 48 h, cell numbers were determined and cytotoxicity was assessed by DAPI staining. Results are shown as the mean ± SEM of the percentage of dead cells (upper panel) and specific cytotoxicity (lower panel) from three independent experiments performed in duplicate wells. [Figure 5] Analytical strategy. Scatter and histogram plots from one healthy donor T-cell aliquot and one representative AML cell line (HL-60) and primary AML specimen (AMP002), respectively, illustrating the strategy pursued to determine tandem diabody-induced cytotoxicity. FSC, forward scatter; SSC, side scatter. [Figure 6] Cytotoxicity screening assay in CD33+ AML cell lines. Parental HL-60 (A, B) and KG-1a (C, D) cells were incubated with healthy donor T cells at either a 1:1 (A, C) or 5:1 (B, D) E:T cell ratio, as indicated, with 10 pM (approximately 1 ng / mL) and 25 pM (approximately 2.5 ng / mL) of one of 22 CD33 / CD3 tandem diabody molecules or a nonbinding control tandem diabody (00). After 48 h, cell numbers were determined, and cytotoxicity was assessed by DAPI staining to quantify drug-specific cytotoxicity. Results are shown as the mean ± SEM of the percentage of DAPI+ cells from three independent experiments performed in replicate wells. Qualitatively similar results were obtained when cytotoxicity was expressed as a percentage of specific cytotoxicity. [Figure 7]Selection of primary AML specimens for study. Frozen aliquots were obtained from a total of 10 primary human AML specimens and used for analysis. The percentage of AML blasts after thawing was determined by flow cytometry based on CD45 / side scatter characteristics. Specimen viability was measured at thawing and 48 hours later in cytokine-containing liquid culture (without the addition of tandem diabody molecules or healthy donor T cells) by flow cytometry using DAPI as a live / dead cell marker. Post-thaw and 48-hour viability results are depicted for all specimens, which were >58% AML blasts. Boxes: primary AML specimens included in the final analysis that showed >50% viability at thawing and >50% viability after 48 hours in cytokine-containing liquid culture. [Figure 8] Tandem diabody-induced cytotoxicity in primary AML specimens. Primary AML specimens were incubated with one of nine tandem diabody molecules at 2.5 pM (approximately 250 pg / mL), 10 pM (approximately 1 ng / mL), and 25 pM (approximately 2.5 ng / mL) without the addition of healthy donor T cells (A), or with healthy donor T cells at an E:T cell ratio of either 1:3 (B) or 1:1 (C) as indicated. After 48 h, cell numbers were determined, and cytotoxicity was assessed by DAPI staining to quantify drug-specific cytotoxicity. Results are shown as the mean ± SEM of the percentage of specific cytotoxicity from experiments performed in replicate wells. [Figure 9] Amino acid sequence of the extracellular domain of human CD33 (aa18-259) (SEQ ID NO:93). [Figure 10-1]Amino acid sequences: (A) Complete sequence of tandem diabody 1 with a C-terminal hexahistidine (6xHis) tag (SEQ ID NO:98); (B) Complete sequence of tandem diabody 2 with a C-terminal hexahistidine (6xHis) tag (SEQ ID NO:99); (C) Complete sequence of tandem diabody 3 with a C-terminal hexahistidine (6xHis) tag (SEQ ID NO:100); (D) Complete sequence of tandem diabody 4 with a C-terminal hexahistidine (6xHis) tag (SEQ ID NO:101); (E) Complete sequence of tandem diabody 5 with a C-terminal hexahistidine (6xHis) tag (SEQ ID NO:102); (F) Complete sequence of tandem diabody 6 with a C-terminal hexahistidine (6xHis) tag (SEQ ID NO:103). (G) the complete sequence of tandem diabody 7 with a C-terminal hexahistidine (6xHis) tag (SEQ ID NO: 104); (H) the complete sequence of tandem diabody 8 with a C-terminal hexahistidine (6xHis) tag (SEQ ID NO: 105); (I) the complete sequence of tandem diabody 9 with a C-terminal hexahistidine (6xHis) tag (SEQ ID NO: 106); (J) the complete sequence of tandem diabody 10 with a C-terminal hexahistidine (6xHis) tag (SEQ ID NO: 107); (K) the complete sequence of tandem diabody 11 with a C-terminal hexahistidine (6xHis) tag (SEQ ID NO: 108); (L) the complete sequence of tandem diabody 12 with a C-terminal hexahistidine (6xHis) tag (SEQ ID NO: 109). NO:109); (M) the complete sequence of tandem diabody 13 with a C-terminal hexahistidine (6xHis) tag (SEQ ID NO:110); (N) the complete sequence of tandem diabody 14 with a C-terminal hexahistidine (6xHis) tag (SEQ ID NO:111); (O) the complete sequence of tandem diabody 15 with a C-terminal hexahistidine (6xHis) tag (SEQ ID NO:112); (P) the complete sequence of tandem diabody 16 with a C-terminal hexahistidine (6xHis) tag (SEQ ID NO:113);(Q) The complete sequence of tandem diabody 17 with a C-terminal hexahistidine (6xHis) tag (SEQ ID NO:114); (R) The complete sequence of tandem diabody 18 with a C-terminal hexahistidine (6xHis) tag (SEQ ID NO:115); (S) The complete sequence of tandem diabody 19 with a C-terminal hexahistidine (6xHis) tag (SEQ ID NO:116); (T) The complete sequence of tandem diabody 20 with a C-terminal hexahistidine (6xHis) tag (SEQ ID NO:117); (U) The complete sequence of tandem diabody 21 with a C-terminal hexahistidine (6xHis) tag (SEQ ID NO:118); (V) The complete sequence of tandem diabody 22 with a C-terminal hexahistidine (6xHis) tag (SEQ ID NO:119). (W) the complete sequence of tandem diabody 23 with a C-terminal hexahistidine (6xHis) tag (SEQ ID NO:120); and (X) the complete sequence of tandem diabody 24 with a C-terminal hexahistidine (6xHis) tag (SEQ ID NO:121). The highlighted sequences represent linkers L1, L2, and L3. [Figure 10-2] See description of Figure 10-1. [Figure 10-3] See description of Figure 10-1. [Figure 10-4] See description of Figure 10-1. [Figure 10-5] See description of Figure 10-1. [Figure 10-6] See description of Figure 10-1. [Figure 10-7] See description of Figure 10-1. [Figure 10-8] See description of Figure 10-1. [Figure 11-1]Amino acid sequences: (A) complete sequence of tandem diabody 1 (SEQ ID NO: 123); (B) complete sequence of tandem diabody 2 (SEQ ID NO: 124); (C) complete sequence of tandem diabody 3 (SEQ ID NO: 125); (D) complete sequence of tandem diabody 4 (SEQ ID NO: 126); (E) complete sequence of tandem diabody 5 (SEQ ID NO: 127); (F) complete sequence of tandem diabody 6 (SEQ ID NO: 128); (G) complete sequence of tandem diabody 7 (SEQ ID NO: 129); (H) complete sequence of tandem diabody 8 (SEQ ID NO: 130); (I) complete sequence of tandem diabody 9 (SEQ ID NO: 131); (J) complete sequence of tandem diabody 10 (SEQ ID NO: 132); (K) complete sequence of tandem diabody 11 (SEQ ID NO: 133). NO:133); (L) the complete sequence of tandem diabody 12 (SEQ ID NO:134); (M) the complete sequence of tandem diabody 13 (SEQ ID NO:135); (N) the complete sequence of tandem diabody 14 (SEQ ID NO:136); (O) the complete sequence of tandem diabody 15 (SEQ ID NO:137); (P) the complete sequence of tandem diabody 16 (SEQ ID NO:138); (Q) the complete sequence of tandem diabody 17 (SEQ ID NO:139); (R) the complete sequence of tandem diabody 18 (SEQ ID NO:140); (S) the complete sequence of tandem diabody 19 (SEQ ID NO:141); (T) the complete sequence of tandem diabody 20 (SEQ ID NO:142); (U) the complete sequence of tandem diabody 21 (SEQ ID NO:143); (V) the complete sequence of tandem diabody 22 (SEQ ID NO:144). (W) the complete sequence of tandem diabody 23 (SEQ ID NO: 145); and (X) the complete sequence of tandem diabody 24 (SEQ ID NO: 146). The highlighted sequences represent linkers L1, L2, and L3. [Figure 11-2] See description of Figure 11-1. [Figure 11-3] See description of Figure 11-1. [Figure 11-4] See description of Figure 11-1. [Figure 11-5] See description of Figure 11-1. [Figure 11-6] See description of Figure 11-1. [Figure 11-7] See description of Figure 11-1. [Figure 11-8] See description of Figure 11-1. [Figure 12] Effect of tandem diabodies 16 and 12 on the growth of HL-60 cells in NOD / scid mice. Eight experimental groups of immunocompromised NOD / scid mice were xenografted by subcutaneous injection of a suspension of 4 x 10 HL-60 cells on day 0. Prior to injection, HL-60 cells were mixed with 3 x 10 purified T cells from a healthy donor. All animals in the experimental groups transplanted with tumor cells and T cells received an intravenous bolus of vehicle (control) or tandem diabodies 16 or 12 at three different dose levels (0.1 μg, 1 μg, and 10 μg) as indicated on days 0, 1, 2, 3, and 4. A vehicle-treated group without effector cells served as an additional negative control. [Figure 13] Antitumor activity of tandem diabody 16 in an AML xenograft model. NOD / scid mice were sublethally irradiated (2 Gy) and subcutaneously inoculated with 4 x 10 HL-60 cells. On day 9, animals received a single bolus injection of anti-asialoGM1 rabbit Ab. On day 10, when tumors reached a volume of 50–150 mm (mean 73 ± 11 mm), 10 animals were assigned to three treatment groups. Groups 2 and 3 (n = 8) were injected intraperitoneally with 1.5 x 10 expanded and activated human T cells. From days 13 to 21 (qdxd9), animals received either tandem diabody 16 (group 3) or vehicle via the lateral tail vein (groups 1 and 2). [Figure 14] Relative abundance (A) and absolute numbers (B) of human AML blasts in the bone marrow (BM) and spleen of NSG mice 38 days after treatment with 5 μg (0.25 mg / kg) or 50 μg (2.5 mg / kg) of CD33 / CD3 tandem diabodies 12 and 16. [Figure 15] Kinetics of CD33 / CD3 tandem diabody 16-mediated target cell lysis. 1x104 calcein-labeled HL-60 target cells were incubated with primary human T cells as effector cells at an E:T ratio of 25:1 in the presence of serial dilutions of tandem diabody 16 or without antibody (w / o) for 30 min, 1 h, 2 h, 3 h, 4 h, or 5 h. At each time point, fluorescent calcein released from lysed target cells was used to calculate specific lysis. The mean and SD of three replicates are plotted. [Figure 16] Kinetics of EC50 and specific lysis values ​​for CD33 / CD3 tandem diabody 16. EC50 values ​​(solid black circles) and tandem diabody 16-mediated target cell lysis (open squares) were measured in a calcein release cytotoxicity assay with incubation times directed by nonlinear regression / sigmoidal dose-response and plotted. [Figure 17] Cytotoxic activity in samples from newly diagnosed, relapsed, and refractory AML patients. DETAILED DESCRIPTION OF THE INVENTION

[0055] Detailed Description of the Invention According to a first aspect, described herein are binding proteins having specificity for at least CD33, preferably human CD33. In some embodiments, the CD33 binding proteins have specificity for, i.e., are cross-reactive with, human and cynomolgus CD33. In some embodiments, these cross-reactive binding proteins bind to human and cynomolgus CD33 with similar affinity.

[0056] CD33 is expressed on myeloid cells, such as blasts of acute myeloid leukemia (AML). Antibody libraries can be screened to isolate antibody domains specific to CD33, such as human CD33. For example, IgM phage display libraries can be screened using recombinant CD33-Fc fusion proteins, including amino acids 1-243 of the extracellular domain of human CD33 (Figure 9, SEQ ID NO:93).

[0057] In some embodiments, the CD33 binding protein has at least one CD33 binding site comprising a light chain variable domain and a heavy chain variable domain. The light chain variable domain comprises light chain CDR1, CDR2, and CDR3, and the heavy chain variable domain comprises heavy chain CDR1, CDR2, and CDR3. In some embodiments, these light chain CDRs (CDR1, CDR2, and CDR3) are selected from the human CDR sequences shown in Table 1 (SEQ ID NOs: 21-41). In some examples, the light chain CDR1 is selected from SEQ ID NOs: 21-27. In some examples, the light chain CDR2 is selected from SEQ ID NOs: 28-34. In some examples, the light chain CDR3 is selected from SEQ ID NOs: 35-41.

[0058] In some embodiments, these heavy chain CDRs (heavy chain CDR1, CDR2, and CDR3) are selected from the human CDR sequences shown in Table 2 (SEQ ID NOs: 42-63). In some examples, heavy chain CDR1 is selected from SEQ ID NOs: 42-48. In some examples, heavy chain CDR2 is selected from SEQ ID NOs: 49-55. In some examples, heavy chain CDR3 is selected from SEQ ID NOs: 56-63.

[0059] In some embodiments, the light and heavy chain CDRs are selected without framework sequences surrounding their respective variable domains, which comprise framework sequences or consensus framework regions from other immunoglobulins, optionally further mutated with and / or replaced by other suitable framework sequences. Thus, in some embodiments, provided herein is a CD33 binding protein comprising a light chain variable domain, wherein light chain CDR1 is SEQ ID NO:21, light chain CDR2 is SEQ ID NO:28, and light chain CDR3 is SEQ ID NO:35. In some embodiments, the CD33 binding protein comprises a light chain variable domain, wherein light chain CDR1 is SEQ ID NO:22, light chain CDR2 is SEQ ID NO:29, and light chain CDR3 is SEQ ID NO:36. In some embodiments, the CD33 binding protein comprises a light chain variable domain, wherein the light chain CDR1 is SEQ ID NO:23, the light chain CDR2 is SEQ ID NO:30, and the light chain CDR3 is SEQ ID NO:37. In some embodiments, the CD33 binding protein comprises a light chain variable domain, wherein the light chain CDR1 is SEQ ID NO:24, the light chain CDR2 is SEQ ID NO:31, and the light chain CDR3 is SEQ ID NO:38. In some embodiments, the CD33 binding protein comprises a light chain variable domain, wherein the light chain CDR1 is SEQ ID NO:25, the light chain CDR2 is SEQ ID NO:32, and the light chain CDR3 is SEQ ID NO:39. In some embodiments, the CD33 binding protein comprises a light chain variable domain, wherein the light chain CDR1 is SEQ ID NO:26, the light chain CDR2 is SEQ ID NO:33, and the light chain CDR3 is SEQ ID NO:40. In some embodiments, the CD33 binding protein comprises a light chain variable domain, wherein the light chain CDR1 is SEQ ID NO:27, the light chain CDR2 is SEQ ID NO:34, and the light chain CDR3 is SEQ ID NO:41.

[0060] Further in some embodiments, provided herein are CD33 binding proteins comprising a heavy chain variable domain, wherein the heavy chain CDR1 is SEQ ID NO:42, the heavy chain CDR2 is SEQ ID NO:49, and the heavy chain CDR3 is SEQ ID NO:56. In some embodiments, the CD33 binding protein comprises a heavy chain variable domain, wherein the heavy chain CDR1 is SEQ ID NO:43, the heavy chain CDR2 is SEQ ID NO:50, and the heavy chain CDR3 is SEQ ID NO:57. In some embodiments, the CD33 binding protein comprises a heavy chain variable domain, wherein the heavy chain CDR1 is SEQ ID NO:43, the heavy chain CDR2 is SEQ ID NO:50, and the heavy chain CDR3 is SEQ ID NO:58. In some embodiments, the CD33 binding protein comprises a heavy chain variable domain, wherein the heavy chain CDR1 is SEQ ID NO:43, the heavy chain CDR2 is SEQ ID NO:50, and the heavy chain CDR3 is SEQ ID NO:59. In some embodiments, the CD33 binding protein comprises a heavy chain variable domain, wherein the heavy chain CDR1 is SEQ ID NO:43, the heavy chain CDR2 is SEQ ID NO:50, and the heavy chain CDR3 is SEQ ID NO:60. In some embodiments, the CD33 binding protein comprises a heavy chain variable domain, wherein the heavy chain CDR1 is SEQ ID NO:44, the heavy chain CDR2 is SEQ ID NO:51, and the heavy chain CDR3 is SEQ ID NO:61. In some embodiments, the CD33 binding protein comprises a heavy chain variable domain, wherein the heavy chain CDR1 is SEQ ID NO:45, the heavy chain CDR2 is SEQ ID NO:52, and the heavy chain CDR3 is SEQ ID NO:62. In some embodiments, the CD33 binding protein comprises a heavy chain variable domain, wherein the heavy chain CDR1 is SEQ ID NO:46, the heavy chain CDR2 is SEQ ID NO:53, and the heavy chain CDR3 is SEQ ID NO:63. In some embodiments, the CD33 binding protein comprises a heavy chain variable domain, wherein the heavy chain CDR1 is SEQ ID NO:47, the heavy chain CDR2 is SEQ ID NO:54, and the heavy chain CDR3 is SEQ ID NO:63.In some embodiments, the CD33 binding protein comprises a heavy chain variable domain, wherein the heavy chain CDR1 is SEQ ID NO:48, the heavy chain CDR2 is SEQ ID NO:55, and the heavy chain CDR3 is SEQ ID NO:63.

[0061] In further embodiments, the CD33 binding protein comprises a variable light chain domain selected from the amino acid sequence SEQ ID NOs:1-10 shown in Table 3. In further embodiments, the CD33 binding protein comprises a variable heavy chain domain selected from the amino acid sequence SEQ ID NOs:11-20 shown in Table 4. In still further embodiments, the CD33 binding protein comprises a variable light chain domain selected from the amino acid sequence SEQ ID NOs:1-10 shown in Table 3 and a variable heavy chain domain selected from the amino acid sequence SEQ ID NOs:11-20 shown in Table 4.

[0062] The term "binding protein" refers to an immunoglobulin derivative with antigen-binding properties, i.e., an immunoglobulin polypeptide or fragment thereof containing an antigen-binding site. A binding protein comprises the variable domain of an antibody or fragment thereof. Each antigen-binding domain is formed by an antibody (i.e., immunoglobulin) variable heavy domain (VH) and an antibody variable light domain (VL) that binds to the same epitope, where the variable heavy domain (VH) comprises three heavy chain complementarity-determining regions (CDRs): CDR1, CDR2, and CDR3, and the variable light domain (VL) comprises three light chain complementarity-determining regions (CDRs): CDR1, CDR2, and CDR3. In some examples, the binding proteins according to some embodiments described herein lack immunoglobulin constant domains. In some examples, the variable light chain domain and variable heavy chain domain that form the antigen-binding site are covalently linked to each other, e.g., by a peptide linker, or in other examples, the variable light chain domain and variable heavy chain domain are noncovalently associated with each other to form the antigen-binding site. The term "binding protein" also refers to antibody fragments or antibody derivatives, including, for example, Fab, Fab', F(ab'), Fv fragments, single-chain Fv, tandem single-chain Fv (scFv), bispecific T-cell engagers (BiTEs), dual affinity retargeting antibodies (DARTs), diabodies, and tandem diabodies (TandAbs). Furthermore, in certain instances, the binding proteins are multivalent, i.e., have two, three, or more binding sites for CD33.

[0063] Table 1: Amino acid sequences of anti-CD33 variable light chain CDR1, CDR2, and CDR3 TIFF0007583014000001.tif239129

[0064] Table 2: Amino acid sequences of anti-CD33 variable heavy chain CDR1, CDR2, and CDR3 TIFF0007583014000002.tif239124

[0065] Table 3: Amino acid sequences of all anti-CD33 variable light chain domains (amino acid sequences of variable light chain CDR1, CDR2 and CDR3 are bold and underlined) TIFF0007583014000003.tif224170

[0066] Table 4: Amino acid sequences of anti-CD33 variable heavy chain domains (amino acid sequences of variable heavy chain CDR1, CDR2 and CDR3 are bold and underlined) TIFF0007583014000004.tif220170

[0067] In some embodiments, the binding protein that confers specificity for CD33 is selected from one of the following combinations of variable heavy and variable light domains that form the human CD33 binding site, as shown in Tables 3 and 4. Non-limiting examples include: (i) SEQ ID NO:1 and SEQ ID NO:11, (ii) SEQ ID NO:2 and SEQ ID NO:12, (iii) SEQ ID NO:3 and SEQ ID NO:13, (iv) SEQ ID NO:4 and SEQ ID NO:14, (v) SEQ ID NO:5 and SEQ ID NO:15, (vi) SEQ ID NO:6 and SEQ ID NO:16, (vii) SEQ ID NO:7 and SEQ ID NO:17, (viii) SEQ ID NO:8 and SEQ ID NO:18, (ix) SEQ ID NO:9 and SEQ ID NO:19, and (x) SEQ ID NO:10 and SEQ ID NO:20.

[0068] Also described herein are binding proteins that not only have specificity for CD33 but also have at least one additional functional domain. In a further embodiment, the at least one additional functional domain is an effector domain. The "effector domain" comprises an antibody binding site specific to effector cells, which can stimulate or induce cytotoxicity, phagocytosis, antigen presentation, and cytokine release. For example, such effector cells include, but are not limited to, T cells. In particular, the effector domain comprises at least one antibody variable heavy chain domain and at least one variable light chain domain that form an antigen-binding site for an antigen on T cells, such as human CD3.

[0069] Thus, in some embodiments, the CD33 binding protein is multifunctional. As used herein, the term multifunctional means that the binding protein exhibits two or more different biological functions. For example, the different biological functions are different specificities for different antigens. In certain examples, the multifunctional CD33 binding protein is multispecific, i.e., has binding specificity for CD33 and one or more additional antigens. In certain examples, the binding protein is bispecific, having specificity for CD33 and CD3. Such bispecific binding proteins include, for example, bispecific monoclonal antibodies of class IgA, IgD, IgE, IgG, or IgM, diabodies, single-chain diabodies (scDbs), tandem single-chain Fvs (scFvs)2, such as Bi-specific T-cell engagers (BiTEs®), dual affinity retargeting antibodies (DARTs™), tandem diabodies (TandAbs®), and flexibodies.

[0070] In certain embodiments, the CD3 binding site of the bispecific CD33 and CD3 binding protein has specificity for human CD3, and in some examples, cynomolgus monkey CD3. An example of such a binding site is a polypeptide comprising the VH domains CDR1, CDR2, and CDR3 from the sequences shown in Table 5 (SEQ ID NOs:64-67) and the VL domains CDR1, CDR2, and CDR3 from the sequences shown in Table 6 (SEQ ID NOs:68-71). In a particular example, the CD3 binding site is a combination of the variable heavy chain domain of SEQ ID NO:64 and the variable light chain domain of SEQ ID NO:68. In a particular example, the CD3 binding site is a combination of the variable heavy chain domain of SEQ ID NO:65 and the variable light chain domain of SEQ ID NO:69. In a particular example, the CD3 binding site is a combination of the variable heavy chain domain of SEQ ID NO:66 and the variable light chain domain of SEQ ID NO:70. In a particular example, the CD3 binding site is a combination of the variable heavy chain domain of SEQ ID NO:67 and the variable light chain domain of SEQ ID NO:71.

[0071] Table 5: Amino acid sequences of anti-CD3 variable heavy chain domains (amino acid sequences of variable heavy chain CDR1, CDR2 and CDR3 are bold and underlined) TIFF0007583014000005.tif84170

[0072] Table 6: Amino acid sequences of anti-CD3 variable light chain domains (amino acid sequences of variable light chain CDR1, CDR2 and CDR3 are bold and underlined) TIFF0007583014000006.tif59170

[0073] In a further embodiment, the CD3 binding site of the bispecific CD33 and CD3 binding protein has a variable heavy chain domain comprising a CDR1 sequence that is STYAMN (SEQ ID NO:72). In a further embodiment, the CD3 binding site of the bispecific CD33 and CD3 binding protein has a variable heavy chain domain comprising a CDR2 sequence that is RIRSKYNNYATYYADSVKD (SEQ ID NO:73). In a further embodiment, the CD3 binding site of the bispecific CD33 and CD3 binding protein has a variable heavy chain domain comprising a CDR3 sequence that is HGNFGNSYVSWFAY (SEQ ID NO:74). In a further embodiment, the CD3 binding site of the bispecific CD33 and CD3 binding protein has a variable heavy chain domain comprising a CDR3 sequence that is HGNFGNSYVSYFAY (SEQ ID NO:75). In yet a further embodiment, the CD3 binding site has a variable heavy chain domain comprising the CDR1, CDR2, and CDR3 sequences that are SEQ ID NOs:72-74, respectively. In yet a further embodiment, the CD3 binding site has a variable heavy chain domain comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs: 72, 73 and 75, respectively.

[0074] In a further embodiment, the CD3 binding site of the bispecific CD33 and CD3 binding protein has a variable heavy chain domain comprising a CDR1 sequence selected from the group consisting of NTYAMN (SEQ ID NO:76), NTYAMH (SEQ ID NO:77) and NKYAMN (SEQ ID NO:78). In a further embodiment, the CD3 binding site of the bispecific CD33 and CD3 binding protein has a variable heavy chain domain comprising a CDR2 sequence selected from the group consisting of RIRNKYNNYATYYADSVKD (SEQ ID NO:79), RIRNKYNNYATEYADSVKD (SEQ ID NO:80), RIRSKYNNYATEYAASVKD (SEQ ID NO:81), RIRNKYNNYATEYAASVKD (SEQ ID NO:82), RIRSKYNNYATYYADSVKG (SEQ ID NO:83) and RIRSKYNNYATEYADSVKS (SEQ ID NO:84). In a further embodiment, the CD3 binding site of the bispecific CD33 and CD3 binding protein has a variable heavy chain domain comprising a CDR3 sequence selected from the group consisting of HGNFGDSYVSWFAY (SEQ ID NO:85), HGNFGNTYVSWFAY (SEQ ID NO:86), HGNFGCSYVSWFAY (SEQ ID NO:87), HGNFGNSYISYWAY (SEQ ID NO:88) and HGNFGNSYVSFFAY (SEQ ID NO:89).

[0075] In still further embodiments, the CD3 binding site has a variable heavy chain domain comprising CDR1, CDR2 and CDR3 sequences which are SEQ ID NOs:76, 73 and 74, respectively; SEQ ID NOs:76, 79 and 74, respectively; SEQ ID NOs:76, 80 and 74, respectively; SEQ ID NOs:76, 81 and 74, respectively; SEQ ID NOs:76, 82 and 74, respectively; SEQ ID NOs:76, 83 and 74, respectively; SEQ ID NOs:72, 83 and 74, respectively; SEQ ID NOs:72, 83 and 85, respectively; SEQ ID NOs:76, 83 and 86, respectively; SEQ ID NOs:77, 83 and 74, respectively; SEQ ID NOs:72, 83 and 87, respectively; SEQ ID NOs:78, 73 and 88, respectively; or SEQ ID NOs:78, 84 and 89, respectively.

[0076] In a further embodiment, the CD3 binding site of the bispecific CD33 and CD3 binding protein has a variable light chain domain comprising a CDR1 sequence that is RSSTGAVTTSNYAN (SEQ ID NO:90). In a further embodiment, the CD3 binding site of the bispecific CD33 and CD3 binding protein has a variable light chain domain comprising a CDR2 sequence that is GTNKRAP (SEQ ID NO:91). In a further embodiment, the CD3 binding site of the bispecific CD33 and CD3 binding protein has a variable light chain domain comprising a CDR3 sequence that is ALWYSNL (SEQ ID NO:92). In yet a further embodiment, the CD3 binding site has a variable light chain domain comprising the CDR1, CD2, and CD3 sequences that are SEQ ID NOs:90-92, respectively.

[0077] In certain examples, the CD3 binding site has high affinity for CD3. Alternatively, in other examples, the CDR1, CDR2, and CDR3 from the heavy and light chain domains, or optionally the variable light and variable heavy chain domains, are derived from other CD3 antibodies, such as, for example, UCHT1, muromonab-CD3 (OKT3), otelixizumab (TRX4), teplizumab (MGA031), or visilizumab (Nuvion).

[0078] In another embodiment, described herein are humanized or fully human CD33 binding proteins and bispecific CD33 and CD3 binding proteins, i.e., of human origin.

[0079] In some embodiments, the bispecific CD33 and CD3 binding proteins have one of the following combinations that provide CD33 and CD3 specificity through variable light and variable heavy domains for CD33 and CD3: but are not limited to: (i) SEQ ID NOs: 2, 12, 65 and 69, (ii) SEQ ID NOs: 3, 13, 65 and 69, (iii) SEQ ID NOs: 4, 14, 65 and 69, (iv) SEQ ID NOs: 5, 15, 65 and 69, (v) SEQ ID NOs: 1, 11, 64 and 68, (vi) SEQ ID NOs: 2, 12, 64 and 68, (vii) SEQ ID NOs: 2, 12, 66 and 70, (viii) SEQ ID NOs: 4, 14, 66 and 70, (ix) SEQ ID NOs: 5, 15, 66 and 70, (x) SEQ ID NO:3, 13, 64 and 68, (xi) SEQ ID NO:3, 13, 67 and 71, (xii) SEQ ID NO:4, 14, 64 and 68, (xiii) SEQ ID NO:5, 15, 64 and 68, (xiv) SEQ ID NO:7, 17, 64 and 68, (xv) SEQ ID NO:6, 16, 64 and 68, (xvi) SEQ ID NO:6, 16, 67 and 71, (xvii) SEQ ID NO:8, 18, 64 and 68, (xviii) SEQ ID NO:9, 19, 64 and 68; (xix) SEQ ID NO:9, 19, 67 and 71, and (xx) SEQ ID NO:10, 20, 64 and 68.

[0080] CDR sequences and conserved variants of heavy and light chain domains In alternative embodiments, the heavy and light chain domains incorporate immunologically active homologs or variants of the CDR sequences described herein. Thus, in some embodiments, the CDR sequences in the heavy or light chain domains that bind to CD33 or CD3 are similar to, but not identical to, the amino acid sequences depicted in SEQ ID NOs:21-63 or 72-92. In particular examples, the CDR variant sequences have 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, or 80% sequence identity to the sequences of SEQ ID NOs:21-63 or 72-90 and are immunologically active.

[0081] In a further example, the CDR variant sequence incorporates 1, 2, 3, 4, or 5 conservative amino acid substitutions. Conservative substitutions include those that substitute a given amino acid for another amino acid with similar properties, and further include exchanges of alanine, valine, leucine, and isoleucine among aliphatic amino acids; exchanges of hydroxyl residues serine and threonine, exchanges of acidic residues aspartate and glutamate, exchanges between amide residues asparagine and glutamine, exchanges of basic residues lysine and arginine, and exchanges of phenylalanine and tyrosine among aromatic residues.

[0082] In still further examples, CDR variant sequences incorporate substitutions that enhance properties of the CDRs, such as increased stability, resistance to proteases and / or binding affinity to CD33 or CD3.

[0083] In other examples, CDR variant sequences are modified to change non-critical residues or residues in non-critical regions. Non-critical amino acids can be identified by known methods such as affinity maturation, CDR walking, site-directed mutagenesis, crystallization, nuclear magnetic resonance, photoaffinity labeling, or alanine-systematic mutagenesis.

[0084] In further alternative embodiments, the CD33 and CD3 binding proteins comprise heavy and light chain domains that are immunologically active homologs or variants of the heavy and light chain domain sequences provided herein. Thus, in some embodiments, the CD33 and CD3 binding proteins comprise heavy or light chain domain sequences that are similar to, but not identical to, the amino acid sequences depicted in SEQ ID NOs: 1-20 or 64-71. In particular examples, the variant heavy or light chain domain sequences have 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, or 80% sequence identity to the sequences of SEQ ID NOs: 1-20 or 64-71 and are immunologically active.

[0085] In further examples, the variant heavy or light chain domain sequences incorporate one, two, three, four, or five conservative amino acid substitutions. Conservative substitutions include those that substitute a given amino acid for another amino acid with similar properties, and further include exchanges of alanine, valine, leucine, and isoleucine among aliphatic amino acids; exchanges of the hydroxyl residues serine and threonine, exchanges of the acidic residues aspartate and glutamate, exchanges between the amide residues asparagine and glutamine, exchanges of the basic residues lysine and arginine, and exchanges of phenylalanine and tyrosine among aromatic residues.

[0086] In yet a further example, the variant heavy or light chain domain sequences incorporate substitutions that enhance properties of the CDRs, such as increased stability, resistance to proteases and / or binding affinity to CD33 or CD3.

[0087] In other examples, the variant heavy or light chain domain sequences are modified to change non-critical residues or residues in non-critical regions. Non-critical amino acids can be identified by known methods such as affinity maturation, CDR walking, site-directed mutagenesis, crystallization, nuclear magnetic resonance, photoaffinity labeling, or alanine scanning mutagenesis.

[0088] CD33 and CD3 bispecific tandem diabody In another embodiment, the CD33 binding protein or bispecific CD33 and CD3 binding protein is a dimer, ie, comprises two polypeptides having antigen binding sites for CD33 and CD3.

[0089] In another aspect, provided herein are dimeric, bispecific CD33 and CD3 binding proteins in the format of a tandem diabody (TandAb®). Such tandem diabodies are constructed by combining four antibody variable binding domains (two heavy chain variable domains (VH) and two light chain variable domains (VL)) in a single gene construct (FIG. 1), allowing for homodimerization. In such tandem diabodies, the linker length is such that intramolecular pairing of the variable domains is prevented, thereby forcing the molecule to pair with the complementary domain of another chain rather than folding back on itself to form a single-chain diabody. The domains are also arranged such that corresponding VH and VL domains pair during this dimerization. After expression from the single gene construct, two identical polypeptide chains fold head-to-tail to form a functional, non-covalent homodimer of approximately 105 kDa (FIG. 1). Despite the lack of intermolecular covalent bonds, this homodimer, once formed, is highly stable, remains intact, and does not revert to the monomeric form.

[0090] Tandem diabodies have many advantageous properties over traditional monoclonal antibodies and other smaller bispecific molecules. Tandem diabodies contain only antibody variable domains and are therefore intended to be free of side effects or nonspecific interactions that can be associated with Fc portions. For example, Fc receptors that can bind to Fc domains are found on numerous cell types, such as leukocytes (e.g., basophils, B cells, eosinophils, natural killer cells, neutrophils, etc.) or Kupffer cells. Because tandem diabodies enable bivalent binding to each of CD33 and CD3, their avidity is similar to that of IgG. Tandem diabodies are approximately 105 kDa in size, smaller than IgG, which may allow for enhanced tumor penetration. However, this size is well above the renal threshold for first-pass clearance and offers pharmacokinetic advantages compared to smaller bispecific formats based on antibody binding domains or non-antibody scaffolds. Furthermore, tandem diabodies have advantages over other bispecific binding proteins, such as BiTE or DART molecules, based on their pharmacokinetic and avidity properties, resulting in longer intrinsic half-lives and rapid cytotoxicity. Tandem diabodies are well expressed in host cells, such as mammalian CHO cells. It is contemplated that robust upstream and downstream manufacturing processes are available for tandem diabodies.

[0091] The CD33 and CD3 bispecific tandem diabodies described herein inhibit CD33 by recruiting cytotoxic T cells. + They are designed to allow specific targeting of tumor cells, improving ADCC (antibody-dependent cell-mediated cytotoxicity) compared to full-length antibodies, which are directed against a single antigen and cannot directly recruit cytotoxic T cells. In contrast, tandem diabodies target CD33 in a highly specific manner by binding the CD3 molecule specifically expressed on these cells. +Tumor cells can be cross-linked with cytotoxic T cells, thereby significantly increasing the cytotoxic potential of such molecules. This mechanism is outlined in Figure 2. Tandem diabodies exhibit potent, specific, and efficient ADCC. It has been reported that T cells can play a role in controlling tumor growth. For example, the presence of cytotoxic T cells in colon tumors and lymph nodes from NHL patients has been shown to correlate with better clinical outcomes. Furthermore, the potential of therapeutics designed to elicit T cell responses has been demonstrated for melanoma vaccines as well as antibodies against CTLA-4, a negative regulator of T cell activation. The tandem diabody described herein binds to cytotoxic T cells by binding to surface-expressed CD3, which forms part of the T cell receptor. Simultaneous binding of this tandem diabody to CD3 and CD33 expressed on the surface of specific tumor cells triggers T cell activation and subsequently mediates tumor cell lysis (Figure 2).

[0092] Thus, a further aspect is a multispecific tandem diabody. In some embodiments, the multispecific tandem diabody has specificity for two, three, or more different epitopes, where the two or more epitopes can be the same or different antigen targets. In certain embodiments, the multispecific tandem diabody is bispecific and tetravalent, i.e., comprises four antigen-binding sites. Such bispecific tandem diabodies bind to human CD3 and human CD33 at at least one antigen-binding site; in a specific example, the tandem diabody binds to human CD3 at two antigen-binding sites and human CD33 at two other antigen-binding sites, i.e., the tandem diabody binds to each antigen bivalently.

[0093] In some embodiments, a bispecific antigen-binding tandem diabody is specific for human CD33 and human CD3, wherein said tandem diabody comprises a first polypeptide and a second polypeptide, each polypeptide having at least four variable chain domains linked sequentially, wherein each polypeptide comprises: (i) a variable heavy (VH) domain specific for human CD33; (ii) a variable light chain (VL) domain specific for human CD33; (iii) a VH domain specific for human CD3; and (iv) a VL domain specific for human CD3.

[0094] In certain embodiments, the bispecific tandem diabody is 62 DQEVQEETQ 70 (SEQ ID NO:94) (amino acid residues 62-70 of SEQ ID NO:93). In particular examples, such tandem diabodies comprise a first polypeptide and a second polypeptide, each polypeptide having at least four variable chain domains linked sequentially, wherein each polypeptide comprises: (i) Human CD33 62 DQEVQEETQ 70 (SEQ ID NO:94) a variable heavy chain domain specific for an epitope of human CD33 within amino acid residues 62-70 of SEQ ID NO:93; (ii) Human CD33 62 DQEVQEETQ 70 (SEQ ID NO:94) a variable light chain domain specific for an epitope of human CD33 within amino acid residues 62-70 of SEQ ID NO:93; (iii) a variable heavy chain domain specific for human CD3; and (iv) a variable light chain domain specific for human CD3.

[0095] In other embodiments, the CD33+ K ≤10 nM, ≤5 nM, ≤1 nM, or ≤0.5 nM for CD33 on cells D A CD33 / CD3 tandem diabody has been described that has an affinity for CD33 + The cells may be selected from tumor cells such as, for example, HL-60 or KG-1.

[0096] In further embodiments, the CD33 / CD3 tandem diabodies described herein have a K of 10 nM, 5 nM or less, or 2 nM or less. D In certain instances, CD3 + It binds to the epsilon chain of CD3 on cells, especially T cells.

[0097] In some embodiments, each polypeptide of the bispecific tandem diabody comprises one of the following combinations of four variable chain domains: (i) SEQ ID NOs: 2, 12, 65 and 69, (ii) SEQ ID NOs: 3, 13, 65 and 69, (iii) SEQ ID NOs: 4, 14, 65 and 69, (iv) SEQ ID NOs: 5, 15, 65 and 69, (v) SEQ ID NOs: 1, 11, 64 and 68, (vi) SEQ ID NOs: 2, 12, 64 and 68, (vii) SEQ ID NOs: 2, 12, 66 and 70, (viii) SEQ ID NOs: 4, 14, 66 and 70, (ix) SEQ ID NOs: 5, 15, 66 and 70, (x) SEQ ID NOs: 3, 13, 64 and 68, (xi) SEQ ID NOs: 3, 13, 67 and 71, (xii) SEQ ID NO:4, 14, 64 and 68, (xiii) SEQ ID NO:5, 15, 64 and 68, (xiv) SEQ ID NO:7, 17, 64 and 68, (xv) SEQ ID NO:6, 16, 64 and 68, (xvi) SEQ ID NO:6, 16, 67 and 71, (xvii) SEQ ID NO:8, 18, 64 and 68, (xviii) SEQ ID NO:9, 19, 64 and 68; (xix) SEQ ID NO:9, 19, 67 and 71, and (xx) SEQ ID NO:10, 20, 64 and 68.

[0098] As used herein, a "dimer" refers to a complex of two polypeptides. In certain embodiments, the two polypeptides are non-covalently bound to each other, particularly provided that there is no covalent bond between the two polypeptides. In certain instances, the two polypeptides have a covalent association, such as a disulfide bond, that helps stabilize the dimer. In certain embodiments, the dimer is a homodimer, i.e., it contains two identical polypeptides. The term "polypeptide" refers to a polymer of amino acid residues linked by amide bonds. In certain instances, the polypeptide is an unbranched single-chain fusion protein. In the polypeptide, the variable antibody domains are linked sequentially. In other instances, the polypeptide may have consecutive amino acid residues in addition to the N- and / or C-terminal residues of the variable domain. For example, such consecutive amino acid residues may include a tag sequence at the C-terminus in some instances, which is intended to be useful for polypeptide purification and detection.

[0099] In one aspect, each polypeptide of the bispecific tandem diabody comprises four variable domains: a variable light chain (VL) and a variable heavy chain (VH) of a CD3 binding protein and a variable light chain (VL) and a variable heavy chain (VH) of a CD33 binding protein. In certain embodiments, the four variable domains are joined by peptide linkers L1, L2, and L3, and in some examples are arranged from N-terminus to C-terminus as follows: Domain Order: (1)VL(CD3)-L1-VH(CD33)-L2-VL(CD33)-L3-VH(CD3); or (2)VH(CD3)-L1-VL(CD33)-L2-VH(CD33)-L3-VL(CD3); or (3)VL(CD33)-L1-VH(CD3)-L2-VL(CD3)-L3-VH(CD33); or (4)VH(CD33)-L1-VL(CD3)-L2-VH(CD3)-L3-VL(CD33).

[0100] According to reported studies, the length of the linker affects the flexibility of the antigen-binding tandem diabody. Thus, in some embodiments, the length of the peptide linkers L1, L2, and L3 is such that a domain of one polypeptide can intermolecularly associate with a domain of another polypeptide to form a dimeric antigen-binding tandem diabody. In certain embodiments, such linkers are "short," i.e., consisting of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acid residues. Thus, in certain examples, the linker consists of approximately 12 amino acid residues or less. When the linker consists of zero amino acid residues, it is a peptide bond. Such short linkers support dimerization between the antibody variable light chain domain and the antibody variable heavy chain domain of different polypeptides by forming the correct antigen-binding site. By shortening the linker to approximately 12 amino acid residues or less, adjacent domains of the same polypeptide chain are generally prevented from interacting intramolecularly with each other. In some embodiments, these linkers consist of about 3 to about 10, eg, 4, 5, or 6, consecutive amino acid residues.

[0101] The amino acid composition of the linker is selected so that it does not interfere with the dimerization of the two polypeptides. For example, linkers containing glycine and serine residues generally provide protease resistance. The amino acid sequence of the linker can be optimized, for example, by phage display methods to improve antigen binding and production yield of the antigen-binding polypeptide dimer. Examples of peptide linkers suitable for tandem diabodies in some embodiments are GGSGGS (SEQ ID NO: 95), GGSG (SEQ ID NO: 96), or GGSGG (SEQ ID NO: 97).

[0102] A non-limiting example of a tandem diabody as described herein is a tandem diabody having anti-CD33 VL and VH domains, anti-CD3 VL and VH domains, domain order, and linker according to Table 7.

[0103] Table 7. Exemplary CD33 / CD3 tandem diabodies (TandAbs) TIFF0007583014000007.tif240141TIFF0007583014000008.tif89140

[0104] In some embodiments, the tandem diabody is attached to a C-terminal hexahistidine (6xHis) tag. In some embodiments, tandem diabodies with a C-terminal hexahistidine (6xHis) tag are tandem diabodies 01 (SEQ ID NO:98), 02 (SEQ ID NO:99), 03 (SEQ ID NO:100), 04 (SEQ ID NO:101), 05 (SEQ ID NO:102), 06 (SEQ ID NO:103), 07 (SEQ ID NO:104), 08 (SEQ ID NO:105), 09 (SEQ ID NO:106), 10 (SEQ ID NO:107), 11 (SEQ ID NO:108), 12 (SEQ ID NO:109), 13 (SEQ ID NO:110), 14 (SEQ ID NO:111), 15 (SEQ ID NO:112), 16 (SEQ ID NO:113), 17 (SEQ ID NO:114), 18 (SEQ ID NO:115), 19 (SEQ ID NO:116), 20 (SEQ ID NO:117), 21 (SEQ ID NO:118), 22 (SEQ ID NO:119), 23 (SEQ ID NO:120), 24 (SEQ ID NO:121), 25 (SEQ ID NO:122), 26 (SEQ ID NO:123), 27 (SEQ ID NO:124), 28 (SEQ ID NO:125), 29 (SEQ ID NO:126), 30 (SEQ ID NO:127), 31 (SEQ ID NO:128), 32 (SEQ ID NO:129), 33 (SEQ ID NO:130), 34 (SEQ ID NO:131), 35 (SEQ ID NO:132), 36 (SEQ ID NO:133), 37 (SEQ ID NO: NO:113), 17 (SEQ ID NO:114), 18 (SEQ ID NO:115), 19 (SEQ ID NO:116), 20 (SEQ ID NO:117), 21 (SEQ ID NO:118), 22 (SEQ ID NO:119), 23 (SEQ ID NO:120), or 24 (SEQ ID NO:121).

[0105] In some embodiments, the tandem diabody is selected from the group consisting of tandem diabodies 01 (SEQ ID NO:123), 02 (SEQ ID NO:124), 03 (SEQ ID NO:125), 04 (SEQ ID NO:126), 05 (SEQ ID NO:127), 06 (SEQ ID NO:128), 07 (SEQ ID NO:129), 08 (SEQ ID NO:130), 09 (SEQ ID NO:131), 10 (SEQ ID NO:132), 11 (SEQ ID NO:133), 12 (SEQ ID NO:134), 13 (SEQ ID NO:135), 14 (SEQ ID NO:136), 15 (SEQ ID NO:137), 16 (SEQ ID NO:138), 17 (SEQ ID NO:139), 18 (SEQ ID NO:190), 19 (SEQ ID NO:191), 20 (SEQ ID NO:192), 21 (SEQ ID NO:193), 22 (SEQ ID NO:194), 23 (SEQ ID NO:195), 24 (SEQ ID NO:196), 25 (SEQ ID NO:197), 26 (SEQ ID NO:198), 27 (SEQ ID NO:199), 28 (SEQ ID NO:200), 29 (SEQ ID NO:201), 30 (SEQ ID NO:199), 31 (SEQ ID NO:201) NO:139), 18 (SEQ ID NO:140), 19 (SEQ ID NO:141), 20 (SEQ ID NO:142), 21 (SEQ ID NO:143), 22 (SEQ ID NO:144), 23 (SEQ ID NO:145), or 24 (SEQ ID NO:146).

[0106] The CD33 binding proteins and CD33 / CD3 bispecific binding proteins (e.g., CD33 / CD3 bispecific tandem diabodies) described herein are, in some embodiments, produced by expressing a polynucleotide encoding a tandem diabody polypeptide that associates with another identical polypeptide to form an antigen-binding tandem diabody. Thus, another aspect is a polynucleotide, e.g., DNA or RNA, that encodes an antigen-binding tandem diabody polypeptide as described herein.

[0107] The polynucleotide is constructed by known methods, such as by combining genes encoding at least four antibody variable domains, separated by peptide linkers or, in other embodiments, directly linked by peptide bonds, into a single gene construct operably linked to a suitable promoter and, optionally, a suitable transcription terminator, and expressing it in bacteria or other suitable expression systems, such as CHO cells. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. The promoter is selected to drive expression of the polynucleotide in the respective host cell.

[0108] In some embodiments, the polynucleotide is inserted into a vector, preferably an expression vector, which represents a further embodiment. The recombinant vector can be constructed according to known methods.

[0109] A variety of expression vector / host systems can be utilized to contain and express polynucleotides encoding the described antigen-binding tandem diabody polypeptides. Examples of expression vectors for expression in E. coli are pSKK (Le Gall et al., J Immunol Methods. (2004) 285(1):111-27) or pcDNA5 (Invitrogen) for expression in mammalian cells.

[0110] Thus, antigen-binding tandem diabodies as described herein are produced, in some embodiments, by introducing vectors encoding polypeptides as described above into host cells and culturing said host cells under conditions whereby the polypeptide chains are expressed and can be isolated and optionally further purified.

[0111] In other embodiments, the CD33 binding proteins or CD33 / CD3 bispecific binding proteins (e.g., CD33 / CD3 bispecific tandem diabodies) described herein have modifications. Exemplary modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, drug conjugation, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, protein processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA-mediated addition of amino acids to proteins such as arginylation, and ubiquitination. In further embodiments, the CD33 binding protein or CD33 / CD3 bispecific binding protein is modified with additional amino acids, such as a leader or secretory sequence, or a sequence for purification of the polypeptide.

[0112] In other aspects, provided herein are pharmaceutical compositions comprising a CD33-binding protein, an antigen-binding tandem diabody, a vector containing a polynucleotide encoding an antigen-binding tandem diabody polypeptide, or a host cell transformed with this vector, and at least one pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" includes, but is not limited to, any carrier that does not interfere with the effectiveness of the biological activity of the component and is not toxic to the patient to whom it is administered. Examples of suitable pharmaceutical carriers are well known in the art and include phosphate-buffered saline solutions, water, emulsions such as oil / water emulsions, various types of wetting agents, sterile solutions, etc. Such carriers can be formulated by conventional methods and administered to a subject in an appropriate dosage. Preferably, the compositions are sterile. These compositions may also contain adjuvants such as preservatives, emulsifiers, and dispersing agents. Prevention of microbial action can be ensured by the inclusion of various antibacterial and antifungal agents.

[0113] Bispecific CD33 / CD3 binding proteins with high affinity binding to CD33 and CD3 are highly active in many primary AML specimens, suggesting that these molecules may be active against human AML across the spectrum of cytogenetic / molecular diseases, even in cases of minimal CD33 expression. Of note, drug-specific cytotoxicity is also observed in the presence of residual autologous T cells and is significantly augmented by the addition of controlled amounts of healthy donor T cells (see Example 6).

[0114] CD33 / CD3 bispecific binding proteins, particularly tandem diabodies, inhibit CD33 in vitro. +It can induce potent cytolysis of leukemia cells. Data indicate that high-affinity binding to both CD33 and CD3 maximizes bispecific protein-induced T cell activation and anti-AML efficacy. High-affinity bispecific binding proteins directed against CD33 / CD3, such as the tandem diabodies described herein, exhibit cytolytic activity in primary AML in vitro. Therefore, these bispecific binding proteins and tandem diabodies are suitable for therapeutic use in the treatment of acute myeloid leukemia (AML) or other hematological malignancies (e.g., myelodysplastic syndrome (MDS) or myeloproliferative disorders (MPD)).

[0115] Therefore, it is provided herein that an antigen-binding tandem diabody as described herein above binds to CD33 + Methods are provided in which an effective amount of CD33 is administered to a subject, e.g., a patient, for the treatment of cancer (e.g., acute myeloid leukemia (AML)), a disease, or a condition. + Cancers include, but are not limited to, acute leukemias such as acute myeloid leukemia, acute lymphoblastic leukemia (ALL), including precursor B-cell lymphoblastic leukemia, myeloid sarcoma, multiple myeloma, acute lymphomas such as acute lymphoblastic lymphoma, chronic myelomonocytic leukemia, etc. + Diseases and conditions include immunosuppressive states or environments resulting from myeloid-derived suppressor cells (MDSCs) in certain cancers and chronic inflammation.

[0116] In some embodiments, antigen-binding tandem diabodies as described herein are administered for the treatment of acute myeloid leukemia (AML). In certain embodiments, antigen-binding tandem diabodies as described herein are administered for the treatment of subtypes of acute myeloid leukemia.

[0117] The FAB classification system divides AML into eight subtypes: AML-M0 (minimal differentiation), AML-M1 (no maturation), AML-M2 (with granulocytic maturation), AML-M3 (promyelocytic leukemia or acute promyelocytic leukemia), AML-4 (acute myelomonocytic leukemia), AML-M5 (acute monoblastic leukemia or monocytic leukemia), AML-M6 (acute erythroleukemia), and AML-M7 (acute megakaryoblastic leukemia). In a specific example, an antigen-binding tandem diabody as described herein is administered for the treatment of AML-M0, AML-M1, AML-M2, AML-M3, AML-M4, AML-M5, AML-M6, or AML-M7.

[0118] The WHO AML Classification System organizes AML according to the following subtypes: AML with recurrent genetic abnormalities, AML with myelodysplasia-associated changes, therapy-related myeloid neoplasm, myeloid sarcoma, myeloproliferation associated with Down's syndrome, blastic plasmacytoid dendritic cell neoplasm, and AML not otherwise classified. In certain other examples, antigen-binding tandem diabodies as described herein are administered for the treatment of AML with recurrent genetic abnormalities, AML with myelodysplasia-associated changes, therapy-related myeloid neoplasm, myeloid sarcoma, myeloproliferation associated with Down's syndrome, blastic plasmacytoid dendritic cell neoplasm, or AML not otherwise classified.

[0119] In some other embodiments, antigen-binding tandem diabodies as described herein are administered for the treatment of newly diagnosed, relapsed, or refractory AML.

[0120] In some embodiments, CD33 and CD3 binding proteins, e.g., antigen-binding tandem diabodies, as described herein are administered to patients who have undergone hematopoietic stem cell transplantation (HCT) for the treatment of relapsed or refractory AML. Patients who have undergone HCT are a specific patient population for whom CD33 and CD3 binding proteins are applicable for the treatment of AML. It is contemplated that by undergoing HCT, patients reestablish their own immune system, including lymphocytes, allowing CD33 and CD3 binding proteins to more effectively bind to cytotoxic T cells and kill tumor cells.

[0121] In many or most cases, patients undergoing HCT have failed previous therapy for the treatment of AML, such as chemotherapy or radiation therapy, and are in remission. In some embodiments, patients undergoing HCT have failed their first chemotherapy or radiation therapy. In some embodiments, patients undergoing HCT have failed a single chemotherapy or radiation therapy. Some AML patients undergoing HCT are in first complete remission (CR1). In some embodiments, AML patients undergoing HCT are relapsed AML patients in second complete remission (CR2).

[0122] In some embodiments, hematopoietic stem cell transplantation is allogeneic (allo-HCT). In allo-HCT, stem cells are sourced from a human leukocyte antigen (HLA)-matched donor other than the patient. The matched donor may or may not be related to the patient. In some cases, a partially matched donor, where one antigen is mismatched, can be used for allo-HCT. Common sources of cells from donors include bone marrow and peripheral blood stem cells. For patients for whom an HLA-matched or partially matched related or unrelated donor is not available, alternative donor sources may be used. Exemplary alternative donor options include umbilical cord transplants or haploidentical transplants. Advantages of allo-HCT include the use of tumor-free grafts and immune-mediated graft-versus-leukemia effects. When infused into the body, donor immune cells can recognize any remaining leukemia cells as foreign and attack them. Disadvantages of allo-HCT include the difficulty of finding a matched or partially matched donor and graft-versus-host disease, in which the immune system established by the donor's cells recognizes the patient's own tissues as foreign and attacks them.

[0123] In some other embodiments, the hematopoietic stem cell transplant is autologous (auto-HCT). Autologous HCT requires the extraction of hematopoietic stem cells from the patient, typically by apheresis, and the storage of the harvested cells in a freezer. The patient is then treated with high-dose chemotherapy, with or without radiation therapy, with the intent of eradicating the patient's malignant cell populations, in exchange for partial or complete bone marrow ablation, i.e., the destruction of the patient's bone marrow function to grow new blood cells. The patient's own stored stem cells are then infused into the patient's bloodstream, where they replace the destroyed tissue and resume the patient's normal blood cell production. Because immune function is restored rapidly, autologous transplants have the advantage of less risk of infection during the immunocompromised period of the procedure. Furthermore, the incidence of patients experiencing acute or chronic graft-versus-host disease rejection is extremely rare because the donor and recipient are the same individual.

[0124] In further embodiments, patients undergo a conditioning regimen prior to HCT. In some embodiments, the conditioning regimen prior to HCT can provide sufficient immunosuppression to ensure engraftment and without significant toxicity. The conditioning regimen can be myeloablative or non-myeloablative, also known as reduced-intensity conditioning (RIC) regimen.

[0125] In some embodiments, the conditioning regimen is myeloablative. Myeloablative conditioning regimens remove bone marrow cells, including AML cells, and are typically performed by total body irradiation (TBI), administration of cyclophosphamide, administration of busulfan, or a combination thereof. Exemplary cyclophosphamides include endoxan, cytoxan, neosar, procytox, revimmune, and cycloblastin. In some embodiments, the conditioning regimen is non-myeloablative, i.e., reduced-intensity pre-transplant (RIC). RIC regimens involve lower doses of chemotherapy and / or radiation than myeloablative treatments. Therefore, RIC regimens are considered milder, not eradicating all bone marrow cells, and can be used in patients, such as elderly patients, who cannot undergo myeloablative conditioning regimens.

[0126] In some embodiments, CD33 and CD3 binding proteins, e.g., antigen-binding tandem diabodies, described herein, are administered to AML patients undergoing auto-HCT after myeloablative conditioning. In some embodiments, antigen-binding tandem diabodies are administered to AML patients undergoing allo-HCT after myeloablative conditioning. In some embodiments, patients undergoing allo-HCT after myeloablative conditioning are in complete remission (CR), and administering a CD33 and CD3 binding protein as described herein after allo-HCT reduces the likelihood of developing relapsed or refractory AML. In some embodiments, patients undergoing allo-HCT after myeloablative conditioning are in CR but have minimal residual disease (MRD), and administering a CD33 and CD3 binding protein as described herein after allo-HCT reduces the likelihood of developing relapsed or refractory AML. In some embodiments, patients undergoing allo-HCT after myeloablative conditioning have MRD, and administration of CD33 and CD3 binding proteins as described herein after allo-HCT reduces the likelihood of developing relapsed or refractory AML.

[0127] Certain preclinical studies have shown that more intensive transplant conditioning treatments result in a pro-inflammatory cytokine environment that supports the progression of acute graft-versus-host disease. An exemplary intensive transplant conditioning treatment includes very high-dose TBI treatment. In some embodiments, administering CD33 and CD3 binding proteins described herein to AML patients undergoing allogeneic HCT after intensive transplant conditioning treatment does not result in a pro-inflammatory cytokine environment, reducing the likelihood of acute graft-versus-host disease.

[0128] In further embodiments, CD33 and CD3 binding proteins, e.g., antigen-binding tandem diabodies, are administered to AML patients undergoing auto-HCT after RIC treatment. In some embodiments, antigen-binding tandem diabodies are administered to AML patients undergoing allo-HCT after RIC treatment. An exemplary minimal-intensity conditioning regimen includes administering fludarabine in combination with TBI. In some embodiments, fludarabine is administered at 30 mg / m for 3 days with 2 Gy of TBI. 2

[0013] The CD33 and CD3 binding proteins described herein are administered at a dose of 100 mg / day. Several studies have reported that non-myeloablative or RIC conditioning regimens are associated with 2-year overall survival rates of 34% to 50%, 2-year non-relapse mortality (NRM) rates of 22% to 34%, acute graft-versus-host disease rates of 33% to 35%, and chronic graft-versus-host disease rates of 41% to 53%. In some embodiments, CD33 and CD3 binding proteins described herein are administered to AML patients undergoing allo-HCT after RIC conditioning regimens. In some embodiments, administering antigen-binding tandem diabodies described herein to AML patients undergoing allo-HCT after RIC conditioning regimens results in improved overall survival, reduced NRM rates, and / or reduced incidence of acute or chronic graft-versus-host disease.

[0129] In some embodiments, CD33 and CD3 binding proteins are administered to AML patients undergoing allo-HCT after RIC treatment. In some embodiments, patients undergoing allo-HCT after RIC treatment are in complete remission (CR), and administering CD33 and CD3 binding proteins as described herein after allo-HCT reduces the likelihood of developing relapsed or refractory AML. In some embodiments, patients undergoing allo-HCT after RIC treatment are in CR but have minimal residual disease (MRD), and administering an antigen-binding tandem diabody as described herein after allo-HCT reduces the likelihood of developing relapsed or refractory AML. In some embodiments, patients undergoing allo-HCT after RIC treatment have MRD, and administering an antigen-binding tandem diabody as described herein after allo-HCT reduces the likelihood of developing relapsed or refractory AML.

[0130] In some embodiments, CD33 and CD3 binding proteins as described herein are administered with donor lymphocytes to patients undergoing allo-HCT during AML progression. In some embodiments, antigen-binding tandem diabodies as described herein are administered without donor lymphocytes to patients undergoing allo-HCT during AML progression.

[0131] In some embodiments, the overall response rate in AML patients administered CD33 and CD3 binding proteins as described herein after allo-HCT is higher than the overall response rate in AML patients administered CD33 and CD3 binding proteins as described herein without prior allo-HCT. In some embodiments, AML patients undergoing allo-HCT after myeloablative or reduced-intensity conditioning have functional T cells for binding CD33 and CD3 binding proteins as described herein, and administering CD33 and CD3 binding proteins as described in the presence of functional T cells results in improved success of treating AML.

[0132] In further embodiments, antigen-binding tandem diabodies as described herein are administered for the treatment of pre-leukemic hematological disorders such as myelodysplastic syndromes (MDS) or myeloproliferative disorders (MPD). In particular examples, antigen-binding tandem diabodies as described herein are administered for the treatment of MDS. In particular examples, antigen-binding tandem diabodies as described herein are administered for the treatment of MPD.

[0133] In other embodiments, antigen-binding tandem diabodies as described herein are administered for the treatment of multiple myeloma. In further embodiments, antigen-binding tandem diabodies as described herein are administered for the treatment of chronic myelomonocytic leukemia (CMML).

[0134] In other embodiments, antigen-binding tandem diabodies as described herein are administered to inhibit or eliminate myeloid-derived suppressor cells (MDSCs). MDSCs highly overexpress CD33 in certain isolated diseased tissues and have potent immunosuppressive activity. In certain human cancers (CD33 + and non-CD33 + ) MDSCs proliferate and express tumor-specific CD4 + Suppresses T cell responses and T regMDSCs are activated to induce T cell proliferation, allowing tumors or cancers to thrive in the microenvironment. In chronic inflammation, MDSCs have been reported to proliferate and be found at the site of inflammation to suppress T cell immune function. In other embodiments, antigen-binding tandem diabodies as described herein are administered to treat conditions associated with MDSCs. In yet other embodiments, antigen-binding tandem diabodies as described herein are administered to treat immunosuppression. In yet other embodiments, antigen-binding tandem diabodies as described herein are administered to treat inflammation suppressed by MDSCs. In yet other embodiments, antigen-binding tandem diabodies as described herein are administered to treat a depressed immune response caused by MDSCs. In yet other embodiments, antigen-binding tandem diabodies as described herein are administered to treat angiogenesis, tumor invasion, or cancer metastasis promoted by MDSCs. In yet other embodiments, antigen-binding tandem diabodies as described herein are administered to treat cancers or tumors that are enhanced, augmented, exacerbated, or increased by MDSCs.

[0135] The antigen-binding tandem diabodies described herein are intended for use as drugs. Administration can be achieved by various methods, such as intravenous, intraperitoneal, subcutaneous, intramuscular, topical, or intradermal administration. In some embodiments, the route of administration depends on the type of treatment and the type of compound included in the pharmaceutical composition. The dosing regimen will be determined by the attending physician and other clinical factors. The amount administered to a single patient will depend on many factors, including the patient's size, body surface area, age, sex, the specific compound being administered, the time and route of administration, the type of treatment, health status, and other drugs being administered concomitantly. An "effective amount" refers to the amount of active ingredient sufficient to affect the course and severity of the disease, thereby causing a reduction or remission of the condition. An "effective amount" useful for treating and / or preventing AML can be determined using known methods.

[0136] In a further embodiment, the antigen-binding tandem diabodies described herein are CD33 +In certain instances, the antigen-binding tandem diabodies described herein are administered in combination with standard treatments for the cancer, disease, or condition. Standard treatments include chemotherapy, immunotherapy, hormone therapy, radiation, surgery, gene therapy, etc. In certain instances, the antigen-binding tandem diabodies described herein are administered in combination with standard treatments for AML. In certain examples, the antigen-binding tandem diabodies described herein are administered in combination with cytarabine, azacitidine, decitabine, anthracyclines (e.g., daunorubicin, idarubicin, doxorubicin, etc.), amsacrine, fludarabine, clofarabine, cladribine, nelarabine, methotrexate, bortezomib, carfilzomib, melphalan, ibrutinib, thalidomide, lenalidomide, pomalidomide, apremilast, epipodophyllotoxins (e.g., etoposide, teniposide, etc.), anthracenediones (e.g., mitoxantrone, pixantrone, losoxantrone, piroxantrone, amethantrone, etc.), anti-CD20 agents (e.g., rituximab, ocrelizumab, ofatumumab), or combinations thereof. In certain examples, the antigen-binding tandem diabodies described herein are administered in combination with cytarabine (ara-C). In certain examples, the antigen-binding tandem diabodies described herein are administered in combination with azacitidine. In certain examples, the antigen-binding tandem diabodies described herein are administered in combination with decitabine. In further examples, the antigen-binding tandem diabodies described herein are administered in combination with an anthracycline (e.g., daunorubicin, idarubicin, doxorubicin, etc.). In other examples, the antigen-binding tandem diabodies described herein are administered in combination with a checkpoint inhibitor (e.g., a PD-1 inhibitor, a CTLA-4 inhibitor, etc.). In yet other examples, the antigen-binding tandem diabodies described herein are administered in combination with an epipodophyllotoxin (e.g., etoposide, teniposide, etc.). In yet another example, an antigen-binding tandem diabody described herein is administered in combination with an anthracenedione (e.g., mitoxantrone, pixantrone, losoxantrone, piroxantrone, amethantrone, etc.).

[0137] The following examples further illustrate the described embodiments without limiting the scope of the invention. [Example]

[0138] Example 1 Cloning of DNA expression constructs encoding single-chain Fv antibodies For bacterial expression of anti-CD33 single-chain Fv (scFv) antibodies in E. coli, the DNA coding sequences of all molecules were cloned into a bacterial expression vector. All expression constructs were designed to contain coding sequences for an N-terminal signal peptide and a C-terminal hexahistidine (6xHis) tag to facilitate antibody secretion into the periplasm and purification, respectively. The amino acid sequences of the VL and VH domains from all anti-CD33 scFv clones are shown in Tables 3 and 4.

[0139] Expression of recombinant anti-CD33 scFv antibody in Escherichia coli Recombinant scFv antibodies were expressed as soluble, secreted proteins in the E. coli periplasm. In the first step, transformed bacteria were inoculated into a small volume of culture medium supplemented with ampicillin and incubated at 28°C for 16 hours. The optical density was then adjusted by adding a second medium supplemented with ampicillin, and the culture was incubated again at 28°C until the optical density at 600 nm reached a range of 0.6-0.8. Protein expression was induced by adding 50 μM IPTG and incubating the culture at 21-28°C at 200 rpm for up to 16 hours. After incubation, the cells were pelleted (30 minutes, 4°C, 7500 rpm) and stored at -20°C until further processing.

[0140] Purification of anti-CD33 single-chain Fv antibody Recombinant scFv was extracted from the E. coli periplasm by centrifugation of the bacterial cell culture, resuspending the cell pellet in buffer, and incubating at room temperature for 30 minutes with gentle agitation. The cells were pelleted, and the supernatant containing the recombinant protein was retained. This procedure was repeated once more, after which the supernatants were pooled and homogenized by sonication. The homogenate was diluted, supplemented with a low concentration of imidazole, and applied to a pre-packed immobilized metal affinity chromatography (IMAC) column (GE Healthcare). The column was washed until a baseline was reached, after which the bound protein was eluted with imidazole buffer. The antibody-containing fractions were pooled and subsequently purified by size-exclusion chromatography (SEC). Finally, the protein eluate was concentrated by ultrafiltration and dialyzed against storage buffer. After low pH treatment (incubation at 37°C for 20–24 hours at pH 3.0), the sample was neutralized using Tris. The purified protein was stored in aliquots at −80°C until use.

[0141] Example 2 Cloning of DNA expression constructs encoding tandem diabodies (TandAbs®) For expression of bispecific tandem diabodies in CHO cells, the coding sequences of all molecules were cloned into a mammalian expression vector system. The anti-CD33 scFv domain from Example 1 was used in combination with the anti-CD3 scFv domain to construct a CD33 / CD3 tandem diabody. The domains are organized as shown in Table 7 and Figure 3. Briefly, gene sequences encoding the anti-CD33 VH and VL domains separated by a peptide linker (VH-linker-VL or VL-linker-VH) were synthesized and subcloned. The resulting construct was digested, and separate VH and VL coding sequences were generated using the BamHI restriction site located within the linker sequence. These VH and VL fragments were then ligated with DNA fragments encoding the anti-CD3 VH and VL domains (VH-linker-VL or VL-linker-VH) to obtain the final construct. Domain order variants 1 to 3 of the CD33 / CD3 tandem diabody are shown in Figure 3. All expression constructs were designed to contain coding sequences for an N-terminal signal peptide and a C-terminal hexahistidine (6xHis) tag to facilitate antibody secretion and purification, respectively.

[0142] Expression of tandem diabodies in stably transfected CHO cells The CHO cell expression system (Flp-In®, Life Technologies), a derivative of CHO-K1 Chinese hamster ovary cells (ATCC, CCL-61) (Kao and Puck, Proc. Natl. Acad Sci USA 1968; 60(4):1275-81), was used. Adherent cells were subcultured according to the standard cell culture protocol provided by Life Technologies.

[0143] For adaptation to growth in suspension, cells were detached from tissue culture flasks and placed in serum-free medium. Suspension-adapted cells were cryopreserved in medium containing 10% DMSO.

[0144] Recombinant CHO cell lines stably expressing the secreted tandem diabody were generated by transfection of suspension-adapted cells. During selection with the antibiotic hygromycin B, viable cell density was measured twice a week, and cells were centrifuged and cultured at 0.1 × 10 6 The cells were resuspended in fresh selection medium at a maximum density of viable cells / mL. Cell pools stably expressing the tandem diabody were harvested after 2–3 weeks of selection, at which point the cells were transferred to standard culture medium in shake flasks. Expression of the recombinant secreted protein was confirmed by protein gel electrophoresis or flow cytometry. Stable cell pools were cryopreserved in DMSO-containing medium.

[0145] Tandem diabodies were produced by secretion into the cell culture supernatant in a stably transfected CHO cell line in a fed-batch culture for 10 days. Cell culture supernatant was harvested after 10 days, typically at >75% culture viability. Samples were collected from the production culture every other day to assess cell density and viability. On the day of harvest, the cell culture supernatant was clarified by centrifugation and vacuum filtration before further use.

[0146] Protein expression titer and product integrity in cell culture supernatants were analyzed by SDS-PAGE.

[0147] Purification of tandem diabodies Tandem diabodies were purified from CHO cell culture supernatants in a two-step procedure. His6-tagged constructs were subjected to Ni-NTA Superflow chromatography in the first step, followed by preparative size-exclusion chromatography (SEC) on a Superdex 200 column in the second step. Eluted tandem diabodies were characterized for their homodimer (tandem diabody) content and pooled if the homodimer content was 90% or greater. Finally, the pooled samples were buffer-exchanged and concentrated by ultrafiltration to a typical concentration of >1 mg / mL. The purity and homogeneity of the final samples (typically >90%) were assessed by SDS-PAGE under reducing and non-reducing conditions, followed by immunoblotting using an anti-His tag antibody and analytical SEC, respectively. The purified proteins were stored in aliquots at -80°C until use.

[0148] The polypeptides of the CD33 / CD3 tandem diabodies are shown in Table 7 and Figure 3. Each tandem diabody consists of two identical polypeptides (Figure 1). The outer linkers, L1 and L3, both consist of the six amino acids GGSGGS (SEQ ID NO:95), while the central peptide linker 2 is variable in length (4-6 amino acids) and has the sequence GGSG (SEQ ID NO:96), GGSGG (SEQ ID NO:97), or GGSGGS (SEQ ID NO:95), respectively.

[0149] Using a series of anti-CD33 and anti-CD3 variable domains, we generated a number of tandem diabody molecules that were stably produced in transfected cell lines and maintained stability at body temperature and after repeated freeze / thaw cycles. To facilitate further development and preclinical toxicity studies, we focused on selecting tandem diabody molecules that demonstrated binding to both human and cynomolgus monkey CD33. Example complete amino acid sequences are shown for the single chains of tandem diabodies 12 (SEQ ID NO:109), 14 (SEQ ID NO:111), and 16 (SEQ ID NO:113) in Figures 10L, 10N, and 10P, respectively. In this example, the order of the variable domains and their linkers in terms of structure is as follows: VL(CD3)-L1-VH(CD33)-L2-VL(CD33)-L3-VH(CD3). The C-terminal hexahistidine (6xHis) tag is cleaved during purification. The complete amino acid sequences of the above-mentioned tandem diabodies after removal of the hexahistidine tag are Tandem Diabody 12 (SEQ ID NO:134), Tandem Diabody 14 (SEQ ID NO:136), and Tandem Diabody 16 (SEQ ID NO:138), as shown in Figures 11L, 11N, and 11P, respectively.

[0150] Example 3 Determining antibody affinity by flow cytometry Cells were incubated with 100 μL of serially diluted CD33 / CD3 tandem diabody. After three washes with FACS buffer, the cells were incubated with 0.1 mL of 10 μg / mL mouse monoclonal anti-His antibody in the same buffer for 45 minutes on ice. After a second wash cycle, the cells were incubated with 0.1 mL of 15 μg / mL FITC-conjugated goat anti-mouse IgG antibody under the same conditions as before. As a control, cells were incubated with anti-His IgG followed by FITC-conjugated goat anti-mouse IgG antibody without anti-CD33 tandem diabody. The cells were then washed again and resuspended in 0.2 mL of FACS buffer containing 2 μg / mL propidium iodide (PI) to exclude dead cells. 1 × 10 4 The fluorescence of live cells was measured using a Beckman-Coulter FC500 MPL flow cytometer with MXP software (Beckman-Coulter, Krefeld, Germany) or a Millipore Guava EasyCyte flow cytometer with Incyte software (Merck Millipore, Schwalbach, Germany). The mean fluorescence intensity of cell samples was calculated using CXP software (Beckman-Coulter, Krefeld, Germany) or Incyte software (Merck Millipore, Schwalbach, Germany). After subtracting the fluorescence intensity values ​​of cells stained with the second and third reagents alone, this value was calculated using the K equation for one-site binding (hyperbolic) in GraphPad Prism (version 6.00 for Windows, GraphPad Software, La Jolla, California, USA). D was used to calculate the value.

[0151] Tandem diabodies were synthesized using human CD3 + and CD33 + Cells and cynomolgus monkey CD3 + and CD33 +Their binding affinity to cells was tested. Exemplary binding data for selected tandem diabodies is summarized in Table 8.

[0152] Table 8. CD3 and CD33 binding characteristics of CD33 / CD3 tandem diabodies TIFF0007583014000009.tif201140

[0153] #K D The ratio cynomolgus CD33 / human CD33 was measured on CHO cells expressing cynomolgus CD33 and human CD33, respectively. D was calculated based on the values. TIFF0007583014000010.tif5128 The ratio hu CD3 / hu CD33 was measured on Jurkat cells (hu CD3). D values, and three human CD33 + Average K of tumor cell lines (HL-60, KG-1, U937) D was calculated based on the

[0154] CD3 binding affinity and cross-reactivity were determined using CD3 + Jurkat cells (provided by Dr. Moldenhauer, DKFZ Heidelberg; human acute T-cell leukemia) and cynomolgus monkey CD3 + CD33 binding and cross-reactivity were assessed in titration and flow cytometry experiments against the HSC-F cell line (JCRB, cat.:JCRB1164). + The following tumor cell lines were evaluated: HL-60 (DSMZ, cat.:ACC 3; human B-cell precursor leukemia), U-937 (DSMZ, cat.:ACC 5; human reticulum cell sarcoma), and KG-1 (DSMZ, cat.:ACC 14; acute myeloid leukemia). D The ratios were calculated using the K D The values ​​were used to calculate.

[0155] The tandem diabody inhibited human CD33 on most tumor cell lines tested. + It showed relatively high affinity for human CD3 (<1 nM), whereas its affinity for human CD3 was determined to be ≤2 nM.

[0156] Example 4 Cytotoxicity assay For the cytotoxicity assay, target cells cultured under standard conditions were harvested, washed, and diluted to 2 × 10 in Diluent C provided in the PKH67 Green Fluorescent Cell Linker Mini Kit. 7 The cells were resuspended to a density of 2 × 10 cells / mL. The cell suspension was then mixed with an equal volume of 2x concentrated PKH67 labeling solution and incubated at RT for 2–5 min. The staining reaction was carried out by adding an equal volume of FCS and incubating for 1 min. After washing the labeled target cells with complete RPMI medium, the cells were counted and plated at 2 × 10 cells / mL in complete RPMI medium. 5 The cells were then resuspended to a density of 2 x 10 cells / mL. 4 Target cells were seeded into individual wells of a microtiter plate at an E:T ratio of 5:1 in the presence of increasing concentrations of the indicated tandem diabody in a total volume of 200 μL / well, along with enriched human T cells as effector cells. Spontaneous cell death in the absence of antibody and target killing by T cells were measured in at least three replicates on each plate. After centrifugation, the assay plates were incubated at 37°C in a humidified atmosphere containing 5% CO2 for the indicated periods. After incubation, the cultures were washed once with FACS buffer and then resuspended in 150 μL of FACS buffer supplemented with 2 μg / mL PI. The absolute number of viable target cells was measured by positive green staining with PKH67 and negative staining with PI using a Beckman-Coulter FC500 MPL flow cytometer (Beckman-Coulter) or a Millipore Guava EasyCyte flow cytometer (Merck Millipore). Based on the measured remaining viable target cells, the percentage of specific cell lysis was calculated according to the following formula: [1-(viable target(サンプル) Number of live targets (自発) (number of subjects) × 100%. Sigmoidal dose-response curve and EC 50 Values ​​were calculated by nonlinear regression / four-parameter logistic fit using GraphPad software. The lysis values ​​obtained for a given antibody concentration were used to calculate a sigmoidal dose-response curve by four-parameter logistic fit analysis using Prism software.

[0157] EC 50 Values ​​are based on the CD33 + The tandem diabodies were also measured in a 20-24 hour assay on U-937 (DSMZ, cat.:ACC5; human reticulum cell sarcoma) target cells. + KG-1 (DSMZ, cat.:ACC14; acute myeloid leukemia) and HL-60 were tested in cytotoxicity assays. Specifically, HL-60 cells were chosen as a model of AML with relatively high CD33 cell surface expression (arbitrary MFI [mean ± SEM]: 3,133 ± 215; n = 3), and KG-1a was chosen as a model of AML with very limited CD33 expression (arbitrary MFI: 277 ± 11; n = 3). Exemplary cytotoxicity data for selected tandem diabodies are summarized in Table 9. Additional cytotoxicity data for the HL-60 cell line are found in the last column of Table 8.

[0158] Table 9. Different CD33 + In vitro efficacy of CD33 / CD3 tandem diabodies against tumor cell lines TIFF0007583014000011.tif36170

[0159] In a FACS-based cytotoxicity assay using primary human T cells as effector cells at an E:T ratio of 5:1 for the indicated target cell lines incubated for 20–24 h, EC 50Values ​​were measured. Each tandem diabody was tested against each tumor cell line in at least two independent experiments. Mean values ​​are presented.

[0160] Example 5 Human CD33 at 48 hours + Further cytotoxicity screening experiments in AML cell lines As mentioned above, significant cytotoxicity was detected as early as 24 hours, but higher levels of toxicity could be detected at 48 hours. For the next assay, the 48-hour time point was chosen. We tested the effect of T cell selection on tandem diabody-induced cytotoxicity. To accomplish this, unstimulated PBMCs were obtained from healthy volunteer donors and CD3 + Cells were isolated by both simple "positive enrichment" using CD3 microbeads and more complex "negative selection" using a microbead cocktail of antibodies against CD14, CD15, CD16, CD19, CD34, CD36, CD56, CD123, and CD235a. As shown in Figure 4, tandem diabody-induced cytotoxicity was greater in negatively selected healthy donor T cells than in positively selected T cells. However, the relative cytotoxic activity of individual tandem diabodies was not affected by the method of T cell selection. Therefore, subsequent assays were performed with positively enriched healthy donor T cells.

[0161] Unstimulated mononuclear cells were collected from healthy adult volunteers via leukapheresis by the Fred Hutchinson Cancer Research Center (FHCRC) Hematopoietic Cell Processing Core (Core Center of Excellence) under a research protocol approved by the FHCRC Institutional Review Board. T cells were enriched by magnetic cell sorting via either CD3 microbeads ("positive enrichment") or a Pan T cell cell isolation kit ("negative selection") (both from Miltenyi Biotec, Auburn, CA), frozen in aliquots, and stored in liquid nitrogen. Thawed cell aliquots were labeled with 3 μM CellVue Burgundy (eBioscience, San Diego, CA) according to the manufacturer's instructions. Purified PBMCs were cultured in the presence of various concentrations of tandem diabody molecules.

[0162] For quantification of drug-induced cytotoxicity, cells were incubated at 37°C (in 5% CO2 and air) at different E:T cell ratios as in Example 4. After 24-72 hours, cell number and drug-induced cytotoxicity were determined with an LSRII cytometer (BD Biosciences) using DAPI to detect nonviable cells and analyzed with FlowJo. AML cells were identified by forward / side scatter characteristics and, in experiments where healthy donor T cells were added, were negative for CellVue Burgundy dye (Figure 5). Drug-induced specific cytotoxicity is presented as follows: % cytotoxicity = 100 × (1 - target viable cells) 処置 / Target live cells 対照 ). Cytotoxicity assay results are presented as mean ± standard error of the mean (SEM). Correlations between continuous sample characteristics were calculated using Spearman's nonparametric correlation. All P values ​​are two-sided. Statistical analysis was performed using GraphPad Prism software.

[0163] In the absence of healthy donor T cells, neither CD33 / CD tandem diabody exerted a significant cytotoxic effect on AML cell lines in the absence of T cells, confirming the absolute requirement for T cells for their cytotoxic effect (data not shown). In the presence of T cells, the extent of specific cytotoxicity induced by the tandem diabodies depended on the tandem diabody concentration and E:T cell ratio. Direct comparison of the CD33 / CD3-directed tandem diabody molecules with one control tandem diabody (00) showed substantial differences in antibody-induced cytotoxicity in both HL-60 cells (Figure 6A / B and Table 10) and KG-1a cells (Figure 6C / D and Table 10), and the results were highly reproducible in repeated experiments. Overall, the degree of tandem diabody-induced cytotoxicity correlated with the binding affinity of CD3 on primary human T cells (for cytotoxicity in KG-1a cells, 25 pM (approximately 2.5 ng / mL) and E:T = 5:1: r = -0.542, p = 0.009; for cytotoxicity in HL-60 cells, 25 pM and E:T = 5:1: r = -0.391, p = 0.07). Tandem diabodies 12, 14, and 16 were highly cytotoxic to both HL-60 and KG-1a cells.

[0164] Table 10. CD25 and CD69 induction and cytotoxicity of CD33 / CD3 tandem diabodies at 48 hours TIFF0007583014000012.tif182170 1 Tandem diabodies (TandAbs) are listed in order of increasing CD3 affinity. 2 CD25 and CD69 induction was measured after 24 hours in unfractionated PBMC cultures. 3 CD33 / CD3 tandem diabody-induced T cell proliferation in unfractionated PBMCs in the presence of CD33+ cells. 4Cytotoxicity (%) after 48 hours in DAPI+ cells at a tandem diabody concentration of 25 pM in the presence of healthy donor T cells at an E:T cell ratio of 5:1 from three independent experiments performed in duplicate wells. ND: CD25 activation not detectable.

[0165] Example 6 Further characterization of tandem diabodies in primary human AML specimens For comprehensive characterization of the cytotoxic properties of these candidates, specimens from AML patients were obtained for research use from the FHCRC specimen repository.

[0166] Frozen aliquots of Ficoll-separated mononuclear cells from pretreatment ("diagnostic") peripheral blood or bone marrow specimens from adult AML patients were obtained from a repository at the FHCRC. The 2008 WHO criteria (Vardiman et al.; Blood. 2009; 114(5):937-951) were used to define AML, and the revised UK Medical Research Council (MRC) criteria (Grimwalde et al.; Blood. 2010; 116(3):354-365) were used to assign cytogenetic risk. Patients provided written informed consent for the collection and use of biospecimens for research purposes under a protocol approved by the FHCRC Institutional Review Board. Clinical data were de-identified in accordance with Health Insurance Portability and Accountability Act regulations. After thawing, cells were stained with directly labeled antibodies recognizing CD33 (clone P67.6; PE-Cy7 conjugate), CD3 (clone SK7; PerCP conjugate), CD34 (clone 8G12; APC conjugate; all from BD Biosciences, San Jose, CA), and CD45 (clone HI30; APC-eFluor® 780 conjugate; eBioscience). To identify nonviable cells, samples were stained with 4',6-diamidino-2-phenylindole (DAPI). At least 10,000 events were acquired on a Canto II flow cytometer (BD Biosciences), and DAPI cells were analyzed using FlowJo (Tree Star, Ashland, OR).

[0167] After thawing, specimens contained >58% AML blasts as determined by flow cytometry based on CD45 / side scatter characteristics. Specimens contained >50% viable cells immediately after thawing and >50% viable cells after 48 hours of cytokine-containing liquid culture (Figure 7). The median age of patients was 58.1 years (range: 23.9-76.2); cytogenetic disease risk was favorable in 2, intermediate in 18, and adverse in 7. Information on NPM1, FLT3, and CEBPA mutation status was incomplete, but one sample contained CEBPA.二重突然変異体 Another sample is known to be NPM1 pos / FLT3-ITD neg Myeloblast and CD3 in the studied specimens + The median percentages of T cells were 86.1% (range: 58.4–97.0%) and 2.0% (range: 0–11.9%), respectively, and the median sample viability after 48 hours of culture was 80.1% (range: 53.6–93.6%). Fifteen of the patients had newly diagnosed AML, whereas 12 had either relapsed (n = 7) or refractory (n = 5) disease at the time of specimen collection. As summarized in Table 11, baseline characteristics of specimens from patients with newly diagnosed AML were similar to those of patients with relapsed / refractory disease with regard to CD33 expression on myeloblasts, amount of autologous T cells, proportion of myeloblasts, and culture viability.

[0168] Addition of tandem diabody molecules to cultures of AML specimens resulted in modest dose-dependent cytotoxicity (Figure 8A), demonstrating that autologous T cells contained in specimens from patients with active AML could be bound to lyse leukemic cells. In the presence of healthy donor T cells, the cytotoxic activity of individual tandem diabodies was strictly dependent on the drug dose and E:T cell ratio (Figure 8B / C). However, high activity of tandem diabodies was observed even in some specimens with very low CD33 expression on AML blasts. Among the tandem diabody molecules, 12 appeared to be the most active, as it had the highest cytotoxicity at low concentrations (2.5 pM (approximately 250 ng / mL) and, to a lesser extent, 10 pM (approximately 1 ng / mL)) at both E:T = 1:3 and E:T = 1:1.

[0169] CD33 / CD3 tandem diabodies were screened in blood samples from representative AML patients. The samples varied with respect to patient gender, age, disease stage (newly diagnosed, relapsed, refractory), degree of CD33 expression, and cytogenetic risk (Table 11). Notably, many of the tested tandem diabodies (e.g., 02, 08, 09, 11, 12, 14, 16, 19, 22, and 23) were highly active in nearly all patient samples across the disease spectrum, as shown in Figure 17. Furthermore, the degree and range of activity was similar across all stages of AML, including newly diagnosed, relapsed, and refractory patients.

[0170] Table 11. Characteristics of primary AML specimens TIFF0007583014000013.tif80170

[0171] Example 7 Different CD33s from various sources express different levels of CD33 + Potency and efficacy of CD33 / CD3 tandem diabodies 12 and 16 on cell lines To assess whether the potency and efficacy of CD33 / CD3 tandem diabodies depend on the CD33 density on target cells, various human CD33 + Tumor cell lines and CHO cells expressing recombinant human CD33 were tested for their CD33 expression levels using the QIFIKIT quantification kit and anti-CD33 mAb WM53. The results in Table 12 show that CD33 density on tumor cell lines ranged from approximately 1,300 SABC (normalized antibody binding capacity) to approximately 46,000 SABC. Expression on CHO-CD33 cells was approximately 197,000 SABC, which was substantially higher than that on tumor cell lines. The CD33 expression levels tested were approximately 197,000 SABC. +All cell lines were used as target cells in at least three independent FACS-based cytotoxicity assays using human T cells as effector cells at a target to effector ratio of 5:1 in the presence of serial dilutions of CD33 / CD3 tandem diabody 12 and tandem diabody 16. In each assay, EC 50 and tandem diabody-mediated lysis values ​​were calculated by nonlinear regression. 50 It is demonstrated that neither the CD33 concentration (value) nor the efficacy (% lysis) correlates with the density of CD33 on the surface of the target cells.

[0172] Notably, at least 12 and 16 exhibit cytotoxic activity against cells such as SEM, which have very low CD33 densities of less than 1500 SABC.

[0173] Table 12. CD33 target cell surface expression and cytotoxic potency of CD33 / CD3 tandem diabodies 12 and 16 TIFF0007583014000014.tif63170

[0174] CD33 + Normalized antibody binding capacity (SABC) against cell lines was determined using QIFIKIT and anti-CD33 mAb WM53. EC of tandem diabody 12 and tandem diabody 16 redirected target cell lysis. 50 Values ​​were determined in a FACS-based cytotoxicity assay using human primary T cells as effector cells at an E:T ratio of 5:1 after 20-24 h of incubation, and in assays with CD33-expressing CHO cells after 40-48 h of incubation. Means and SD of at least three independent assays are shown.

[0175] Example 8 TandAb activation of T cells and killing of AML cells in vitro The TandAb was applied to purified human T cells and VPD-450-labeled human CD33 +Leukemia cell line KG-1, or CD33 - The cells were incubated with the human ALL cell line G2 (E:T 5:1). Flow cytometry was used to assess target cell lysis by the TandAb (10 -15 ~10 -8 M; 24 hours, 37℃).

[0176] Incubation of TandAbs 12, 16, and 19 with human T cells efficiently lysed KG-1 cells (IC50 ~ 0.01, 0.5, and 5 pM, respectively). Up to 40% of T cells were activated (CD25+) and showed increased cytotoxic activity. Control TandAbs with an irrelevant target, 00 (>10 -7 M) did not cause significant killing of KG-1 in vitro. Separately, 16 induced lysis of KG-1 cells (IC50 = 5 × 10 -12 M), while 1 × 10 -8 M had no effect on CD33-G2 cells. This result suggests that CD33 / CD3 TandAb inhibits CD33 + Leukemia cells (KG-1) and primary CD33 + Targeting AML blasts results in activated T cells that potently lyse tumor cells.

[0177] Example 9 Epitope mapping To identify the CD33-binding epitope, tandem diabodies containing different CD33-binding moieties were subjected to epitope mapping using CLIPS Technology (Pepscan).

[0178] CLIPS Technology facilitates the structuring of peptides into single loops, double loops, triple loops, sheet folds, helical folds, and combinations thereof, offering the possibility to map discontinuous epitopes of target molecules.

[0179] An array of over 7000 independent peptides was synthesized and the binding of each antibody to the peptides was tested by ELISA.

[0180] Tandem diabodies 12, 14, 16, and 22 stretch across the first Ig-like domain of human CD33. 62 DQEVQEETQ 70 (SEQ ID NO:94). The respective amino acid stretches are underlined and bolded in Figures 10 and 11. Tandem diabodies 01, 02, 04, 06, 08, 09, 13, and 23 share the same CD33 binding domain as tandem diabodies 12, 14, 16, and 12 (SEQ ID NOs:2 and 12, 3 and 13, 5 and 15, 9 and 19), and are therefore contemplated to also bind this epitope.

[0181] Example 10 Dose response in a preventative in vivo tumor model Tandem diabodies 12 and 16 were compared at different dose levels in a prophylactic HL-60 tumor xenograft model in NOD / scid mice reconstituted with human T cells. Three dose levels were selected to achieve a dose response: 10, 1, and 0.1 μg (0.5, 0.05, and 0.005 mg / kg).

[0182] Eight experimental groups of immunodeficient NOD / scid mice received 4 × 10 6 A suspension of HL-60 cells was injected subcutaneously. 3 × 10 cells were isolated from buffy coats (healthy donors) using negative selection prior to injection. 6 The tumor cells were mixed with T cells from 100% donor-specific donors. To address the potential for donor-specific T cell variability, each experimental group was subdivided into three cohorts, each receiving T cells from only one individual donor. All animals in the experimental groups transplanted with tumor cells and T cells received intravenous boluses of either vehicle (control) or 16 or 12 doses of three different dose levels (0.1 μg, 1 μg, and 10 μg) as indicated on days 0, 1, 2, 3, and 4 (qdxd5). One vehicle-treated group without effector cells served as an additional control. Table 13 summarizes the group assignments and dosing schedules.

[0183] (Table 13) TIFF0007583014000015.tif198170

[0184] Treatment groups for in vivo dose-response studies in the HL-60 xenograft model. All animals in the control group steadily developed tumors and showed homogeneous tumor growth. The presence of T cells had no effect on tumor growth. No differences in HL-60 proliferation were observed with or without T cells in the vehicle-treated control group.

[0185] Treatment with both test items revealed a clear dose-dependent antitumor effect (Figure 12). No substantial differences were found between the two tandem diabodies. The plot of mean tumor volume in Figure 12 is limited to Day 29, when the majority of treatment groups were completed. The study continued through Day 45, and animals were observed for tumor-free survival. In the groups treated with 10 μg or 1 μg of 16, six of nine animals were tumor-free at the end of the observation period, and five of nine animals receiving 10 μg of 12 were tumor-free at Day 45. One animal remained tumor-free when treated with 1 μg of 12.

[0186] All control animals developed tumors robustly and showed homogeneous tumor growth. Treatment with either tandem diabody revealed a dose-dependent antitumor effect, with no substantial differences between the two tandem diabodies observed by day 29.

[0187] Detectable differences were only observed after long-term observation (45 days), at which point the low-dose and control groups had already terminated due to the growth of large tumors. The group treated with 16 had more tumor-free animals.

[0188] Example 11 Established tumor model 16 was utilized to generate a xenograft model in NOD / scid mice bearing pre-established HL-60 tumors to demonstrate proof of concept.

[0189] Briefly, female immunodeficient NOD / scid mice were sublethally irradiated (2 Gy) and 4 × 10 6 HL-60 cells were inoculated subcutaneously. On day 9, animals received a single bolus injection of anti-asialoGM1 rabbit antibody (Wako, Neuss, Germany) to deplete mouse natural killer (NK) cells. On day 10, tumors grew to 50–150 mm. 3 (Average 73±11mm 3 Once the volume reached 1.5 × 10 cells, animals were assigned to three treatment groups: groups 2 and 3 (8 animals each) received 1.5 × 10 cells; 7 were injected intraperitoneally with activated human T cells. Prior to injection, T cells were isolated from buffy coats (healthy donors) using negative selection. T cells were expanded and activated using a T cell activation / expansion kit according to the manufacturer's instructions (Miltenyi Biotech). To address potential donor variability, groups 2 and 3 were subdivided into two cohorts, each of which received expanded and activated T cells from a single donor. Each cohort received T cells derived from only one individual T cell donor.

[0190] Table 14. Treatment groups of the established HL-60 xenograft model TIFF0007583014000016.tif53170

[0191] From day 13 onwards, animals in group 3 were 105 mm 3 The mean tumor volumes are shown in Table 1 and were treated with a total of nine intravenous doses of 50 μg of tandem diabody 16 (qdx9d). Table 14 shows the group assignments and dosing schedules. Groups 1 and 2 were treated with vehicle only. Body weights and tumor volumes were measured up to day 27.

[0192] All animals steadily developed tumors, which were evident by day 6. The mean tumor volume of vehicle-treated Groups 1 and 2 (HL-60) animals continued to increase until the end of the study on day 27 (FIG. 13). In Group 2 animals that received primary activated human T cells in addition to HL-60 tumor cells, the mean tumor volume increased more rapidly compared to Group 1 (HL-60 only).

[0193] Repeated intravenous treatment with tandem diabody 16 (50 μg / animal; 2.5 mg / kg) from days 13 to 21 (qdxd9) in the presence of human T cells (Group 3) rapidly delayed tumor growth compared to Groups 1 and 2. Tandem diabody 16 delayed tumor growth in Group 3 by approximately 4 to 5 days compared to the vehicle-treated control group (Group 2). Statistically significant differences in the period from days 6 to 27 were identified between Group 2 (HL-60, T cells, vehicle) and Group 3 (HL-60, T cells, 16) on days 22 (p<0.05), 23 (p<0.01), and 27 (p<0.01) (two-way repeated measures ANOVA with Bonferroni post-hoc test). Due to the unusually slow tumor growth in Group 1, no statistically significant differences existed between Groups 1 and 3.

[0194] When comparing tumor growth in Cohort 1 and Cohort 2 among groups receiving T cells from different donors, no donor-specific variability in T cell activity was observed (see Table 14).

[0195] Example 10 demonstrates the successful development of a xenograft model in NOD / scid mice bearing pre-established HL-60 tumors (AML) and intraperitoneally implanted human T cells. Repeated administration of tandem diabody 16 at a single dose level resulted in a statistically significant delay in tumor growth compared to the respective vehicle-treated control groups. The generated data are comparable to published results from similar studies with CD33 / CD3 BiTE™ (Aigner et al., 2012; Leukemia, 2013, Apr;27(5):1107-15).

[0196] Example 12 Efficacy of CD33 / CD3 tandem diabody in AML PDX model in NSG mice CD33 + Leukemia is 2-4% CD3 +Cryopreserved cells from AML patients, including T cells, were used to establish AML PDX models in NSG mice. One hour after tumor cell injection into irradiated (250 cGy) NSG mice, CD33 / CD3 tandem diabody 16 or 12 was injected intravenously in a 200 μL bolus at one of two doses (50 μg or 5 μg; n = 8 mice per group). Additional injections of tandem diabody were administered daily for the next four days. Mice were weighed weekly and then sacrificed on day 38. Peripheral blood, bone marrow, and spleen were collected for flow cytometric analysis (huCD33, huCD34, huCD45, muCD45, huCD14, huCD3, huCD4, huCD8, and 7AAD). Results are shown in Figure 14.

[0197] Figure 14 shows that untreated mice had substantial amounts of human blasts in the bone marrow and spleen after 38 days. In contrast, mice receiving daily intravenous injections of tandem diabody 12 or 16 displayed substantially lower numbers of human AML blasts in the bone marrow and spleen. Potent anti-AML effects of the CD33 / CD3 tandem diabody were observed at both dose levels (5 μg and 50 μg / injection).

[0198] The anti-AML effects observed for both CD33 / CD3 tandem diabodies 12 and 16 were much stronger than those of the CD123 / CD3 DART® antibody targeting AML in the same mouse model (Hussaini et al.: “Targeting CD123 In Leukemic Stem Cells Using Dual Affinity Re-Targeting Molecules (DART®) November 15, 2013; Blood: 122 (21)). In contrast to the CD33 / CD3 tandem diabody, which eliminated almost all AML blasts in the bone marrow and spleen, Hussaini et al. reported that CD123 / CD3 DART® only reduced the number of AML blasts in the bone marrow and spleen of PDX models by 50-1000-fold at 2.5 and 0.25 mg / kg, and CD123 / CD3 They report that DART™, at 0.5 mg / kg, reduced the number of AML blasts in the bone marrow and spleen of PDX models by only 40-78%.

[0199] Example 13 Rapid initiation of target cell lysis mediated by CD33 / CD3 tandem diabody 16 To assess the kinetics of target cell lysis mediated by the CD33 / CD3 tandem diabody, calcein release cytotoxicity assays were performed at different incubation times. + HL-60 target cells were incubated with serially diluted tandem diabody 16 in the presence of primary human T cells as effector cells at an E:T ratio of 25:1 for 30 min, 1 h, 2 h, 3 h, 4 h, or 5 h. Calcein released from lysed target cells was used to measure EC 50The EC values ​​were calculated and nonlinear regression / sigmoidal dose-response was used to calculate target cell lysis mediated by tandem diabody 16. Figure 15 shows the unexpectedly rapid onset of target cell lysis mediated by tandem diabody, with over 40% lysis observed after 30 minutes of incubation with saturating concentrations of tandem diabody. After 4 hours of incubation, target cell lysis reached over 90%. Table 15 and Figure 16 show the EC values ​​determined for tandem diabody 16 at incubation times ranging from 30 minutes to 5 hours. 50 The results summarize the maximum potency (lowest EC6) after 2 hours of incubation under the assay conditions used. 50 value) and further demonstrate that the target cells were nearly completely lysed after 5 hours of incubation. Collectively, these results demonstrate very rapid, potent, and effective target cell lysis mediated by the CD33 / CD3 tandem diabody.

[0200] Table 15. EC determined for Tandem Diabody 16 50 and kinetics of dissolution values TIFF0007583014000017.tif57131

[0201] Example 14 Proof-of-concept clinical trial protocol for administration of CD33 / CD3 tandem diabodies to patients with AML This is a Phase I / II clinical trial to study the CD33 / CD3 tandem diabody 16 as a treatment for acute myeloid leukemia (AML).

[0202] Research purpose 1st: Maximum tolerated dose of CD33 / CD3 tandem diabody 16 Second: To determine whether in vitro responses of CD33 / CD3 tandem diabody 16 correlate with clinical responses

[0203] Phase I The maximum tolerated dose (MTD) will be determined in the Phase I section of the study. 1.1 The maximum tolerated dose (MTD) will be determined in the Phase I section of the study. 1.2 Patients who meet the eligibility criteria will be enrolled in the trial for CD33 / CD3 tandem diabody 16. 1.3 The goal is to identify the highest dose of CD33 / CD3 tandem diabody 16 that can be safely administered without severe or unmanageable side effects in participants. The dose given will depend on the number of participants enrolled in previous studies and how well the dose was tolerated. Not all participants will receive the same dose.

[0204] Phase II 2.1 The next Phase II section will address the MTD, and its goal is to determine whether treatment with CD33 / CD3 tandem diabody 16 results in a response rate of at least 20%. Primary objective of Phase II---To determine whether at least 20% of patients achieved a clinical response (blast response, minimal response, partial response, or complete response) with treatment with CD33 / CD3 tandem diabody 16.

[0205] Eligibility AML confirmed by peripheral blood and bone marrow analysis and fulfilling WHO criteria, excluding patients with acute promyelocytic leukemia (APL). Patients with AML refractory to first-line induction chemotherapy, with relapsed disease, or who are 60 years of age or older and, according to the treating physician, are unsuitable for standard cytotoxic therapy due to age, performance status, and / or adverse risk factors. Age ≥ 18 years old Karnofsky performance status ≥ 50% or ECOG performance status 0-2 Life expectancy ≥ 6 weeks

[0206] While specific embodiments have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It will be understood that various alternatives to the embodiments described herein may be utilized in practicing the present embodiments. The following claims define the scope of the invention, and it is intended that methods and structures within the scope of these claims and their equivalents be covered thereby. Sequence information SEQUENCE LISTING <110> AMPHIVENA THERAPEUTICS, INC. <120> METHODS OF USING BISPECIFIC CD33 AND CD3 BINDING PROTEINS <150> US 62 / 168,641 <151> 2015-05-29 <150> US 62 / 266,438 <151> 2015-12-11 <160> 146 <170> PatentIn version 3.5 <210> 1 <211> 108 <212> PRT <213> Homo sapiens <400> 1 Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Gln 1 5 10 15 Thr Ala Met Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Thr Thr Val 20 25 30 His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr 35 40 45 Asp Asp Asn Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Ser Thr Ala Thr Leu Thr Ile Asn Arg Val Glu Ala Gly 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Gly Ser Asp His 85 90 95 Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 2 <211> 110 <212> PRT <213> Homo sapiens <400> 2 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Ser Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu 85 90 95 Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 3 <211> 110 <212> PRT <213> Homo sapiens <400> 3 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu 85 90 95 Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 4 <211> 110 <212> PRT <213> Homo sapiens <400> 4 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu 85 90 95 Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 5 <211> 110 <212> PRT <213> Homo sapiens <400> 5 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu 85 90 95 Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 6 <211> 110 <212> PRT <213> Homo sapiens <400> 6 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Ser Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Asp Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu 85 90 95 Asn Gly Ala Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 7 <211> 111 <212> PRT <213> Homo sapiens <400> 7 Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser 85 90 95 Leu Ser Asp Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 8 <211> 110 <212> PRT <213> Homo sapiens <400> 8 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Ile Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Lys Gly Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 9 <211> 110 <212> PRT <213> Homo sapiens <400> 9 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Ser Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Ser Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 10 <211> 110 <212> PRT <213> Homo sapiens <400> 10 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asp Asn 20 25 30 Val Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Thr Asn Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Ser Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Ala Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 11 <211> 119 <212> PRT <213> Homo sapiens <400> 11 Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Asn Tyr 20 25 30 Gly Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Leu Ile Ser Tyr Asp Gly Asn Lys Lys Phe Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Ala Ile Ser Arg Asp Thr Ser Lys Asn Thr Val Asp 65 70 75 80 Leu Gln Met Thr Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Asp Arg Leu Glu Ser Ala Ala Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 <210> 12 <211> 122 <212> PRT <213> Homo sapiens <400> 12 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Ala Asn Thr Asp Phe Ser Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 13 <211> 122 <212> PRT <213> Homo sapiens <400> 13 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Ala Val Thr Asp Tyr Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 14 <211> 122 <212> PRT <213> Homo sapiens <400> 14 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Ala Asn Thr Asp Tyr Ser Phe Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 15 <211> 122 <212> PRT <213> Homo sapiens <400> 15 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Ala Asn Thr Asp Tyr Ser Leu Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 16 <211> 123 <212> PRT <213> Homo sapiens <400> 16 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Val Val Pro Ala Ala Ile Asp Tyr Tyr Gly Met Asp Val 100 105 110 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 17 <211> 119 <212> PRT <213> Homo sapiens <400> 17 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 1 5 10 15 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Arg His Lys Arg Gly Ser Asp Ala Phe Asp Ile Trp Gly Gln Gly 100 105 110 Thr Thr Val Thr Val Ser Ser 115 <210> 18 <211> 122 <212> PRT <213> Homo sapiens <400> 18 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Tyr Pro Ile Phe Gly Ser Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Tyr Tyr Tyr Asp Ser Ser Glu Trp Ala Phe Asp Ile Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 19 <211> 122 <212> PRT <213> Homo sapiens <400> 19 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Ser Ala His Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Tyr Tyr Tyr Asp Ser Ser Glu Trp Ala Phe Asp Ile Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 20 <211> 122 <212> PRT <213> Homo sapiens <400> 20 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Asp Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Ser Ala His Tyr Ser Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Tyr Tyr Tyr Asp Ser Ser Glu Trp Ala Phe Asp Ile Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 21 <211> 11 <212> PRT <213> Homo sapiens <400> 21 Gly Gly Asn Asn Ile Gly Ser Thr Thr Val His 1 5 10 <210> 22 <211> 13 <212> PRT <213> Homo sapiens <400> 22 Ser Gly Ser Arg Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 23 <211> 13 <212> PRT <213> Homo sapiens <400> 23 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 24 <211> 14 <212> PRT <213> Homo sapiens <400> 24 Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His 1 5 10 <210> 25 <211> 13 <212> PRT <213> Homo sapiens <400> 25 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Ile Val Asn 1 5 10 <210> 26 <211> 13 <212> PRT <213> Homo sapiens <400> 26 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Lys 1 5 10 <210> 27 <211> 13 <212> PRT <213> Homo sapiens <400> 27 Ser Gly Ser Ser Ser Asn Ile Gly Asp Asn Val Val Asn 1 5 10 <210> 28 <211> 7 <212> PRT <213> Homo sapiens <400> 28 Asp Asp Asn Glu Arg Pro Ser 1 5 <210> 29 <211> 7 <212> PRT <213> Homo sapiens <400> 29 Gly Asn Asn Gln Arg Pro Ser 1 5 <210> 30 <211> 7 <212> PRT <213> Homo sapiens <400> 30 Ser Asp Asn Gln Arg Pro Ser 1 5 <210> 31 <211> 7 <212> PRT <213> Homo sapiens <400> 31 Gly Asn Ser Asn Arg Pro Ser 1 5 <210> 32 <211> 7 <212> PRT <213> Homo sapiens <400> 32 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 33 <211> 7 <212> PRT <213> Homo sapiens <400> 33 Ser Asn Asn Gln Arg Ser Ser 1 5 <210> 34 <211> 7 <212> PRT <213> Homo sapiens <400> 34 Ser Thr Asn Lys Arg Pro Ser 1 5 <210> 35 <211> 9 <212> PRT <213> Homo sapiens <400> 35 Gln Val Trp Asp Ser Gly Ser Asp His 1 5 <210> 36 <211> 9 <212> PRT <213> Homo sapiens <400> 36 Ala Thr Trp Asp Asp Ser Leu Ile Gly 1 5 <210> 37 <211> 9 <212> PRT <213> Homo sapiens <400> 37 Ala Thr Trp Asp Asp Ser Leu Asn Gly 1 5 <210> 38 <211> 9 <212> PRT <213> Homo sapiens <400> 38 Gln Ser Tyr Asp Ser Ser Leu Ser Asp 1 5 <210> 39 <211> 9 <212> PRT <213> Homo sapiens <400> 39 Ala Ala Trp Asp Asp Ser Leu Lys Gly 1 5 <210> 40 <211> 9 <212> PRT <213> Homo sapiens <400> 40 Ala Ala Trp Asp Asp Ser Leu Asn Gly 1 5 <210> 41 <211> 9 <212> PRT <213> Homo sapiens <400> 41 Ala Ala Trp Asp Asp Ser Leu Ser Ala 1 5 <210> 42 <211> 6 <212> PRT <213> Homo sapiens <400> 42 Ser Asn Tyr Gly Ile His 1 5 <210> 43 <211> 6 <212> PRT <213> Homo sapiens <400> 43 Thr Ser Tyr Asp Ile Asn 1 5 <210> 44 <211> 6 <212> PRT <213> Homo sapiens <400> 44 Thr Ser Tyr Tyr Met His 1 5 <210> 45 <211> 6 <212> PRT <213> Homo sapiens <400> 45 Thr Ser Tyr Trp Ile Gly 1 5 <210> 46 <211> 6 <212> PRT <213> Homo sapiens <400> 46 See See Tyr Ala Ile See 1 5 <210> 47 <211> 6 <212> PRT <213> Homo sapiens <400> 47 Ser Ser Tyr Gly Ile Ser 1 5 <210> 48 <211> 6 <212> PRT <213> Homo sapiens <400> 48 Asp Ser Tyr Ala Ile Ser 1 5 <210> 49 <211> 17 <212> PRT <213> Homo sapiens <400> 49 Leu Ile Ser Tyr Asp Gly Asn Lys Lys Phe Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 50 <211> 17 <212> PRT <213> Homo sapiens <400> 50 Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 51 <211> 18 <212> PRT <213> Homo sapiens <400> 51 Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe 1 5 10 15 Gln Gly <210> 52 <211> 17 <212> PRT <213> Homo sapiens <400> 52 Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln 1 5 10 15 Gly <210> 53 <211> 17 <212> PRT <213> Homo sapiens <400> 53 Gly Ile Tyr Pro Ile Phe Gly Ser Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 54 <211> 17 <212> PRT <213> Homo sapiens <400> 54 Gly Ile Ile Pro Ile Phe Gly Ser Ala His Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 55 <211> 17 <212> PRT <213> Homo sapiens <400> 55 Gly Ile Ile Pro Ile Phe Gly Ser Ala His Tyr Ser Gln Lys Phe Gln 1 5 10 15 Gly <210> 56 <211> 10 <212> PRT <213> Homo sapiens <400> 56 Asp Arg Leu Glu Ser Ala Ala Phe Asp Tyr 1 5 10 <210> 57 <211> 13 <212> PRT <213> Homo sapiens <400> 57 Asp Arg Ala Asn Thr Asp Phe Ser Tyr Gly Met Asp Val 1 5 10 <210> 58 <211> 13 <212> PRT <213> Homo sapiens <400> 58 Asp Arg Ala Val Thr Asp Tyr Tyr Tyr Gly Met Asp Val 1 5 10 <210> 59 <211> 13 <212> PRT <213> Homo sapiens <400> 59 Asp Arg Ala Asn Thr Asp Tyr Ser Phe Gly Met Asp Val 1 5 10 <210> 60 <211> 13 <212> PRT <213> Homo sapiens <400> 60 Asp Arg Ala Asn Thr Asp Tyr Ser Leu Gly Met Asp Val 1 5 10 <210> 61 <211> 14 <212> PRT <213> Homo sapiens <400> 61 Asp Val Val Pro Ala Ala Ile Asp Tyr Tyr Gly Met Asp Val 1 5 10 <210> 62 <211> 10 <212> PRT <213> Homo sapiens <400> 62 His Lys Arg Gly Ser Asp Ala Phe Asp Ile 1 5 10 <210> 63 <211> 13 <212> PRT <213> Homo sapiens <400> 63 Glu Tyr Tyr Tyr Asp Ser Ser Glu Trp Ala Phe Asp Ile 1 5 10 <210> 64 <211> 125 <212> PRT <213> Homo sapiens <400> 64 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Ala Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Tyr Phe 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 65 <211> 125 <212> PRT <213> Homo sapiens <400> 65 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Ala Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 66 <211> 125 <212> PRT <213> Homo sapiens <400> 66 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Ala Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 67 <211> 125 <212> PRT <213> Homo sapiens <400> 67 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Ala Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 68 <211> 110 <212> PRT <213> Homo sapiens <400> 68 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Ala Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ser Arg 50 55 60 Phe Ser Gly Ser Leu Ile Gly Asp Lys Ala Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 69 <211> 110 <212> PRT <213> Homo sapiens <400> 69 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ala Arg 50 55 60 Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 70 <211> 110 <212> PRT <213> Homo sapiens <400> 70 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ser Arg 50 55 60 Phe Ser Gly Ser Leu Ile Gly Asp Lys Ala Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 71 <211> 110 <212> PRT <213> Homo sapiens <400> 71 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ser Arg 50 55 60 Phe Ser Gly Ser Leu Ile Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 72 <211> 6 <212> PRT <213> Homo sapiens <400> 72 Ser Thr Tyr Ala Met Asn 1 5 <210> 73 <211> 19 <212> PRT <213> Homo sapiens <400> 73 Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser 1 5 10 15 Val Light Asp <210> 74 <211> 14 <212> PRT <213> Homo sapiens <400> 74 His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe Ala Tyr 1 5 10 <210> 75 <211> 14 <212> PRT <213> Homo sapiens <400> 75 His Gly Asn Phe Gly Asn Ser Tyr Val Ser Tyr Phe Ala Tyr 1 5 10 <210> 76 <211> 6 <212> PRT <213> Homo sapiens <400> 76 Asn Thr Tyr Ala Met Asn 1 5 <210> 77 <211> 6 <212> PRT <213> Homo sapiens <400> 77 Asn Thr Tyr Ala Met His 1 5 <210> 78 <211> 6 <212> PRT <213> Homo sapiens <400> 78 Asn Lys Tyr Ala Met Asn 1 5 <210> 79 <211> 19 <212> PRT <213> Homo sapiens <400> 79 Arg Ile Arg Asn Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser 1 5 10 15 Val Light Asp <210> 80 <211> 19 <212> PRT <213> Homo sapiens <400> 80 Arg Ile Arg Asn Lys Tyr Asn Asn Tyr Ala Thr Glu Tyr Ala Asp Ser 1 5 10 15 Val Light Asp <210> 81 <211> 19 <212> PRT <213> Homo sapiens <400> 81 Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Glu Tyr Ala Ala Ser 1 5 10 15 Val Light Asp <210> 82 <211> 19 <212> PRT <213> Homo sapiens <400> 82 Arg Ile Arg Asn Lys Tyr Asn Asn Tyr Ala Thr Glu Tyr Ala Ala Ser 1 5 10 15 Val Light Asp <210> 83 <211> 19 <212> PRT <213> Homo sapiens <400> 83 Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser 1 5 10 15 Val Lys Gly <210> 84 <211> 19 <212> PRT <213> Homo sapiens <400> 84 Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Glu Tyr Ala Asp Ser 1 5 10 15 Val Lys Ser <210> 85 <211> 14 <212> PRT <213> Homo sapiens <400> 85 His Gly Asn Phe Gly Asp Ser Tyr Val Ser Trp Phe Ala Tyr 1 5 10 <210> 86 <211> 14 <212> PRT <213> Homo sapiens <400> 86 His Gly Asn Phe Gly Asn Thr Tyr Val Ser Trp Phe Ala Tyr 1 5 10 <210> 87 <211> 14 <212> PRT <213> Homo sapiens <400> 87 His Gly Asn Phe Gly Cys Ser Tyr Val Ser Trp Phe Ala Tyr 1 5 10 <210> 88 <211> 14 <212> PRT <213> Homo sapiens <400> 88 His Gly Asn Phe Gly Asn Ser Tyr Ile Ser Tyr Trp Ala Tyr 1 5 10 <210> 89 <211> 14 <212> PRT <213> Homo sapiens <400> 89 His Gly Asn Phe Gly Asn Ser Tyr Val Ser Phe Phe Ala Tyr 1 5 10 <210> 90 <211> 14 <212> PRT <213> Homo sapiens <400> 90 Arg Ser Ser Thr Gly Ala Val Thr Thr Ser Asn Tyr Ala Asn 1 5 10 <210> 91 <211> 7 <212> PRT <213> Homo sapiens <400> 91 Gly Thr Asn Lys Arg Ala Pro 1 5 <210> 92 <211> 7 <212> PRT <213> Homo sapiens <400> 92 Ala Leu Trp Tyr Ser Asn Leu 1 5 <210> 93 <211> 242 <212> PRT <213> Homo sapiens <400> 93 Asp Pro Asn Phe Trp Leu Gln Val Gln Glu Ser Val Thr Val Gln Glu 1 5 10 15 Gly Leu Cys Val Leu Val Pro Cys Thr Phe Phe His Pro Ile Pro Tyr 20 25 30 Tyr Asp Lys Asn Ser Pro Val His Gly Tyr Trp Phe Arg Glu Gly Ala 35 40 45 Ile Ile Ser Arg Asp Ser Pro Val Ala Thr Asn Lys Leu Asp Gln Glu 50 55 60 Val Gln Glu Glu Thr Gln Gly Arg Phe Arg Leu Leu Gly Asp Pro Ser 65 70 75 80 Arg Asn Asn Cys Ser Leu Ser Ile Val Asp Ala Arg Arg Arg Asp Asn 85 90 95 Gly Ser Tyr Phe Phe Arg Met Glu Arg Gly Ser Thr Lys Tyr Ser Tyr 100 105 110 Lys Ser Pro Gln Leu Ser Val His Val Thr Asp Leu Thr His Arg Pro 115 120 125 Lys Ile Leu Ile Pro Gly Thr Leu Glu Pro Gly His Ser Lys Asn Leu 130 135 140 Thr Cys Ser Val Ser Trp Ala Cys Glu Gln Gly Thr Pro Pro Ile Phe 145 150 155 160 Ser Trp Leu Ser Ala Ala Pro Thr Ser Leu Gly Pro Arg Thr Thr His 165 170 175 Ser Ser Val Leu Ile Ile Thr Pro Arg Pro Gln Asp His Gly Thr Asn 180 185 190 Leu Thr Cys Gln Val Lys Phe Ala Gly Ala Gly Val Thr Thr Glu Arg 195 200 205 Thr Ile Gln Leu Asn Val Thr Tyr Val Pro Gln Asn Pro Thr Thr Gly 210 215 220 Ile Phe Pro Gly Asp Gly Ser Gly Lys Gln Glu Thr Arg Ala Gly Val 225 230 235 240 Val His <210> 94 <211> 9 <212> PRT <213> Homo sapiens <400> 94 Asp Gln Glu Val Gln Glu Glu Thr Gln 1 5 <210> 95 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 95 Gly Gly Ser Gly Gly Ser 1 5 <210> 96 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 96 Gly Gly Ser Gly 1 <210> 97 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 97 Gly Gly Ser Gly Gly 1 5 <210> 98 <211> 494 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 98 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ala Arg 50 55 60 Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr 130 135 140 Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr 180 185 190 Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Asp Arg Ala Asn Thr Asp Phe Ser Tyr Gly 210 215 220 Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro 245 250 255 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly 260 265 270 Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys 275 280 285 Leu Leu Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg 290 295 300 Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly 305 310 315 320 Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp 325 330 335 Ser Leu Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 340 345 350 Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 355 360 365 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 370 375 380 Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly 385 390 395 400 Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr 405 410 415 Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg 420 425 430 Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr 435 440 445 Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn 450 455 460 Ser Tyr Val Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 465 470 475 480 Val Ser Ser Ala Ala Ala Gly Ser His His His His His His 485 490 <210> 99 <211> 494 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 99 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ala Arg 50 55 60 Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr 130 135 140 Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr 180 185 190 Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Asp Arg Ala Val Thr Asp Tyr Tyr Tyr Gly 210 215 220 Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro 245 250 255 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly 260 265 270 Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys 275 280 285 Leu Leu Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg 290 295 300 Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly 305 310 315 320 Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp 325 330 335 Ser Leu Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 340 345 350 Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 355 360 365 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 370 375 380 Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly 385 390 395 400 Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr 405 410 415 Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg 420 425 430 Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr 435 440 445 Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn 450 455 460 Ser Tyr Val Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 465 470 475 480 Val Ser Ser Ala Ala Ala Gly Ser His His His His His His 485 490 <210> 100 <211> 494 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 100 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ala Arg 50 55 60 Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr 130 135 140 Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr 180 185 190 Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Asp Arg Ala Asn Thr Asp Tyr Ser Phe Gly 210 215 220 Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro 245 250 255 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly 260 265 270 Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys 275 280 285 Leu Leu Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg 290 295 300 Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly 305 310 315 320 Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp 325 330 335 Ser Leu Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 340 345 350 Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 355 360 365 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 370 375 380 Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly 385 390 395 400 Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr 405 410 415 Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg 420 425 430 Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr 435 440 445 Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn 450 455 460 Ser Tyr Val Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 465 470 475 480 Val Ser Ser Ala Ala Ala Gly Ser His His His His His His 485 490 <210> 101 <211> 494 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 101 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ala Arg 50 55 60 Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr 130 135 140 Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr 180 185 190 Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Asp Arg Ala Asn Thr Asp Tyr Ser Leu Gly 210 215 220 Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro 245 250 255 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly 260 265 270 Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys 275 280 285 Leu Leu Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg 290 295 300 Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly 305 310 315 320 Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp 325 330 335 Ser Leu Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 340 345 350 Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 355 360 365 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 370 375 380 Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly 385 390 395 400 Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr 405 410 415 Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg 420 425 430 Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr 435 440 445 Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn 450 455 460 Ser Tyr Val Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 465 470 475 480 Val Ser Ser Ala Ala Ala Gly Ser His His His His His His 485 490 <210> 102 <211> 495 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 102 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ala Arg 50 55 60 Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr 130 135 140 Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr 180 185 190 Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Asp Arg Ala Asn Thr Asp Tyr Ser Phe Gly 210 215 220 Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr 245 250 255 Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile 260 265 270 Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro 275 280 285 Lys Leu Leu Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp 290 295 300 Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser 305 310 315 320 Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp 325 330 335 Asp Ser Leu Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val 340 345 350 Leu Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 355 360 365 Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser 370 375 380 Gly Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 385 390 395 400 Gly Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn 405 410 415 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 420 425 430 Arg Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys 435 440 445 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly 450 455 460 Asn Ser Tyr Val Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val 465 470 475 480 Thr Val Ser Ser Ala Ala Ala Gly Ser His His His His His His 485 490 495 <210> 103 <211> 495 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 103 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ala Arg 50 55 60 Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr 130 135 140 Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr 180 185 190 Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Asp Arg Ala Asn Thr Asp Tyr Ser Leu Gly 210 215 220 Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr 245 250 255 Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile 260 265 270 Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro 275 280 285 Lys Leu Leu Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp 290 295 300 Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser 305 310 315 320 Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp 325 330 335 Asp Ser Leu Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val 340 345 350 Leu Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 355 360 365 Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser 370 375 380 Gly Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 385 390 395 400 Gly Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn 405 410 415 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 420 425 430 Arg Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys 435 440 445 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly 450 455 460 Asn Ser Tyr Val Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val 465 470 475 480 Thr Val Ser Ser Ala Ala Ala Gly Ser His His His His His His 485 490 495 <210> 104 <211> 491 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 104 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Ala Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ser Arg 50 55 60 Phe Ser Gly Ser Leu Ile Gly Asp Lys Ala Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Val Val 115 120 125 Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser 130 135 140 Phe Ser Asn Tyr Gly Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly 145 150 155 160 Leu Glu Trp Val Ala Leu Ile Ser Tyr Asp Gly Asn Lys Lys Phe Tyr 165 170 175 Ala Asp Ser Val Lys Gly Arg Phe Ala Ile Ser Arg Asp Thr Ser Lys 180 185 190 Asn Thr Val Asp Leu Gln Met Thr Ser Leu Arg Pro Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Lys Asp Arg Leu Glu Ser Ala Ala Phe Asp Tyr 210 215 220 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Ser Gly Gly 225 230 235 240 Ser Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly 245 250 255 Gln Thr Ala Met Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Thr Thr 260 265 270 Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val 275 280 285 Tyr Asp Asp Asn Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly 290 295 300 Ser Asn Ser Gly Ser Thr Ala Thr Leu Thr Ile Asn Arg Val Glu Ala 305 310 315 320 Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Gly Ser Asp 325 330 335 His Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly Ser 340 345 350 Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln 355 360 365 Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe 370 375 380 Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu 385 390 395 400 Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr 405 410 415 Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser 420 425 430 Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr 435 440 445 Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn Ser Tyr Val 450 455 460 Ser Tyr Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 465 470 475 480 Ala Ala Ala Gly Ser His His His His His His 485 490 <210> 105 <211> 496 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 105 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu 85 90 95 Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly 100 105 110 Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val 115 120 125 Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr 130 135 140 Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly 145 150 155 160 Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr 165 170 175 Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp 180 185 190 Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp 195 200 205 Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn Ser Tyr 210 215 220 Val Ser Tyr Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 225 230 235 240 Ser Gly Gly Ser Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser 245 250 255 Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ser 260 265 270 Ser Thr Gly Ala Val Thr Thr Ser Asn Tyr Ala Asn Trp Val Gln Gln 275 280 285 Lys Pro Gly Lys Ala Pro Lys Ala Leu Ile Gly Gly Thr Asn Lys Arg 290 295 300 Ala Pro Gly Val Pro Ser Arg Phe Ser Gly Ser Leu Ile Gly Asp Lys 305 310 315 320 Ala Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr 325 330 335 Tyr Cys Ala Leu Trp Tyr Ser Asn Leu Trp Val Phe Gly Gln Gly Thr 340 345 350 Lys Val Glu Ile Lys Gly Gly Ser Gly Gly Ser Gln Val Gln Leu Val 355 360 365 Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser 370 375 380 Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asp Ile Asn Trp Val 385 390 395 400 Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro 405 410 415 Asn Ser Gly Asn Thr Gly Phe Ala Gln Lys Phe Gln Gly Arg Val Thr 420 425 430 Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser 435 440 445 Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Ala 450 455 460 Asn Thr Asp Phe Ser Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Leu 465 470 475 480 Val Thr Val Ser Ser Ala Ala Ala Gly Ser His His His His His His 485 490 495 <210> 106 <211> 494 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 106 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ser Arg 50 55 60 Phe Ser Gly Ser Leu Ile Gly Asp Lys Ala Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr 130 135 140 Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr 180 185 190 Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Asp Arg Ala Asn Thr Asp Phe Ser Tyr Gly 210 215 220 Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro 245 250 255 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly 260 265 270 Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys 275 280 285 Leu Leu Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg 290 295 300 Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly 305 310 315 320 Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp 325 330 335 Ser Leu Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 340 345 350 Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 355 360 365 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 370 375 380 Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly 385 390 395 400 Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr 405 410 415 Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg 420 425 430 Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr 435 440 445 Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn 450 455 460 Ser Tyr Val Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 465 470 475 480 Val Ser Ser Ala Ala Ala Gly Ser His His His His His His 485 490 <210> 107 <211> 494 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 107 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ser Arg 50 55 60 Phe Ser Gly Ser Leu Ile Gly Asp Lys Ala Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr 130 135 140 Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr 180 185 190 Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Asp Arg Ala Asn Thr Asp Tyr Ser Phe Gly 210 215 220 Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro 245 250 255 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly 260 265 270 Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys 275 280 285 Leu Leu Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg 290 295 300 Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly 305 310 315 320 Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp 325 330 335 Ser Leu Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 340 345 350 Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 355 360 365 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 370 375 380 Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly 385 390 395 400 Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr 405 410 415 Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg 420 425 430 Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr 435 440 445 Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn 450 455 460 Ser Tyr Val Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 465 470 475 480 Val Ser Ser Ala Ala Ala Gly Ser His His His His His His 485 490 <210> 108 <211> 494 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 108 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ser Arg 50 55 60 Phe Ser Gly Ser Leu Ile Gly Asp Lys Ala Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr 130 135 140 Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr 180 185 190 Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Asp Arg Ala Asn Thr Asp Tyr Ser Leu Gly 210 215 220 Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro 245 250 255 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly 260 265 270 Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys 275 280 285 Leu Leu Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg 290 295 300 Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly 305 310 315 320 Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp 325 330 335 Ser Leu Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 340 345 350 Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 355 360 365 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 370 375 380 Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly 385 390 395 400 Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr 405 410 415 Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg 420 425 430 Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr 435 440 445 Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn 450 455 460 Ser Tyr Val Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 465 470 475 480 Val Ser Ser Ala Ala Ala Gly Ser His His His His His His 485 490 <210> 109 <211> 494 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 109 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Ala Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ser Arg 50 55 60 Phe Ser Gly Ser Leu Ile Gly Asp Lys Ala Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr 130 135 140 Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr 180 185 190 Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Asp Arg Ala Val Thr Asp Tyr Tyr Tyr Gly 210 215 220 Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro 245 250 255 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly 260 265 270 Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys 275 280 285 Leu Leu Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg 290 295 300 Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly 305 310 315 320 Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp 325 330 335 Ser Leu Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 340 345 350 Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 355 360 365 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 370 375 380 Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly 385 390 395 400 Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr 405 410 415 Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg 420 425 430 Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr 435 440 445 Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn 450 455 460 Ser Tyr Val Ser Tyr Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 465 470 475 480 Val Ser Ser Ala Ala Ala Gly Ser His His His His His His 485 490 <210> 110 <211> 494 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 110 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ser Arg 50 55 60 Phe Ser Gly Ser Leu Ile Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr 130 135 140 Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr 180 185 190 Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Asp Arg Ala Val Thr Asp Tyr Tyr Tyr Gly 210 215 220 Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro 245 250 255 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly 260 265 270 Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys 275 280 285 Leu Leu Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg 290 295 300 Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly 305 310 315 320 Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp 325 330 335 Ser Leu Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 340 345 350 Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 355 360 365 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 370 375 380 Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly 385 390 395 400 Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr 405 410 415 Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg 420 425 430 Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr 435 440 445 Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn 450 455 460 Ser Tyr Val Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 465 470 475 480 Val Ser Ser Ala Ala Ala Gly Ser His His His His His His 485 490 <210> 111 <211> 494 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 111 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Ala Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ser Arg 50 55 60 Phe Ser Gly Ser Leu Ile Gly Asp Lys Ala Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr 130 135 140 Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr 180 185 190 Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Asp Arg Ala Asn Thr Asp Phe Ser Tyr Gly 210 215 220 Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro 245 250 255 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly 260 265 270 Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys 275 280 285 Leu Leu Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg 290 295 300 Phe Ser Gly Ser Lys Ser Gly Ser Ser Ala Ser Leu Ala Ile Ser Gly 305 310 315 320 Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp 325 330 335 Ser Leu Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 340 345 350 Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 355 360 365 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 370 375 380 Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly 385 390 395 400 Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr 405 410 415 Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg 420 425 430 Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr 435 440 445 Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn 450 455 460 Ser Tyr Val Ser Tyr Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 465 470 475 480 Val Ser Ser Ala Ala Ala Gly Ser His His His His His His 485 490 <210> 112 <211> 494 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 112 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Ala Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ser Arg 50 55 60 Phe Ser Gly Ser Leu Ile Gly Asp Lys Ala Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr 130 135 140 Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr 180 185 190 Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Asp Arg Ala Asn Thr Asp Tyr Ser Phe Gly 210 215 220 Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro 245 250 255 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly 260 265 270 Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys 275 280 285 Leu Leu Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg 290 295 300 Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly 305 310 315 320 Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp 325 330 335 Ser Leu Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 340 345 350 Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 355 360 365 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 370 375 380 Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly 385 390 395 400 Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr 405 410 415 Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg 420 425 430 Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr 435 440 445 Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn 450 455 460 Ser Tyr Val Ser Tyr Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 465 470 475 480 Val Ser Ser Ala Ala Ala Gly Ser His His His His His His 485 490 <210> 113 <211> 494 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 113 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Ala Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ser Arg 50 55 60 Phe Ser Gly Ser Leu Ile Gly Asp Lys Ala Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr 130 135 140 Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr 180 185 190 Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Asp Arg Ala Asn Thr Asp Tyr Ser Leu Gly 210 215 220 Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro 245 250 255 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly 260 265 270 Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys 275 280 285 Leu Leu Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg 290 295 300 Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly 305 310 315 320 Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp 325 330 335 Ser Leu Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 340 345 350 Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 355 360 365 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 370 375 380 Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly 385 390 395 400 Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr 405 410 415 Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg 420 425 430 Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr 435 440 445 Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn 450 455 460 Ser Tyr Val Ser Tyr Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 465 470 475 480 Val Ser Ser Ala Ala Ala Gly Ser His His His His His His 485 490 <210> 114 <211> 492 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 114 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Ala Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ser Arg 50 55 60 Phe Ser Gly Ser Leu Ile Gly Asp Lys Ala Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser 130 135 140 Phe Thr Ser Tyr Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly 145 150 155 160 Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr 165 170 175 Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile 180 185 190 Ser Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala 195 200 205 Met Tyr Tyr Cys Ala Arg His Lys Arg Gly Ser Asp Ala Phe Asp Ile 210 215 220 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Ser Gly Gln 225 230 235 240 Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg 245 250 255 Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr 260 265 270 Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 275 280 285 Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 290 295 300 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln 305 310 315 320 Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu 325 330 335 Ser Asp Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly 340 345 350 Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val 355 360 365 Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr 370 375 380 Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly 385 390 395 400 Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr 405 410 415 Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp 420 425 430 Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp 435 440 445 Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn Ser Tyr 450 455 460 Val Ser Tyr Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 465 470 475 480 Ser Ala Ala Ala Gly Ser His His His His His His 485 490 <210> 115 <211> 492 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 115 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp 50 55 60 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Ala Arg His Gly Asn Phe Gly Asn Ser Tyr Val Ser Tyr Phe 100 105 110 Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Ser 115 120 125 Gly Gly Ser Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala 130 135 140 Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile 145 150 155 160 Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala 165 170 175 Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro 180 185 190 Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile 195 200 205 Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr 210 215 220 Asp Ser Ser Leu Ser Asp Val Val Phe Gly Gly Gly Thr Lys Leu Thr 225 230 235 240 Val Leu Gly Gly Ser Gly Gln Val Gln Leu Val Gln Ser Gly Ala Glu 245 250 255 Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly 260 265 270 Tyr Ser Phe Thr Ser Tyr Trp Ile Gly Trp Val Arg Gln Met Pro Gly 275 280 285 Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr 290 295 300 Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys 305 310 315 320 Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp 325 330 335 Thr Ala Met Tyr Tyr Cys Ala Arg His Lys Arg Gly Ser Asp Ala Phe 340 345 350 Asp Ile Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Ser 355 360 365 Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala 370 375 380 Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala 385 390 395 400 Val Thr Thr Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys 405 410 415 Ala Pro Lys Ala Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val 420 425 430 Pro Ser Arg Phe Ser Gly Ser Leu Ile Gly Asp Lys Ala Thr Leu Thr 435 440 445 Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu 450 455 460 Trp Tyr Ser Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile 465 470 475 480 Lys Ala Ala Ala Gly Ser His His His His His His 485 490 <210> 116 <211> 495 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 116 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Ala Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ser Arg 50 55 60 Phe Ser Gly Ser Leu Ile Gly Asp Lys Ala Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr 130 135 140 Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr 180 185 190 Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Asp Val Val Pro Ala Ala Ile Asp Tyr Tyr 210 215 220 Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly 225 230 235 240 Gly Ser Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr 245 250 255 Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile 260 265 270 Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro 275 280 285 Lys Leu Leu Ile Tyr Ser Asp Asn Gln Arg Pro Ser Gly Val Pro Asp 290 295 300 Arg Phe Ser Gly Ser Lys Ser Gly Ser Ser Ala Ser Leu Ala Ile Ser 305 310 315 320 Gly Leu Gln Ser Asp Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp 325 330 335 Asp Ser Leu Asn Gly Ala Val Phe Gly Gly Gly Thr Lys Leu Thr Val 340 345 350 Leu Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 355 360 365 Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser 370 375 380 Gly Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 385 390 395 400 Gly Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn 405 410 415 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 420 425 430 Arg Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys 435 440 445 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly 450 455 460 Asn Ser Tyr Val Ser Tyr Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val 465 470 475 480 Thr Val Ser Ser Ala Ala Ala Gly Ser His His His His His His 485 490 495 <210> 117 <211> 495 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 117 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ser Arg 50 55 60 Phe Ser Gly Ser Leu Ile Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr 130 135 140 Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr 180 185 190 Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Asp Val Val Pro Ala Ala Ile Asp Tyr Tyr 210 215 220 Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly 225 230 235 240 Gly Ser Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr 245 250 255 Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile 260 265 270 Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro 275 280 285 Lys Leu Leu Ile Tyr Ser Asp Asn Gln Arg Pro Ser Gly Val Pro Asp 290 295 300 Arg Phe Ser Gly Ser Lys Ser Gly Ser Ser Ala Ser Leu Ala Ile Ser 305 310 315 320 Gly Leu Gln Ser Asp Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp 325 330 335 Asp Ser Leu Asn Gly Ala Val Phe Gly Gly Gly Thr Lys Leu Thr Val 340 345 350 Leu Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 355 360 365 Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser 370 375 380 Gly Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 385 390 395 400 Gly Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn 405 410 415 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 420 425 430 Arg Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys 435 440 445 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly 450 455 460 Asn Ser Tyr Val Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val 465 470 475 480 Thr Val Ser Ser Ala Ala Ala Gly Ser His His His His His His 485 490 495 <210> 118 <211> 494 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 118 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Ala Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ser Arg 50 55 60 Phe Ser Gly Ser Leu Ile Gly Asp Lys Ala Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr 130 135 140 Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Gly Ile Tyr Pro Ile Phe Gly Ser Ala Asn Tyr 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr 180 185 190 Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Glu Tyr Tyr Tyr Asp Ser Ser Glu Trp Ala 210 215 220 Phe Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro 245 250 255 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly 260 265 270 Ser Asn Ile Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys 275 280 285 Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg 290 295 300 Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly 305 310 315 320 Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp 325 330 335 Ser Leu Lys Gly Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 340 345 350 Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 355 360 365 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 370 375 380 Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly 385 390 395 400 Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr 405 410 415 Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg 420 425 430 Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr 435 440 445 Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn 450 455 460 Ser Tyr Val Ser Tyr Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 465 470 475 480 Val Ser Ser Ala Ala Ala Gly Ser His His His His His His 485 490 <210> 119 <211> 494 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 119 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Ala Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ser Arg 50 55 60 Phe Ser Gly Ser Leu Ile Gly Asp Lys Ala Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr 130 135 140 Phe Ser Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Ser Ala His Tyr 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr 180 185 190 Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Glu Tyr Tyr Tyr Asp Ser Ser Glu Trp Ala 210 215 220 Phe Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro 245 250 255 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly 260 265 270 Ser Asn Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys 275 280 285 Leu Leu Ile Tyr Ser Asn Asn Gln Arg Ser Ser Gly Val Pro Asp Arg 290 295 300 Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly 305 310 315 320 Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp 325 330 335 Ser Leu Asn Gly Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 340 345 350 Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 355 360 365 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 370 375 380 Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly 385 390 395 400 Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr 405 410 415 Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg 420 425 430 Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr 435 440 445 Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn 450 455 460 Ser Tyr Val Ser Tyr Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 465 470 475 480 Val Ser Ser Ala Ala Ala Gly Ser His His His His His His 485 490 <210> 120 <211> 494 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 120 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ser Arg 50 55 60 Phe Ser Gly Ser Leu Ile Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr 130 135 140 Phe Ser Ser Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Ser Ala His Tyr 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr 180 185 190 Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Glu Tyr Tyr Tyr Asp Ser Ser Glu Trp Ala 210 215 220 Phe Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro 245 250 255 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly 260 265 270 Ser Asn Thr Val Lys Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys 275 280 285 Leu Leu Ile Tyr Ser Asn Asn Gln Arg Ser Ser Gly Val Pro Asp Arg 290 295 300 Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly 305 310 315 320 Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp 325 330 335 Ser Leu Asn Gly Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 340 345 350 Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 355 360 365 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 370 375 380 Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly 385 390 395 400 Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr 405 410 415 Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg 420 425 430 Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr 435 440 445 Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn 450 455 460 Ser Tyr Val Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 465 470 475 480 Val Ser Ser Ala Ala Ala Gly Ser His His His His His His 485 490 <210> 121 <211> 494 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic polypeptide <400> 121 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Ala Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ser Arg 50 55 60 Phe Ser Gly Ser Leu Ile Gly Asp Lys Ala Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr 130 135 140 Phe Asp Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Ser Ala His Tyr 165 170 175 Ser Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr 180 185 190 Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Glu Tyr Tyr Tyr Asp Ser Ser Glu Trp Ala 210 215 220 Phe Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro 245 250 255 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly 260 265 270 Asp Asn Val Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys 275 280 285 Leu Leu Ile Tyr Ser Thr Asn Lys Arg Pro Ser Gly Val Pro Asp Arg 290 295 300 Phe Ser Gly Ser Lys Ser Gly Ser Ser Ala Ser Leu Ala Ile Ser Gly 305 310 315 320 Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp 325 330 335 Ser Leu Ser Ala Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 340 345 350 Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 355 360 365 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 370 375 380 Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly 385 390 395 400 Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr 405 410 415 Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg 420 425 430 Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr 435 440 445 Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn 450 455 460 Ser Tyr Val Ser Tyr Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 465 470 475 480 Val Ser Ser Ala Ala Ala Gly Ser His His His His His His 485 490 <210> 122 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic 6xHis tag <400> 122 His His His His His His 1 5 <210> 123 <211> 483 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 123 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ala Arg 50 55 60 Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr 130 135 140 Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr 180 185 190 Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Asp Arg Ala Asn Thr Asp Phe Ser Tyr Gly 210 215 220 Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro 245 250 255 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly 260 265 270 Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys 275 280 285 Leu Leu Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg 290 295 300 Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly 305 310 315 320 Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp 325 330 335 Ser Leu Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 340 345 350 Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 355 360 365 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 370 375 380 Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly 385 390 395 400 Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr 405 410 415 Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg 420 425 430 Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr 435 440 445 Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn 450 455 460 Ser Tyr Val Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 465 470 475 480 Val Ser Ser <210> 124 <211> 483 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 124 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ala Arg 50 55 60 Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr 130 135 140 Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr 180 185 190 Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Asp Arg Ala Val Thr Asp Tyr Tyr Tyr Gly 210 215 220 Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro 245 250 255 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly 260 265 270 Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys 275 280 285 Leu Leu Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg 290 295 300 Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly 305 310 315 320 Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp 325 330 335 Ser Leu Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 340 345 350 Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 355 360 365 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 370 375 380 Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly 385 390 395 400 Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr 405 410 415 Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg 420 425 430 Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr 435 440 445 Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn 450 455 460 Ser Tyr Val Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 465 470 475 480 Val Ser Ser <210> 125 <211> 483 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 125 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ala Arg 50 55 60 Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr 130 135 140 Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr 180 185 190 Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Asp Arg Ala Asn Thr Asp Tyr Ser Phe Gly 210 215 220 Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro 245 250 255 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly 260 265 270 Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys 275 280 285 Leu Leu Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg 290 295 300 Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly 305 310 315 320 Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp 325 330 335 Ser Leu Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 340 345 350 Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 355 360 365 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 370 375 380 Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly 385 390 395 400 Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr 405 410 415 Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg 420 425 430 Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr 435 440 445 Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn 450 455 460 Ser Tyr Val Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 465 470 475 480 Val Ser Ser <210> 126 <211> 483 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 126 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ala Arg 50 55 60 Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr 130 135 140 Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr 180 185 190 Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Asp Arg Ala Asn Thr Asp Tyr Ser Leu Gly 210 215 220 Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro 245 250 255 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly 260 265 270 Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys 275 280 285 Leu Leu Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg 290 295 300 Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly 305 310 315 320 Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp 325 330 335 Ser Leu Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 340 345 350 Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 355 360 365 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 370 375 380 Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly 385 390 395 400 Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr 405 410 415 Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg 420 425 430 Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr 435 440 445 Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn 450 455 460 Ser Tyr Val Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 465 470 475 480 Val Ser Ser <210> 127 <211> 484 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 127 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ala Arg 50 55 60 Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr 130 135 140 Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr 180 185 190 Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Asp Arg Ala Asn Thr Asp Tyr Ser Phe Gly 210 215 220 Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr 245 250 255 Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile 260 265 270 Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro 275 280 285 Lys Leu Leu Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp 290 295 300 Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser 305 310 315 320 Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp 325 330 335 Asp Ser Leu Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val 340 345 350 Leu Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 355 360 365 Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser 370 375 380 Gly Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 385 390 395 400 Gly Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn 405 410 415 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 420 425 430 Arg Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys 435 440 445 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly 450 455 460 Asn Ser Tyr Val Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val 465 470 475 480 Thr Val Ser Ser <210> 128 <211> 484 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 128 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ala Arg 50 55 60 Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr 130 135 140 Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr 180 185 190 Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Asp Arg Ala Asn Thr Asp Tyr Ser Leu Gly 210 215 220 Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr 245 250 255 Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile 260 265 270 Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro 275 280 285 Lys Leu Leu Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp 290 295 300 Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser 305 310 315 320 Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp 325 330 335 Asp Ser Leu Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val 340 345 350 Leu Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly 355 360 365 Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser 370 375 380 Gly Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 385 390 395 400 Gly Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn 405 410 415 Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 420 425 430 Arg Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys 435 440 445 Thr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly 450 455 460 Asn Ser Tyr Val Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val 465 470 475 480 Thr Val Ser Ser <210> 129 <211> 480 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 129 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Ala Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ser Arg 50 55 60 Phe Ser Gly Ser Leu Ile Gly Asp Lys Ala Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Val Val 115 120 125 Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser 130 135 140 Phe Ser Asn Tyr Gly Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly 145 150 155 160 Leu Glu Trp Val Ala Leu Ile Ser Tyr Asp Gly Asn Lys Lys Phe Tyr 165 170 175 Ala Asp Ser Val Lys Gly Arg Phe Ala Ile Ser Arg Asp Thr Ser Lys 180 185 190 Asn Thr Val Asp Leu Gln Met Thr Ser Leu Arg Pro Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Lys Asp Arg Leu Glu Ser Ala Ala Phe Asp Tyr 210 215 220 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Ser Gly Gly 225 230 235 240 Ser Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly 245 250 255 Gln Thr Ala Met Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Thr Thr 260 265 270 Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val 275 280 285 Tyr Asp Asp Asn Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly 290 295 300 Ser Asn Ser Gly Ser Thr Ala Thr Leu Thr Ile Asn Arg Val Glu Ala 305 310 315 320 Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Gly Ser Asp 325 330 335 His Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly Ser 340 345 350 Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln 355 360 365 Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe 370 375 380 Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu 385 390 395 400 Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr 405 410 415 Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser 420 425 430 Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr 435 440 445 Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn Ser Tyr Val 450 455 460 Ser Tyr Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 465 470 475 480 <210> 130 <211> 485 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 130 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu 85 90 95 Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gly 100 105 110 Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val 115 120 125 Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr 130 135 140 Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly 145 150 155 160 Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr 165 170 175 Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp 180 185 190 Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp 195 200 205 Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn Ser Tyr 210 215 220 Val Ser Tyr Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 225 230 235 240 Ser Gly Gly Ser Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser 245 250 255 Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ser 260 265 270 Ser Thr Gly Ala Val Thr Thr Ser Asn Tyr Ala Asn Trp Val Gln Gln 275 280 285 Lys Pro Gly Lys Ala Pro Lys Ala Leu Ile Gly Gly Thr Asn Lys Arg 290 295 300 Ala Pro Gly Val Pro Ser Arg Phe Ser Gly Ser Leu Ile Gly Asp Lys 305 310 315 320 Ala Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr 325 330 335 Tyr Cys Ala Leu Trp Tyr Ser Asn Leu Trp Val Phe Gly Gln Gly Thr 340 345 350 Lys Val Glu Ile Lys Gly Gly Ser Gly Gly Ser Gln Val Gln Leu Val 355 360 365 Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser 370 375 380 Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asp Ile Asn Trp Val 385 390 395 400 Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro 405 410 415 Asn Ser Gly Asn Thr Gly Phe Ala Gln Lys Phe Gln Gly Arg Val Thr 420 425 430 Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser 435 440 445 Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Ala 450 455 460 Asn Thr Asp Phe Ser Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Leu 465 470 475 480 Val Thr Val Ser Ser 485 <210> 131 <211> 483 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 131 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ser Arg 50 55 60 Phe Ser Gly Ser Leu Ile Gly Asp Lys Ala Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr 130 135 140 Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr 180 185 190 Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Asp Arg Ala Asn Thr Asp Phe Ser Tyr Gly 210 215 220 Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro 245 250 255 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly 260 265 270 Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys 275 280 285 Leu Leu Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg 290 295 300 Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly 305 310 315 320 Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp 325 330 335 Ser Leu Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 340 345 350 Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 355 360 365 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 370 375 380 Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly 385 390 395 400 Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr 405 410 415 Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg 420 425 430 Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr 435 440 445 Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn 450 455 460 Ser Tyr Val Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 465 470 475 480 Val Ser Ser <210> 132 <211> 483 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 132 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ser Arg 50 55 60 Phe Ser Gly Ser Leu Ile Gly Asp Lys Ala Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr 130 135 140 Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr 180 185 190 Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Asp Arg Ala Asn Thr Asp Tyr Ser Phe Gly 210 215 220 Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro 245 250 255 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly 260 265 270 Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys 275 280 285 Leu Leu Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg 290 295 300 Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly 305 310 315 320 Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp 325 330 335 Ser Leu Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 340 345 350 Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 355 360 365 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 370 375 380 Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly 385 390 395 400 Lys Gly Leu Glu Trp Val Gly Arg Ile Arg Ser Lys Tyr Asn Asn Tyr 405 410 415 Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg 420 425 430 Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr 435 440 445 Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Gly Asn Phe Gly Asn 450 455 460 Ser Tyr Val Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr 465 470 475 480 Val Ser Ser <210> 133 <211> 483 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 133 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr 20 25 30 Ser Asn Tyr Ala Asn Trp Val Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 40 45 Gly Leu Ile Gly Gly Thr Asn Lys Arg Ala Pro Gly Val Pro Ser Arg 50 55 60 Phe Ser Gly Ser Leu Ile Gly Asp Lys Ala Thr Leu Thr Ile Ser Ser 65 70 75 80 Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Ala Leu Trp Tyr Ser 85 90 95 Asn Leu Trp Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Gly 100 105 110 Ser Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys 115 120 125 Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr 130 135 140 Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly 145 150 155 160 Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Phe 165 170 175 Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr 180 185 190 Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala 195 200 205 Val Tyr Tyr Cys Ala Arg Asp Arg Ala Asn Thr Asp Tyr Ser Leu Gly 210 215 220 Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 225 230 235 240 Ser Gly Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro 245 250 255 Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly 260 265 270 Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys 275 280 285 Leu Leu Ile Tyr Gly Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg 290 295 300 Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly 305 310 315 320 Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp 325 330 335 Ser Leu Ile Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 340 345 350 Gly Gly Ser Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 355 360 365 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 370 375 380 Phe Thr Phe Ser Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly 385 390 395 400 Lys Gly Leu Glu Trp Val Gly Arg Ile A...

Claims

1. A medicament for the treatment of acute myeloid leukemia (AML) in a patient who has undergone hematopoietic stem cell transplantation, the medicament comprising a tandem diabody comprising a first polypeptide and a second polypeptide, each polypeptide having at least four variable chain domains linked sequentially; wherein each polypeptide is (i) a variable heavy (VH) domain specific for human CD33; (ii) a variable light (VL) domain specific for human CD33; (iii) a VH domain specific for human CD3; and (iv) a VL domain specific for human CD3 Including, The variable chain domain comprises: VL(CD3)-L1-VH(CD33)-L2-VL(CD33)-L3-VH(CD3); VH(CD3)-L1-VL(CD33)-L2-VH(CD33)-L3-VL(CD3); VL(CD33)-L1-VH(CD3)-L2-VL(CD3)-L3-VH(CD33); or VH(CD33)-L1-VL(CD3)-L2-VH(CD3)-L3-VL(CD33) are linked sequentially by peptide linkers L1, L2 and L3 in the order (i) a VL domain specific for human CD33 comprising a CDR1 sequence according to SEQ ID NO:22, a CDR2 sequence according to SEQ ID NO:29, and a CDR3 sequence according to SEQ ID NO:36; a VH domain specific for human CD33 comprising a CDR1 sequence according to SEQ ID NO: 43, a CDR2 sequence according to SEQ ID NO: 50, and a CDR3 sequence selected from the group consisting of SEQ ID NOs: 58-60; A VL domain specific for human CD3 comprises a CDR1 sequence according to SEQ ID NO:90, a CDR2 sequence according to SEQ ID NO:91, and a CDR3 sequence according to SEQ ID NO:92; and A VH domain specific for human CD3 comprises a CDR1 sequence according to SEQ ID NO:72, a CDR2 sequence according to SEQ ID NO:73, and a CDR3 sequence according to SEQ ID NO:75; (ii) the VL domain specific for human CD33 comprises a CDR1 sequence according to SEQ ID NO:23, a CDR2 sequence according to SEQ ID NO:30, and a CDR3 sequence according to SEQ ID NO:37; a VH domain specific for human CD33 comprising a CDR1 sequence according to SEQ ID NO: 44, a CDR2 sequence according to SEQ ID NO: 51, and a CDR3 sequence according to SEQ ID NO: 61; A VL domain specific for human CD3 comprises a CDR1 sequence according to SEQ ID NO:90, a CDR2 sequence according to SEQ ID NO:91, and a CDR3 sequence according to SEQ ID NO:92; and A VH domain specific for human CD3 comprises a CDR1 sequence according to SEQ ID NO:72, a CDR2 sequence according to SEQ ID NO:73, and a CDR3 sequence according to SEQ ID NO:75; or (iii) the VL domain specific for human CD33 comprises a CDR1 sequence according to SEQ ID NO:26, a CDR2 sequence according to SEQ ID NO:33, and a CDR3 sequence according to SEQ ID NO:40; a VH domain specific for human CD33 comprising a CDR1 sequence according to SEQ ID NO: 47, a CDR2 sequence according to SEQ ID NO: 54, and a CDR3 sequence according to SEQ ID NO: 63; A VL domain specific for human CD3 comprises a CDR1 sequence according to SEQ ID NO:90, a CDR2 sequence according to SEQ ID NO:91, and a CDR3 sequence according to SEQ ID NO:92; and A VH domain specific for human CD3 comprises a CDR1 sequence according to SEQ ID NO: 72, a CDR2 sequence according to SEQ ID NO: 73, and a CDR3 sequence according to SEQ ID NO: 75; Medicine.

2. The method of claim 1, wherein the transplant is allogeneic.

3. The method of claim 1, wherein the transplant is autologous.

4. The VL domain specific for human CD33 comprises a CDR1 sequence according to SEQ ID NO: 22, a CDR2 sequence according to SEQ ID NO: 29, and a CDR3 sequence according to SEQ ID NO: 36; a VH domain specific for human CD33 comprising a CDR1 sequence according to SEQ ID NO: 43, a CDR2 sequence according to SEQ ID NO: 50, and a CDR3 sequence selected from the group consisting of SEQ ID NOs: 58-60; A VL domain specific for human CD3 comprises a CDR1 sequence according to SEQ ID NO:90, a CDR2 sequence according to SEQ ID NO:91, and a CDR3 sequence according to SEQ ID NO:92; and A VH domain specific for human CD3 comprises a CDR1 sequence according to SEQ ID NO: 72, a CDR2 sequence according to SEQ ID NO: 73, and a CDR3 sequence according to SEQ ID NO: 75; The pharmaceutical composition according to any one of claims 1 to 3.

5. The VL domain specific for human CD33 comprises a CDR1 sequence according to SEQ ID NO: 23, a CDR2 sequence according to SEQ ID NO: 30, and a CDR3 sequence according to SEQ ID NO: 37; a VH domain specific for human CD33 comprising a CDR1 sequence according to SEQ ID NO: 44, a CDR2 sequence according to SEQ ID NO: 51, and a CDR3 sequence according to SEQ ID NO: 61; A VL domain specific for human CD3 comprises a CDR1 sequence according to SEQ ID NO:90, a CDR2 sequence according to SEQ ID NO:91, and a CDR3 sequence according to SEQ ID NO:92; and A VH domain specific for human CD3 comprises a CDR1 sequence according to SEQ ID NO: 72, a CDR2 sequence according to SEQ ID NO: 73, and a CDR3 sequence according to SEQ ID NO: 75; The pharmaceutical composition according to any one of claims 1 to 3.

6. The VL domain specific for human CD33 comprises a CDR1 sequence according to SEQ ID NO: 26, a CDR2 sequence according to SEQ ID NO: 33, and a CDR3 sequence according to SEQ ID NO: 40; a VH domain specific for human CD33 comprising a CDR1 sequence according to SEQ ID NO: 47, a CDR2 sequence according to SEQ ID NO: 54, and a CDR3 sequence according to SEQ ID NO: 63; A VL domain specific for human CD3 comprises a CDR1 sequence according to SEQ ID NO:90, a CDR2 sequence according to SEQ ID NO:91, and a CDR3 sequence according to SEQ ID NO:92; and A VH domain specific for human CD3 comprises a CDR1 sequence according to SEQ ID NO: 72, a CDR2 sequence according to SEQ ID NO: 73, and a CDR3 sequence according to SEQ ID NO: 75; The pharmaceutical composition according to any one of claims 1 to 3.

7. The pharmaceutical according to any one of claims 1 to 6, wherein the linkers L1, L2 and L3 each consist of 12 or less amino acid residues.

8. The pharmaceutical composition of any one of claims 1 to 7, wherein the linkers L1, L2 and L3 are each independently selected from SEQ ID NO: 95, SEQ ID NO: 96, or SEQ ID NO:

97.

9. The medicament of any one of claims 1 to 8, wherein the tandem diabody comprises a sequence selected from the group consisting of SEQ ID NOs: 134, 137, 138, 141, and 144.

10. The method of any one of claims 1 to 9, wherein the tandem diabody is tandem diabody 12 (SEQ ID NO: 134) or 16 (SEQ ID NO: 138).

11. The pharmaceutical agent according to any one of claims 1 to 10, which is used in combination with cytarabine, azacitidine, decitabine, anthracycline, fludarabine, clofarabine, cladribine, nelarabine, methotrexate, bortezomib, carfilzomib, melphalan, ibrutinib, thalidomide, lenalidomide, pomalidomide, apremilast, epipodophyllotoxin, anthracenedione, rituximab, ocrelizumab, ofatumumab, or a combination thereof.

12. The pharmaceutical composition of any one of claims 1 to 11, wherein the AML is AML with a recurrent genetic abnormality, AML with myelodysplasia-associated changes, therapy-related myeloid neoplasm, myeloid sarcoma, myeloproliferation associated with Down's syndrome, blastic plasmacytoid dendritic cell neoplasm, or AML not otherwise classified.

13. The pharmaceutical composition according to any one of claims 1 to 12, wherein the AML is AML-M0, AML-M1, AML-M2, AML-M3, AML-M4, AML-M5, AML-M6, or AML-M7.

14. A bispecific antigen-binding tandem diabody specific for human CD33 and human CD3 comprising a sequence selected from SEQ ID NOs: 134, 137, 138, 141, and 144.

15. The bispecific antigen-binding tandem diabody of claim 14, which is tandem diabody 12 comprising SEQ ID NO:

134.

16. The bispecific antigen-binding tandem diabody of claim 14, which is tandem diabody 15 comprising SEQ ID NO:

137.

17. The bispecific antigen-binding tandem diabody of claim 14, which is tandem diabody 16 comprising SEQ ID NO:

138.

18. The bispecific antigen-binding tandem diabody of claim 14, which is tandem diabody 19 comprising SEQ ID NO:

141.

19. The bispecific antigen-binding tandem diabody of claim 14, which is tandem diabody 22 comprising SEQ ID NO: 144.

Citation Information

Patent Citations

  • Interspecies-specific binding domain

    JP2010524851A

  • Xenospecific PSMA×CD3 dual-specific monoclonal antibody

    JP2012504403A